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Abstract 
 
The successful transmission of devil facial tumour disease (DFTD) as an allograft between 
Tasmanian devils raises many immunological questions about the disease, the devil’s immune 
system and their interplay. Research on DFTD and devil immunology feed into an overarching 
goal of developing a protective vaccine against DFTD. 
 
The effects of DFTD on haematology and serum biochemistry parameters in the Tasmanian 
devil have been published. DFTD’s effects on the immunological components of the devil’s 
peripheral blood however, continue to be explored. T lymphocyte subsets and 
immunoglobulins provide useful indicators of immune competence, and have been assessed in 
the lymphoid organs of healthy devils and those with DFTD. To examine the peripheral blood 
T lymphocyte subsets of a wild population of Tasmanian devils, a novel method using 
immunohistochemistry on formalin fixed blood clots was developed. This overcame the 
limitations of available reagents and the remote field location where samples were collected. 
An ELISA was developed to measure the relative levels of IgM and IgG in serum from healthy 
and diseased devils. Devils with DFTD had reduced percentages of CD4+ and CD8+ 
lymphocytes, and increased IgM and IgG serum levels compared to healthy devils. The effect 
of age, sex and season on these components was also evaluated in healthy devils. Significant 
differences between age groups (juveniles and adults) were found for both T lymphocytes and 
immunoglobulins. Seasonal effects were noted for CD4+ lymphocytes and the CD4:CD8 ratio. 
There was no detectable sex effect on any of the components. 
 
DFTD is an aggressive cancer with most devils dying within 6 to 12 months of clinical signs 
first appearing. The long-standing assumption that DFTD always escapes the devil’s immune 
response was addressed by looking for the presence of serum IgG antibodies against DFTD in 
a population of wild devils. Likewise, tumour biopsies were examined for the presence of 
tumour infiltrating lymphocytes as an indication of cell mediated immune responses. 
Approximately 10% of wild devils were capable of mounting an immune response against the 
disease. This correlated with tumour regression in four out of the six devils with a demonstrated 
immune response. 
 
The epigenetic down-regulation of the major histocompatibility complex class I molecule 
(MHC-I) is considered a principle mechanism by which the DFTD cells escape the devil’s 
 xii 
immune response. This down-regulation is reversible and DFTD cells incubated with the 
cytokine interferon gamma (IFN-g) express surface MHC-I. These cells are expected to be 
immunogeneic and thus formed the basis for two pilot immunisation trials on a total of six 
devils, including one adjuvant-only control, and one non-immunised control for live DFTD 
cell challenge. The immune responses induced by these immunisations were measured. A 
subsequent challenge with live DFTD cells was given to three of the immunised devils. 
Tumours developed in two of the devils but subsequent immunotherapy comprising a single 
subcutaneous injection of live DFTD cells expressing surface MHC-I, resulted in tumour 
regression in both devils. Serial biopsies of the regressing tumours demonstrated their immune 
mediated rejection. 
 
The State government’s Save the Tasmanian Devil Program’s “wild devil recovery” project 
allowed for the immunisation protocol used in one of the above trials to be carried out on 19 
captive held devils prior to their wild release. The relatively large sample size allowed for a 
more robust assessment of the immune responses measured. There were 15 out of the 19 devils 
that developed anti-DFTD IgG antibodies in response to the immunisations prior to their 
release. The effects age and sex had on the responses were also considered. Juvenile (one year 
old) devils had significantly higher antibody responses than adults, and female devils showed 
higher antibody responses than males. Inevitable variations in the protocol administered, due 
to variable trapping success, meant some comparison between the number of immunisations 
each devil received could also be made. Post release monitoring trips showed serum antibody 
levels reduced over time in the small number of devils that were retrapped during these trips.  
 
While this thesis was underway, a second transmissible cancer affecting Tasmanian devils was 
discovered in 2014. This was named DFT2 and bears similar morphological features to DFT1 
(the first DFTD). Genetic analyses confirmed that DFT2 arose independently to DFT1. The 
presence of immune cross-recognition of DFT1 and DFT2 in devils was explored.  Both 
immunised and wild devils with serum IgG antibody responses against DFT1 showed similar 
responses against DFT2. This suggests that DFT1 and DFT2 have common antigens and a 
single vaccine could protect against both tumours.
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Chapter 1. Literature review 
 
1.1. Introduction 
 
The Tasmanian devil (Sarcophilus harrisii) is threatened with extinction in the wild by an 
aggressive, transmissible and fatal cancer known as devil facial tumour disease (DFTD). The 
devil is the world’s largest extant carnivorous marsupial and unique to the island state of 
Tasmania. It is listed as endangered by the International Union for the Conservation of Nature 
as a result of the DFTD epidemic (Hawkins et al., 2008). 
 
The extinction in the wild of the Tasmanian devil would have profound impacts. It is an 
internationally recognised species with an iconic status and inhabits a unique ecological niche. 
As devil populations decline this niche is at risk of being filled by feral cats and potentially 
foxes, the consequences of which would prove disastrous for native species (Hollings et al., 
2014, Hawkins et al., 2006). 
 
DFTD is a contagious cancer, passed between devils by biting. A viral aetiology was initially 
suspected when the transmission pattern became apparent (Ladds et al., 2003), however, it is 
now clear the tumour cells are the sole aetiological agent (Pearse and Swift, 2006, Murchison 
et al., 2012). As discussed below, this is a rare event in nature, as the tumour must not only 
find a way to infect the new host, but also evade the host’s immune mechanisms in order to 
colonise the tissues. This form of tumour transmission is apparent in only one other mammalian 
species, the domestic dog, which is affected by canine transmissible venereal tumour (CTVT) 
(Rebbeck et al., 2009). CTVT provides a useful comparison to DFTD. Notably, new 
transmissible cancers have been recently described in soft-shell clams, suggesting that 
transmissible cancers might be more common in nature than originally thought (Metzger et al., 
2015, Metzger et al., 2016). 
 
Research investigating the devil’s immune system and immune responses has shown these to 
be functional and comparable to other mammalian species. A major limitation of marsupial 
immunology research is the lack of species specific or cross-reactive reagents such as 
monoclonal antibodies, leaving many knowledge gaps to be explored. For example, the 
immune cell populations and serum immunoglobulin levels of devils are largely unknown. 
These components have been shown to be involved in cancer immunology and therefore have 
 4 
particular relevance when examining the association between DFTD and the devil’s immune 
system. 
 
While it is useful to draw on the vast body of knowledge acquired from human and rodent 
immunology studies, the recognition of interspecies differences with respect to immunology is 
widespread and needs to be considered when assessing the devil’s immune system. So too does 
the effect the environment plays on immune responses, and “wild immunology” as the field 
that addresses these effects has obvious applications to Tasmanian devil research. 
 
Measures to conserve the Tasmanian devil include the maintenance of a genetically sustainable 
captive insurance population, the translocation of healthy devils to disease free areas, and 
research aimed at developing a protective DFTD vaccine. The latter has been underway since 
2006. While it is a challenging process, several characteristics of the DFTD cell e.g. its 
relatively stable nature, make the vaccine approach a worthwhile pursuit. Cancer vaccine 
development is a rapidly expanding field in medical research and requires the consideration of 
many possible approaches and options. Most have merit and the vast range of possibilities can 
be a double-edged sword for DFTD vaccine research particularly given the limitations inherent 
in working with an endangered species, such as the access to appropriate numbers of devils for 
suitably powered clinical trials.  Detection of immune responses to immunisation trials is 
another difficulty that arises when working with a species for which there are few appropriate 
reagents available.  
 
Ever since modelling predicted the likelihood that DFTD would drive devils to extinction 
(McCallum et al., 2007), human interventions such as those listed above, have been pursued. 
Perhaps not surprisingly, nature has also responded to the dramatic decline in the devil 
population with reproductive compensation seeing an increase in precocial breeding, and 
possibly an increase in female young born to diseased mothers (Jones et al., 2008b, Lachish et 
al., 2009). 
 
It is encouraging to note that no local devil extinctions have yet occurred, even in the north east 
of the state where DFTD has been present the longest (Environment, 2016). While there is 
evidence that devil population bottlenecks have occurred in the past (Bruniche-Olsen et al., 
2014), these were due to climate change and hunting, and the species’ ability to rebound from 
the current DFTD driven decline is untested and uncertain. The ecological impacts of the 
 5 
current population decline are measurable and significant (Fancourt et al., 2015, Hollings et 
al., 2014, McQuillan, 2009) and therefore human attempts to slow the decline are warranted.  
 
The devil’s immune system, DFTD and their interplay provide the opportunity to explore and 
link the two unique fields of marsupial immunology and transmissible cancers. This research 
feeds into the overarching goal of DFTD vaccine development, but the process concurrently 
provides insights into each field. As such, the relevance of this research is likely to extend 
beyond the devil and DFTD as species extinction, emerging infectious diseases, and diseases 
as causes of or contributing factors to extinction become more commonplace (Ceballos et al., 
2015, Jones et al., 2008a, Macphee and Greenwood, 2013, Heard et al., 2013). 
 
1.2. Origins of DFTD 
 
Cancer is the result of uncontrolled cell division that evades the host’s immune surveillance 
function. Cancer cells typically die with their host, but DFTD has the remarkable feature of 
being a clonally transmissible cancer (Pearse and Swift, 2006, Murchison et al., 2010), 
spreading from one individual to the next and outliving its host in the process. CTVT, the only 
other naturally occurring transmissible tumour of vertebrates, is a sexually transmitted cancer 
of dogs with a worldwide distribution (Rebbeck et al., 2009) and will be discussed later in this 
review. 
 
Carcinogens, infectious agents and genetic predisposition are the usual contributors to the 
cause of cancer. It is unknown what gave rise to the first DFT, but genomic analysis 
demonstrated this primary tumour appeared in a female devil around 20 years ago (Murchison 
et al., 2012). DFTD was first observed in 1996 in the far north east of Tasmania (Hawkins et 
al., 2006) and has since spread to affect the majority of the species’ geographic range, and up 
to 90% of individuals within certain locations (McCallum et al., 2007). It is believed to cause 
mortality in all affected animals, seemingly within 6  to 12 months of the tumour’s appearance 
(Hawkins et al., 2006). Death results from starvation depending on the size and location of the 
tumours, or from metastases and subsequent organ failure. 
 
Deep sequencing of the DFTD transcriptome revealed the tumour to be of Schwann cell origin 
(Murchison et al., 2010). Several genes involved in the myelination of axons are up-regulated 
in DFTD cells when compared to control tissues. In addition, protein expression was 
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determined by immunohistochemical analyses providing convincing evidence for the Schwann 
cell origin of DFTD (Tovar et al., 2011). 
 
1.3. Pathology of DFTD 
 
The defining characteristic of DFTD, as the name suggests, is the presence of locally aggressive 
tumour/s on the facial area. In addition, tumours occur inside the mouth (gingival mucosa, hard 
palate, lips), and on the head and neck. More than one tumour can be present on a given animal 
and there is considerable variation in size and external appearance. A DFTD pathology study 
found the majority of tumours to be well circumscribed, greater than 3 cm, and ulcerated (Loh 
et al., 2006). The tumours often show epithelial break up, necrosis, exudation and bacterial 
contamination (Figs 1.1 to 1.3). Metastases are a common finding (65% of cases in Loh’s 
study), and occur primarily in the draining lymph nodes, lungs and kidneys (Fig. 1.4).  
 
DFTD cells have been described as pleomorphic, round to spindle-shaped and with large 
central nuclei, arranged in nodules or bundles and enclosed by a thin pseudo-capsule (Loh et 
al., 2006). Variable levels of mitoses, necrosis and poor infiltration of inflammatory cells were 
also described (Fig. 1.5 a,b). The anaplasia exhibited by the DFTD cells (Loh et al., 2006) is 
consistent with the highly malignant nature of the tumour (Eberhart and Burger, 2003). 
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Figures 1.1 – 1.4. Devil facial tumour disease, Tasmanian devil. Figures 1.1 and 1.2. Right upper lip 
and right cheek, solitary ulcerated mass. Figure 1.3. Right upper gum, multiple ulcerated masses. Figure 
1.4. Right and left kidneys, devil facial tumour disease metastases in the cortex of both kidneys. 
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Figures 1.5 and 1.6. Devil facial tumour disease (DFTD), skin, Tasmanian devil. Figure 1.5. (a) DFTD 
tumour cells are distributed in the subcutaneous tissues, forming nodules in the dermis and 
subcutaneous tissue. (b) The neoplastic cells are round to spindle shaped with central nuclei and scant 
cytoplasm. Haematoxylin and eosin. Figure 1.6. (a) DFTD cells show specific labelling for the Schwann 
cell marker periaxin. (b) Strong cytoplasmic labelling of DFTD tumour cells with the marker periaxin. 
Immunohistochemistry for periaxin. 
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Based on immunohistochemical techniques, DFTD has been classified as a sarcoma, since it is 
negative for epithelial markers such as cytokeratin, epithelial membrane antigen and von 
Willebrand factor, and positive for S-100 and vimentin. Further research identified expression 
of proteins associated with the peripheral nerve system. Importantly, a Schwann cell marker, 
periaxin, was found to be highly expressed in 100% of primary DFTD tumours, DFTD 
metastases, cultured DFTD cells and mouse DFTD xenografts (Fig. 1.6 a,b) (Tovar et al., 
2011). Corroborating this finding, gene expression analyses of DFTs identified an 
overexpression of genes related to the myelination pathway of peripheral nerve tissue, 
specifically Schwann cells (Murchison et al., 2010). 
 
An independent review of chemical residues found in healthy devils and those affected with 
DFTD was commissioned by the Save the Tasmanian Devil Program (STDP) (Ross, 2008). 
The chemicals selected for investigation included heavy metals, herbicides and pesticides. 
Residues of dioxins, dibenzofurans, polychlorinated biphenyls (PCBs), brominated diphenyl 
ethers, arsenic, cadmium and lead were detected in the fat and/or liver of most animals but at 
levels similar to those found in other species at the top of the food chain, including humans. 
There were no significant differences in residue levels between the healthy and diseased devils 
and the author concluded there was no apparent link between these chemicals and DFTD. 
 
1.4. Allograft theory of DFTD transmission 
 
Transmissible cancers are an extremely rare occurrence in nature but evidence for the clonality 
of DFTD is conclusive, both from karyotypic and genetic perspectives. Pioneering research on 
DFT chromosomes demonstrated that the karyotypic rearrangement of 11 DFTs was complex 
and identical for each of the tumours examined. The karyotype of DFTD tumour cells showed 
several abnormalities, including the loss of both chromosomes 2 and both sex chromosomes, 
and the addition of four new unidentified markers. Since it is theoretically impossible that each 
DFT acquired the same complex rearrangement by chance it was concluded that DFTs are 
clones derived from the same original tumour and the allograft theory of disease transmission 
was put forward. In addition, the authors identified one host with a pericentric inversion of one 
of the chromosomes 5, but its DFT contained no such inversion, demonstrating that this DFT 
could not have arisen from its host (Pearse and Swift, 2006). This clonal hypothesis was 
supported by chromosome painting which further characterised the marker chromosomes 
showing them to be derived from chromosomes 1, 5 and X  (Deakin et al., 2012). These authors 
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noted that chromosomes 1 were mislabelled as chromosomes 2 in the original research. 
Chromosome painting also identified significant regions of homology between normal and 
DFT chromosomes.  
 
The genetic evidence supporting DFT’s clonal origin has been acquired from microsatellite 
and MHC genotyping as well as whole genome analysis. Matched tumour and host samples 
from 15 devils, and blood samples from 11 non-diseased individuals were genotyped at four 
polymorphic microsatellite loci, and MHC class I and II loci. While 90% of sampled devils 
had unique genotypes, all the tumours were identical at multiple microsatellite and MHC loci, 
supporting the tumour’s clonal nature (Siddle et al., 2007). A larger study of 25 matched 
tumour and host samples, and 10 samples from non-diseased devils were acquired from 16 
locations across Tasmania. Fourteen microsatellite loci were genotyped and all tumours shared 
a comparable genotype across all loci, independent of location, sex or age of the devil 
(Murchison et al., 2010). Both studies found that the tumour genotype was distinct from that 
of the host devils. Thus it would be impossible for DFTs to have arisen from the host’s own 
tissues and consequently supporting the tumour allograft theory. 
 
Finally, whole genome analysis (Miller et al., 2011, Murchison et al., 2012) further 
substantiated the tumour’s clonal origin and allograft theory of transmission by demonstrating 
that DFTs share structural variants and copy number changes distinct from their hosts. 
 
It is relevant to note here the contribution of telomere length and telomerase activity to the 
continued proliferation of DFT cells. Ujvari et al suggested the cells monitor and regulate the 
length of individual telomeres to favour their genomic stability and possibly increased 
proliferation (Ujvari et al., 2012). 
 
1.5. Evidence for direct tumour cell transmission 
 
The successful experimental induction of DFTD in naïve devils by the transfer of cultured 
tumour cells and/or cells from primary DFTs took place several years ago, although this has 
not been formally described (Pyecroft et al., 2007). More recently, two captive devils were 
challenged with live DFTD cells following an immunisation trial. Eventually both devils 
developed palpable tumours from 25,000 live DFTD cells. These experiments supported the 
theory that DFTD cells are successfully transferred from an infected devil to another (Kreiss 
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et al., 2015). The identification of viable tumour cells on the canine teeth of DFTD infected 
devils provided evidence for the natural mechanism of DFTD transmission (Obendorf, 2008). 
 
The closest relatives of the Tasmanian devil are other members of the Dasyurid family, 
including the spotted-tailed quoll (Dasyurus maculatus) and the eastern quoll (Dasyurus 
viverrinus), both of which are present in Tasmania. There is no evidence of DFTD naturally 
occurring in these species although transmission trials have not been performed. DFTD 
transmission trials were carried out on mice, but only severely immunocompromised mouse 
strains developed tumours after implantation (Pinfold et al., 2014). 
 
These independent lines of evidence convincingly characterise DFTD as a transmissible 
tumour that acts as an allograft and evades the host immune system. There are three possible 
explanations for how a tumour allograft could establish in the devil population:  
1. devils have a poor immune response or are immunosuppressed;  
2. devils are matched at the Major Histocompatibility Complex, or  
3. the tumour cells evade the host’s immune system.  
Each of these theories has been explored and are summarised below. 
 
1.6. The Tasmanian devil’s immune response 
 
The early consensus that marsupials had a primitive immune system has been overturned with 
current research showing their immune response to be closely akin to that of eutherian 
mammals (Belov et al., 2013). The overall similarity of the mammalian immune systems with 
respect to development, components and complexity is noteworthy given that divergence of 
marsupials from their eutherian counterparts occurred 148 million years ago (Bininda-Emonds 
et al., 2007). 
 
1.6.1. Innate immune response of the Tasmanian devil 
 
Tasmanian devils are carnivores, specialised scavengers and opportunistic predators. Their diet 
and biting behaviour expose them to a wide range and high level of bacteria and parasites, yet 
there is little evidence that wild devils succumb to disease of significance from such pathogens 
(Obendorf et al., 1990). It is logical to assume that devils have fully functional innate 
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phagocytic and humoral immune responses since these provide primary protection against 
bacterial and parasitic pathogens. 
 
Unsurprisingly, the devil’s neutrophils have been shown to be highly efficient at phagocytosis. 
Using functional assays such as the production of oxidizing compounds to kill bacteria and the 
demonstration of phagocytic uptake and killing of E. coli, this aspect of their innate immune 
response was shown to be proficient (Kreiss et al., 2008).  
 
1.6.2. Humoral immune response of the Tasmanian devil 
 
B cells producing immunoglobulin (Ig) M and IgG are present in devil lymphoid tissue 
(Howson et al., 2014). Devils rapidly responded to immunisation of horse red blood cells, with 
a single injection resulting in measurable IgG antibody titres after one week  (Kreiss, 2009). 
The relatively high titres were maintained throughout the eight month period of testing. A 
booster given six months after the first immunisation resulted in strong secondary responses. 
These results provided evidence that the devil has competent humoral immune responses and 
memory. Demonstrating the devil’s ability to mount an antibody response against xenogeneic 
tumour cells, Tasmanian devils immunised with the K562 human leukaemia cell line developed 
high antibody titres following a second immunisation (Brown et al., 2011). The usefulness of 
serum IgM and IgG analysis with respect to devil immunology and DFTD research, and the 
presence of anti-DFTD IgG antibodies are discussed later in this review.  
 
1.6.3. Cell mediated immune response of the Tasmanian devil 
 
Although Tasmanian devils resist most bacterial and parasitic insults, they and other dasyurids 
have a higher incidence of tumours compared to other marsupial families (Attwood and 
Woolley, 1973, Griner, 1979, Canfield et al., 1990). Cell-mediated immunity plays a crucial 
role in both tumour and allograft rejection and in light of the devil’s susceptibility to tumours, 
and the allograft nature of DFTD, a thorough understanding of the devil’s cell mediated 
immune response is required. Detailed investigation and clarification of immune cell function 
is significantly hampered by the lack of species-specific reagents (Belov et al., 2013). For 
example, antibodies against devil CD4 and CD8 T cells have only recently been developed and 
only for use in immunohistochemical preparations (Howson et al., 2014). The applications for 
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peripheral blood analysis of CD4+ and CD8+ lymphocytes in other species, and how these 
would contribute to devil immunology and DFTD research are addressed later in this review. 
 
T cell proliferation assays revealed the devils to have a relatively robust mitogen-induced 
response confirming T cell immune capacity (Kreiss et al., 2008, Stewart et al., 2008). Notably, 
devils affected with DFTD had similar mitogen-induced responses as their disease-free 
counterparts suggesting that immune suppression, at least at the level of lymphocyte 
proliferation, does not explain susceptibility to DFTD. 
 
In addition to demonstrating antibody responses to K562 cells, Brown et al also provided 
evidence of strong cytotoxic responses against the K562 cells in the presence of immune serum 
(Brown et al., 2011). Antibody dependent cell mediated cytotoxicity (ADCC) carried out by 
natural killer (NK) cells provides an explanation for this, and implies a possible route for 
inducing an anti-DFTD response. It is unclear whether NK cells can be activated against DFTD 
cells in the presence of anti-DFTD antibodies. 
 
While there are gaps in the knowledge, all research to date suggests the devils have a fully 
functional immune system comparable to that of other mammals, and a limited immune 
response does not explain the successful transmission of DFTD. 
 
1.7. Genetic diversity and the Major Histocompatibility Complex (MHC) 
 
Low genetic diversity of Tasmanian devils is expected given they are an island species 
(Frankham, 1997), and devils have been shown to exhibit low heterozygosity and allelic 
diversity at microsatellite loci (Jones et al., 2004). However, these results give information on 
population history e.g. relatedness and previous population bottlenecks, whereas analysis of 
MHC diversity better represents a population’s “fitness” and ability to counter disease 
challenges.   
 
The MHC is a cluster of genes occurring in all vertebrates and is the most polymorphic portion 
of the mammalian genome. These genes were first associated with foreign tissue (allograft) 
transplantation, but are now known to be essential in the immune recognition of pathogens and 
tumour cells. In addition, MHC molecules provoke vigorous T cell responses against 
incompatible cells and regulate the immunological mechanisms of tissue graft rejection (Li and 
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Raghavan, 2010). The diversity of MHC genes (i.e. polymorphism) provides the foundation 
for specific immune responses against infectious agents such as bacteria and viruses.  
 
A diversity of MHC molecules allows presentation of different antigen fragments from the 
infectious agents to a diverse range of T cells. This produces a stronger immune response than 
that when only a few antigen fragments are presented. Thus, MHC diversity contributes to 
disease resistance within a species. However, it was less the infectious nature of DFTD and 
more so its similarity to an allograft and consequent failure to be rejected by the Tasmanian 
devil’s immune system that put the spotlight on the devil’s MHC. 
 
Low diversity of MHC class I (MHC-I) in Tasmanian devils has been verified by sequence 
analysis (Siddle et al., 2007). An exploration of the MHC diversity in historical and ancient 
devil samples showed very similar levels to the modern devil population suggesting that low 
MHC diversity has been a feature of the species for the last 10,000 years (Morris et al., 2013). 
This research supported the intuitive explanation that low genetic diversity in devils may be a 
factor that makes devils more susceptible to allograft acceptance. This was, however, countered 
by subsequent skin graft transplant experiments (Kreiss et al., 2011). Cheetahs are another 
example of a wild species recognised as having extremely low genetic diversity, and allogeneic 
skin grafts between cheetahs were performed to test MHC variation (O'Brien et al., 1985, 
Sanjayan and Crooks, 1996). Of the 14 cheetahs, only three showed signs of rejection, which 
took at least 40 days. Monomorphism at the MHC complex was suggested as the probable 
cause. In contrast, allogeneic skin graft experiments performed on Tasmanian devils (Kreiss et 
al., 2011) found that all seven recipient devils rejected the grafts within 14 days. The 
immunologic mechanism of the rejection was confirmed by the characteristic infiltration of 
CD3+ lymphocytes. This suggests competent T-cell activity against the allografts, implying 
the immune system of individual devils recognise foreign MHC and should have the potential 
to mount a response against DFTD.  
 
This demonstration of a functional immune system and sufficient genetic diversity to reject 
allografts (other than DFT) suggests that intrinsic tumour properties are responsible for 
escaping the devil’s immune response.  
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1.8. Immune escape mechanisms of DFTD 
 
1.8.1. Overview of tumour immune escape mechanisms 
 
Immune escape mechanisms have been recognised in a wide variety of tumours including 
melanoma, mammary carcinoma and various adenocarcinomas (Seliger et al., 2001, Kim et al., 
2007). These include down-regulation or defective expression of MHC-I, down-regulation or 
defective mechanisms of antigen processing, and secretion of immunosuppressive cytokines. 
Inhibition of antigen presenting cells, in particular dendritic cells, is recognised as a significant 
immune escape mechanism of tumours in people and mice (Tourkova et al., 2009). 
 
1.8.2. Down-regulation of MHC-I 
 
Since 2007 DFTD cells have been known to possess MHC- I transcripts (Siddle et al., 2007). 
The presumption that MHC-I was expressed on the DFTD cell surface supported the hypothesis 
that the devils, with their reduced MHC diversity, did not identify the tumour cells’ foreign 
MHC, thus allowing successful establishment and proliferation of the tumour. It has since been 
demonstrated however that DFTD cells down-regulate expression of their MHC genes and this 
represents a key mechanism by which the tumour evades immune system detection (Siddle et 
al., 2013). Of great significance is that expression of MHC-I molecules can be restored on 
DFTD cells both in vitro and in vivo. The former has been demonstrated by treating cells with 
the cytokine interferon gamma (IFN-γ). The in vivo expression of MHC-I has been 
demonstrated, albeit rarely, on DFTD biopsies which have positive staining with 
immunohistochemistry for beta 2 microglobulin (a component of MHC-I). This finding has 
implications for vaccine development and will be discussed further in this review. 
 
1.8.3. Immunosuppressive cytokines and inhibition of antigen presenting cells 
 
Secretion of immunosuppressive cytokines by tumours of Schwann cell origin has been 
demonstrated as a mechanism for escaping immune detection (Watanabe et al., 2001). The 
tumour-promoting role of transforming growth factor beta (TGF-β) in the microenvironment 
of human cancers has been reviewed (Jakowlew, 2006, Moutsopoulos et al., 2008, Kaminska 
et al., 2005) and its significant role in the progression and regression of experimentally induced 
CTVT has been explored (Hsiao et al., 2008). The anti-inflammatory cytokine interleukin 10 
(IL10) has a complex and vast array of functions but its significance with respect to immune 
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escape lies in its ability to suppress both T cell proliferation and the production of inflammatory 
cytokines such as interleukin 1 (IL1) and tissue necrosis factor (TNF), and to impede the roles 
of antigen presenting cells (Sato et al., 2011). 
 
Identification of IL10 and TGF-β transcripts in the DFTD transcriptome suggested that 
synthesis of cytokines by DFTD cells could allow evasion of the devil’s immune response and 
enhance tumour growth. This was supported by unpublished immunohistochemistry results for 
DFTD biopsies that detected IL10 and TGF-β in the DFTD tumour cells (Howson, 2011). 
Quantitative PCR results did not show up-regulation of these cytokines nor of vascular 
endothelial growth factor A (VEGF-A) or interleukin 6 when compared to normal devil tissue 
(Morris and Belov, 2013). However, since cytokine concentrations as low as 0.1 ng/ml are 
active, and since tumor biopsies include non-neoplastic cells, a more precise method to assess 
protein expression by DFTD cells would be valuable as a complementary method to quantify 
these cytokines (Siddle and Kaufman, 2015, Woods et al., 2015). 
 
The presence of immature, but absence of mature dendritic cells within the DFT stroma has 
been noted and it was hypothesised the tumour cells, potentially via TGF-β, are actively 
preventing dendritic cell maturation (Howson et al., 2014). TGF-β has also been associated 
with the development of tolerogenic dendritic cells. Lastly, TGF-β inhibits the function of NK 
cells, which would typically recognise cells not expressing MHC-I as abnormal and eliminate 
them. 
 
In summary, evidence demonstrates that devils have an effective immune response and 
adequate MHC diversity to recognise and reject allografts. This suggests that the lack of 
immune recognition of DFTD is due to the tumor cells’ immune escape mechanisms. Down-
regulation of MHC by DFTD cells is possibly the most important of these mechanisms 
allowing for DFTD transmission between devils.  
 
1.9. Different strains and ploidy of DFTD  
 
Four strains of DFTD have been identified on the basis of their different karyotypes (Pearse et 
al., 2012). These authors suggest that the variants are likely to have different biological 
characteristics with respect to factors such as transmission and virulence, although there are 
few corroborating data for this. Based on chromosome painting and gene mapping, it has been 
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suggested that the minimal cytogenetic differences among tumor strains may not have clinical 
implications (Deakin et al., 2012). An increase in tetraploidy was observed in DFTs in devils 
from the Forestier Peninsula where disease suppression by selective culling was trialed (Ujvari 
et al., 2014). Since polyploid cells are often larger and may be slower to divide (Otto, 2007) 
this could have consequences for tumor growth. Because devils were removed from that site, 
long-term effects of tetraploidy in that population could not be assessed. The influence of 
ploidy was observed in a longitudinal study in northwest Tasmania where a high initial 
prevalence of tetraploid tumors in the study site was associated with low DFTD infection rates 
and limited host population effects. When the diploid DFTD variant reached the site, it replaced 
the tetraploid variant, causing disease prevalence and population effects to rapidly increase 
(Hamede et al., 2015). 
 
1.10. Transmissible cancers, and a comparison between CTVT and DFTD 
	
Prior to 2015, the only naturally occurring transmissible cancers known to exist were CTVT in 
dogs, and DFTD in Tasmanian devils. However, in 2015-16, six more transmissible cancers 
were reported. These were five cases of disseminated neoplasia in different species of molluscs 
(Metzger et al., 2015, Metzger et al., 2016); and Devil Facial Tumour 2 (DFT2), a second 
transmissible facial cancer affecting Tasmanian devils (Pye et al., 2016). DFT2 is grossly 
indistinguishable from the original DFTD, but the two tumours have distinct histopathological 
features and karyotypes, and they differ from each other and their host devils at microsatellite 
loci, structural variants and at MHC loci. The karyotype of DFT2 contains an X and a Y 
chromosome indicative of a male origin which contrasts to the female origin of DFT1 (Pye et 
al., 2016, Murchison et al., 2012). 
 
CTVT is an estimated 11,000 years old (Murchison et al., 2014) and has been the subject of 
extensive research since its transmissible nature was first noted in 1876. CTVT provides a 
useful comparison with DFTD given some striking similarities and pronounced differences. 
The following is a brief summary of three reviews comparing CTVT and DFTD (Murchison, 
2008, Siddle and Kaufman, 2012, Belov, 2012). 
 
DFTD’s malignant and fatal nature is the most pronounced difference between it and CTVT. 
Typical cases of CTVT rarely metastasise or cause fatality in immunocompetent hosts. 
Interestingly the tumours share the same immune escape mechanism of MHC-I down-
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regulation as they establish themselves in the host. This “progressive phase” of CTVT whereby 
only 3% of tumour cells express MHC-I is followed by the stationary or regressive phase, 
characterised by cessation of tumour growth. This phase is associated with increased 
expression of cell surface MHC-I, lymphocyte infiltration and increased levels of the host-
derived IFN-γ (Hsiao et al., 2008). The fact that MHC-I expression can be restored on both 
CTVT and DFTD cells demonstrates lack of expression is due to regulatory mechanisms rather 
than structural defects and has obvious implications for tumour recognition by the host immune 
system. Restoration of MHC-I expression occurs during the course of CTVT infection, 
suggesting this tumour has reached an equilibrium with its host, allowing the survival of both. 
This balance does not exist between DFTD and the devil. DFTD is currently driving its host 
toward extinction and by default itself. If time allows, DFTD may evolve to a less aggressive 
disease with up-regulation of MHC-I (reflecting the course of CTVT) providing one possible 
outcome of evolutionary development. 
 
Serum IgG antibody against CTVT cells has been demonstrated in CTVT-affected dogs, 
suggesting a humoral immune response to the disease (Cohen, 1980, Cohen, 1972). A humoral 
immune response in the form of IgG antibodies against DFTD cells was also evident in devils 
undergoing a DFTD immunisation trial (Kreiss et al., 2015). While cell-mediated immunity is 
primarily responsible for anti-tumor activity, IgG antibody production against DFTD is a 
significant finding in a disease characterised by its successful immune escape mechanisms.  
 
1.11. T lymphocytes and immunoglobulins:  indicators of immune function; the effect of 
cancer 
 
1.11.1. T lymphocytes  
 
The CD4+ T helper cells and CD8+ cytotoxic T lymphocytes have critical roles in cell 
mediated and anti-tumour immune responses, but they also act as indicators of immune 
function. The ratio of CD4:CD8 cells in the peripheral blood is used frequently in human 
medicine as an indicator of immune competence. This applies particularly to HIV infection but 
a reduced ratio is also associated with a variety of conditions including viral, parasitic and 
bacterial infections, trauma and malnutrition (Walker and Warnatz, 2006). 
 
 19 
Lymphopenia is a common finding in advanced cancer patients and all lymphocyte subsets are 
affected, in particular CD4+ lymphocytes (Whiteside, 2006, Kuss et al., 2004). Not only are 
there fewer T lymphocytes in patients with malignancies, but they show reduced responses to 
antigens and mitogens (Whiteside, 2006). This suggests cancer has an adverse effect on 
immune competence, and potentially increases susceptibility to infection (Kuss et al., 2004). 
 
The T lymphocyte subset populations are also affected by season, age and sex in humans, and 
this has been explored in some other species (Heaton et al., 2002a, Heaton et al., 2002b, Martin 
et al., 2008, Fares, 2013). A seasonal effect on total lymphocyte counts in healthy adult male 
Tasmanian devils has been recorded (Peck et al., 2015) although the same study found no 
significant differences between age groups or sex on lymphocyte or total white cell counts. 
 
Analysis of the peripheral blood T cell subpopulations has been used in human medicine to 
understand and predict organ transplant (allograft) rejection (Miqueu et al., 2010, Kreijveld et 
al., 2008, Cravedi and Mannon, 2009) suggesting this would also provide insights into DFTD’s 
behavior as an allograft. Patients experiencing organ rejection crises were shown to have 
significantly higher CD4:CD8 ratios than patients with stable graft function (Kiparski et al., 
1990). A study to determine the appropriateness of reducing immunosuppressive therapy in 
patients following renal transplant found that an increased CD4:T regulatory cell (Treg) ratio 
prior to cessation of medication was a strong predictor of graft rejection following medication 
withdrawal (Kreijveld et al., 2008). An alteration in naïve, effector and memory T cells over 
time was also observed in graft rejectors.  
 
CD4+ and CD8+ T lymphocytes have been identified in the lymphoid organs of healthy devils 
and those with DFTD (Howson et al., 2014). Due to a lack of appropriate reagents, T cell subset 
analysis of the peripheral blood of devils and how they are affected by DFTD has not been 
explored. 
 
1.11.2. Serum immunoglobulins  
 
The serum levels of plasma proteins such as IgM and IgG are altered in response to certain 
conditions including infection, trauma and neoplasia (O'Connell et al., 2005). The effect of 
DFTD on total protein, albumin and globulin levels in the serum of devils has been assessed 
(Peck et al., 2015, Peck et al., 2016) and examination of DFTD’s association with serum IgM 
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and IgG levels has been approached at the RNA level (Ujvari et al., 2016). Exploration of the 
globulin fractions in serum of devils with DFTD has not been carried out, and nor has DFTD’s 
effect on serum IgM and IgG at the protein level. 
 
While it was originally thought that immunoglobulins were only produced by B lymphocytes, 
the production and secretion of IgG by various epithelial cancerous cells (lung, liver, prostate, 
breast) has since been demonstrated (Niu et al., 2012, Chen and Gu, 2007, Qiu et al., 2003). 
These cancerous immunoglobulins (cIgG’s) are believed to have a dual function, promoting 
growth and proliferation of the cells, as well as providing protection against anti-cancer 
components of host serum (Lee, 2014). Past experiments have inadvertently found no evidence 
that DFTD cells secrete IgG. For example, the no serum controls for an IgG response against 
DFTD cells in both flow cytometry and ELISA were negative (Kreiss et al., 2015). Likewise, 
there was no evidence for the presence of IgG when DFTD sections were stained via 
immunohistochemistry (Howson et al., 2014). 
 
1.12. Anti-cancer antibodies in serum and their prognostic value 
 
A large number of tumour associated antigens (TAA’s) have been explored with respect to the 
humoral immune responses they induce and the associated prognostic value of the responses 
(Whiteside, 2006, Reuschenbach et al., 2009). Cell mediated (CMI) rather than humoral 
immunity tends to play the primary role in tumour immunity, particularly with respect to 
cytotoxic lymphocyte activity. However, demonstration of an antibody class switched humoral 
immune response against cellular immunogens is indicative of a CD4 T cell response. This 
typically occurs via presentation of peptides on the MHC class II molecules of antigen 
presenting cells (APCs) to T helper cells which then provide “help” to B cells and the 
subsequent proliferation of B cells and antibody production.  
 
Some antibodies against TAA’s seem to be markers of exposure or immunopathology rather 
than showing any functional relevance or protective role. Antibodies against p53 (tumour 
suppressor protein) and MUC1 (an epithelial mucin overexpressed in the majority of 
adenocarcinomas) have been explored for their prognostic value. Mutations of p53 are found 
in more than half of all cancers, and poor survival of patients with p53 antibodies has been 
demonstrated in many studies (Reuschenbach et al., 2009). In contrast, antibodies against 
MUC1 are associated with improved survival in cancer patients. It has been suggested that 
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cancer vaccines targeting the MUC1 antigens might benefit from addressing CD4 and B cell 
responses as well as cytotoxic cellular immune responses (Reuschenbach et al., 2009). 
 
Evidence of antibody production correlating with anti-tumour activity has been observed in 
human cases of breast and pancreatic cancers both of which express MUC1 antigens, as well 
as CTVT (Blixt et al., 2011, Hamanaka et al., 2003, Cohen, 1972). On the other hand, antibody 
responses in melanoma patients were associated with a poor prognosis (Zornig et al., 2014). 
 
The prognostic value of anti-DFTD antibodies is currently unknown. However, the relative 
ease of identifying antibody compared with cytotoxic responses applies particularly to wild 
animals for which sample collection and processing can be challenging, and for which there 
are few species-specific reagents available. Although serum antibodies against DFTD can be 
induced in immunised devils (Kreiss et al., 2015) there has been no convincing evidence of an 
antibody response against DFTD in wild devils.  Since there are few examples of disease being 
the primary cause of extinction of a species, it is not unexpected that some wild devils will 
survive a DFTD challenge presumably by way of a detectable immune response. 
 
1.13. Comparative immunology and wild immunology  
 
Comparative immunology is a discipline recognised since the 1960’s and is defined as the 
analysis of shared and diverging aspects of immunology among species (Wang et al., 2009). 
Evolutionarily distant species share several immunological features some of which are quite 
subtle, for example the conservation of TGF-b, vascular endothelial growth factor (VEGF) and 
various chemokines e.g. interleukin (IL) 8 in invertebrates and vertebrates. Growth factor and 
cytokine function can be shared across vertebrates as illustrated by human TGF-b’s effect on 
the function of fish macrophages (Conrad et al., 2007). 
 
In contrast, differences can occur between quite closely related species. Human and mouse 
immune systems are the most widely studied but do not always reflect those of other species. 
For example, both pigs and ruminants differ notably to humans in their T lymphocyte 
populations. These species have higher numbers of gd T cells in the peripheral blood (up to 
25% in adult cattle, 60% in calves) compared to humans and mice (1 - 5%). In humans, the 
function of these gd T cells is cytokine production, antigen presentation and immune regulation 
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whereas in ruminants they have a predominantly regulatory role (Guzman et al., 2014). 
Regarding CD4+ and CD8+ T lymphocytes, healthy pigs and ruminants have a significant 
peripheral blood population of double negative cells, and pigs also have a double positive cell 
population. Pigs have a higher percentage of CD8+ than CD4+ lymphocytes in their peripheral 
blood and lymphoid organs i.e. the inverse proportion of humans, mice and domestic species. 
They also have an inverted lymph node structure whereby the typical medullary tissue is 
external to the follicle-containing “paracortex” (Binns, 1982). 
 
The purpose for such variations is not clear, but presumably they provide novel mechanisms 
for antigen recognition and roles for regulatory function. While it is easy to find striking 
examples of conservation across species with respect to the immune system, differences are 
also apparent. These differences highlight the imprudence of automatically translating 
immunological findings from one species directly to another.  
 
Marsupials and eutherian mammals diverged nearly 150 million years ago so while variations 
are expected, research to date has found remarkable immunological similarities between the 
two groups. Many immune system components in marsupials are comparable to other 
mammalian species including lymph node architecture, cytokine production, and the role of 
MHC (Belov et al., 2013). The first marsupial species to have the presence of CD4 and CD8 
confirmed in their tissues were the opossum (Monodelphis domestica) and the tammar wallaby 
(Macropus eugenii). Signature features of both eutherian molecules were maintained in the 
marsupials (Duncan et al., 2007, Duncan et al., 2009). 
 
Differences between marsupials and eutherians include the lack of immunoglobulin D (Miller, 
2010), a single IgG allotype (Sun et al., 2013), and a T cell receptor (TCRµ) unique to 
marsupials (Parra et al., 2007). Little is known about the peripheral T cell subset populations 
of marsupials due to a lack of reagents. The recent development of an anti-koala monoclonal 
antibody binding fresh CD4+ T cells has allowed the characterization of this population of cells 
in healthy and diseased koalas (Mangar et al., 2016). The ability to do the same for devils 
would provide greater insight to their immune system. Not only would it allow for comparison 
with other species, but it would inform how the devil’s T cell population, critical for cell 
mediated immunity and anti-tumour responses, is affected by DFTD.  
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Comparative immunology has some crossover with wild immunology which is a relatively 
recent discipline that has emerged from the increasing recognition that immunity is affected by 
exposure to a wide range of pathogens (Jolles et al., 2015, Pedersen and Babayan, 2011, 
Babayan et al., 2011). Wild immunology has been proposed as the “missing link between 
laboratory based immunology and human, wildlife and domesticated animal health” (Pedersen 
and Babayan, 2011). While experiments on inbred strains of laboratory animals have made 
great contributions to immunology research, the highly controlled laboratory environment 
ignores the effects that genetic and environmental diversity play. These elements of diversity 
are central to wild immunology. The inherent limitations in studying wild animals include a 
lack of specific reagents and annotated genomes, along with the statistical constraints 
associated with individual and population variation. Much of this applies to Tasmanian devil 
immunology research, although the annotated genome is available (Murchison et al., 2012).  
 
Despite the limitations of wild immunology, successful studies have been carried out. For 
example, the wild population of Soay sheep was shown to demonstrate superior antibody 
responsiveness in association with reduced reproduction but increased survival in adult females 
i.e. immune and reproductive system tradeoffs (Graham et al., 2010). Antibody responses in 
wild compared to captive hyenas have highlighted the importance of environmental modulators 
of immunity (Flies et al., 2015). 
 
As alluded to, marsupial immunology research straddles both fields of comparative and wild 
immunology. DFTD has necessitated considerable advances in the understanding of the devils’ 
immune system and as such devil immunology has made notable contributions to these fields. 
The same can be said for koala immunology. Koalas share the status of iconic Australian 
marsupial with the devils, and are faced with disease threats from chlamydia and koala 
retrovirus (KoRV) just as devils are threatened by DFTD. Likewise, a chlamydia vaccine for 
koalas is being pursued just as vaccine development is one of the adopted approaches to address 
DFTD.  The parallels between koala and devil immunology research are marked, particularly 
with respect to exploring immune system responses of marsupial species for which few specific 
reagents are available. Together they exemplify the challenging and innovative disciplines of 
comparative and particularly wild immunology. 
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1.14. Epidemiology of DFTD and compensatory responses of devils to population decline  
 
DFTD was first observed in 1996 at Mount William National Park in the state’s far northeast, 
and has since spread to cover the majority of the state. Figure 1.7 shows its current distribution. 
Most pathogenic diseases are dependent on a critical density of their host population for 
transmission so when a population falls below a certain density, the causal pathogen dies out. 
However, DFTD prevalence is maintained in devil populations that have suffered significant 
(up to 90%) declines, which strongly suggests that DFTD follows a frequency dependent 
pattern of transmission (McCallum et al., 2009). This transmission pattern is typical of sexually 
transmitted diseases (STDs) and field studies indicate that bite wounds peak during the mating 
season giving DFTD characteristics of an STD (Hamede et al., 2008). 
 
 
Figure 1.7. Map of Tasmania showing the distribution of devil facial tumour disease (DFTD) from 
1996 to 2015. Each dot represents 1 case of DFTD confirmed by histology; stars represent locations 
mentioned in the text. 
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There is a high DFTD prevalence (at least 50%) amongst adult devils in populations where 
disease is well established (McCallum et al., 2009) and it is rare to find devils over three years 
of age in these areas despite a natural life expectancy of up to six years in the wild. There is no 
consistent evidence to show a difference between the sexes in DFTD prevalence (McCallum 
et al., 2009). 
 
A rise in precocial breeding by female devils in diseased populations, explained by increased 
food availability and growth rates resulting in earlier sexual maturity, demonstrates 
reproductive compensation for population decline (Lachish et al., 2009). These authors also 
noted that diseased females showed a propensity for producing female biased litters when 
compared to their healthy sisters suggesting that sex allocation bias is a result of DFTD 
infection. 
 
DFTD driven population decline may result in selection for more submissive individuals since 
it is the more aggressive devils that are likely to acquire infection (Hamede et al., 2013). 
However, this may be offset by the likelihood that more aggressive males will breed 
successfully. One study that explored particular regions of the devil genome in three 
geographically distinct populations found concordant signatures of genetic selection in all three 
populations after DFTD had entered the populations (Epstein et al., 2016). This hints at gene 
selection in response to DFTD and further research will determine if there is any association 
between those genes and increased devil survival or indeed DFTD resistance. 
 
1.15. Management options available to prevent species extinction 
 
A range of management options has been considered to save the Tasmanian devil from 
extinction which are summarised in Table 1.1 along with their advantages and disadvantages. 
Some options, such as captive breeding and translocation have already been successfully 
implemented, whereas others have either proved unsuccessful e.g. disease suppression, or are 
being currently researched e.g. vaccine development.  
 
This review has already alluded to DFTD evolution, and certainly the development of a less 
aggressive disease would favour survival of the host and by consequence the disease. It is 
possible that a more benign form of DFTD will evolve given enough time and devil hosts, and 
it is conceivable that implementation of certain management options might interfere with the 
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evolutionary process. However, given the rapid and devastating effects of DFTD to date with 
no real evidence for these abating, it would be irresponsible to neglect intervention and let the 
disease take its course knowing the implications of devil extinction. 
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Table 1.1. Proposed management tools to save the Tasmanian devil from extinction  
Management tool Reasoning Advantages Disadvantages 
Captive breeding 
Captive breeding provides an insurance 
population in case a species becomes 
extinct in the wild. One of the first 
initiatives to save the Tasmanian devil 
from extinction was the establishment of a 
captive insurance population, which 
currently holds approximately 500 
individuals. Ideally 95% of the genetic 
diversity present in the founder population 
is represented within these captive devils. 
Different management breeding options 
utilised include: 
Intensive breeding; devils are kept in 
isolation or small groups and mate 
selection is strictly controlled during the 
breeding season 
Extensive breeding; devils are kept in 
groups in large double-fenced areas. 
Breeding is loosely controlled, mate 
choice is largely defined by the animal 
Eliminate risk of DFTD 
with appropriate 
quarantine regulations 
Target breeding to 
preserve genetic 
diversity 
Availability of 
individuals for research 
projects to further the 
understanding of devil 
and DFTD biology 
Expensive 
Devils might lose ‘wild’ 
behaviour 
Decreasing fecundity 
with each generation 
Genetically important 
animals might not breed 
Post-breeding animals 
require ongoing care 
Vaccine 
development 
An effective vaccine against DFTD might 
allow the repopulation of DFTD-affected 
areas with vaccinated devils from the 
current captive insurance population. It is 
conceivable that disease-free wild devils 
could be vaccinated in significant numbers 
given that many populations have proven 
amenable to trapping and handling.  
One encouraging aspect regarding the 
likelihood of vaccine development is the 
high conservation of tumour morphology 
and genotype implying that tumour 
antigens are conserved, thus giving the 
immune system a stable target. (Woods et al., 2015) 
Opportunity to prevent  
disease 
Possibility to induce 
‘herd immunity’ 
Complements other 
management strategies 
The process of vaccine 
research improves the 
understanding of devil 
immunology and DFTD. 
This knowledge could be 
applicable to other 
marsupials and other 
transmissible cancers 
Expensive to produce and 
to deliver 
Need to trap the animals 
for injection 
Current research suggests 
the need for several 
boosters 
It might change disease 
dynamics and DFTD 
evolution 
Population 
reinforcement 
This term refers to the reintroduction of a 
species to its indigenous habitat with the 
aim of enhancing the local population. 
Several areas of Tasmania have had drastic 
declines of the devil population following 
DFTD appearance and these areas would 
be suitable for reinforcement. 
 
To augment the local 
population and thus re-
establish the ecosystem 
balance that existed prior 
to DFTD’s arrival 
Improve genetic 
diversity 
Reintroduced healthy 
devils will be at risk of 
contracting DFTD 
Devils might disperse 
elsewhere. 
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Management tool Reasoning Advantages Disadvantages 
Translocation 
The first translocation of Tasmanian devils 
occurred at the end of 2012, to Maria 
Island. Other islands offshore of Tasmania 
are being considered. 
 
Islands’ natural 
boundaries prevent the 
incursion of diseased 
animals 
Devils can retain ‘wild 
behaviour’ 
Once the population is 
established, reduced 
management compared 
to other populations. 
 
Impact on other species 
and the ecosystem 
balance 
Need to monitor for 
inbreeding, 
overpopulation and 
welfare. 
 
 
Disease 
suppression 
through culling 
 
A disease suppression trial took place in a 
semi-isolated peninsula in the southeast of 
Tasmania between 2004 and 2010. 
DFTD’s prevalence remained the same as 
other unmanaged sites. This management 
tool is ineffective because of the long 
incubation period, frequency-dependent 
nature of DFTD, no current pre-clinical 
test and the failure to capture trap-shy 
animals. (Beeton and McCallum, 2011)  
 
Possibility to keep a 
functional population in 
its original area 
Animals can be 
euthanised before the 
onset of severe clinical 
illness. 
 
Unfeasible unless a high 
proportion of the 
population is trapped(Beeton 
and McCallum, 2011) 
It does not allow for 
natural resistance to 
develop 
Possible change in 
tumour biology (Ujvari et al., 
2014) 
Fencing 
Fencing has been used as part of wildlife 
management in different contexts with 
varying degrees of success. (Poor et al., 2014, Phillips 
et al., 2012) 
Provides a barrier to 
DFTD 
 
Expensive 
Chance that incursion of 
diseased animals might 
occur 
Interfering with the 
ecosystem and natural 
flow of native animals in 
and out of the area 
Need to monitor for 
inbreeding and 
overpopulation 
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1.16. DFTD vaccine development 
 
1.16.1. Rationale for DFTD vaccine development 
 
The highly conserved DFTD cell morphology and genotype lends itself to vaccine development 
(Woods et al., 2007) as does the demonstration that DFTD cells are immunogeneic (Kreiss et 
al., 2015). Likewise, evidence that devils have effective T cell function and the ability to mount 
an antibody response to immunisations (Kreiss et al., 2015, Brown et al., 2011) support vaccine 
research. Finally, the ability to up-regulate MHC-I on DFTD cells in vitro provides scope for 
vaccine development with the likelihood that MHC expression of foreign antigen will establish 
allorecognition (Siddle and Kaufman, 2012). 
 
The development of a protective vaccine against DFTD would allow a vaccination protocol to 
be included as part of the Save the Tasmanian Devil Program’s “wild devil recovery” project 
(DPIPWE). The aim of the project is to release devils from the captive insurance population 
and Maria Island (home to a translocated DFTD-free devil population) to augment wild 
populations that have been decimated by DFTD (Samantha Fox pers. comms 2016). It is also 
conceivable that populations of wild devils could be effectively vaccinated given that 
approximately 80% of devils should enter traps (Beeton and McCallum, 2011).  
 
Although development of a protective DFTD vaccine is challenging, the progress made to date 
is encouraging and has advanced the understanding of this cancer and the devil’s immune 
system. Transmissible cancers and marsupial immunology are two unique fields of research. 
Exploring their underlying features provides further insight into the immune escape 
mechanisms of transmissible cancers and the immune systems of marsupials that may have 
applications beyond the more immediate goal of DFTD vaccine development.  
 
1.16.2. Cancer vaccines 
 
Anti-cancer immunisation is a complex, multifactorial field and the optimal combination of 
antigens and adjuvants for different cancers is under active investigation (Melero et al., 2014). 
The antigenic basis of a vaccine requires a choice between whole tumour cells and isolated 
tumour peptides. Whole tumour cell vaccines utilise an array of tumour associated antigens 
(TAA’s) containing epitopes for both cytotoxic T cells and T helper cells. The simultaneous 
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presentation of both MHC-I and MHC-II restricted antigens theoretically provide the 
advantage of generating a stronger overall anti-tumour response (Chiang et al., 2010). The 
alternative approach is to use isolated tumour peptides. A primary benefit of this method is that 
the risk of tumour development due to administration of whole cell derived preparations is 
eliminated. The drawbacks of peptide only vaccines include the difficulty of identifying 
appropriate antigens, and the increased risk of tumour escape with single epitopes (Chiang et 
al., 2010). 
 
Some studies show better clinical outcomes using whole cell tumour vaccines compared to 
defined antigen (Neller et al., 2008). Since DFTD research to date has relied on the whole 
tumour cell preparations (Brown et al., 2011, Kreiss et al., 2015) an overview of this approach 
is provided here.  Whole tumour cell vaccines require the cells to be made non-viable to prevent 
tumour inoculation developing out of the vaccine. Similarly, live tumour cells are often poorly 
immunogeneic and some can suppress immune responses (Chiang et al., 2010). These issues 
are addressed by using necrotic or apoptotic tumour cells. Necrosis is traumatic cell death due 
to injury and differs to apoptosis, also known as programmed cell death, which is a regulated 
and controlled process. There are numerous methods to achieve these states, all of which can 
enhance the immunogenicity of the cells in the process.  
 
The most common method to induce necrosis of tumour cells is freeze-thaw cycles. Necrotic 
cells release heat shock proteins (HSPs) which are involved in antigen binding and presentation 
to the immune system. This makes them potentially useful adjuncts to cancer vaccines (Chen 
et al., 2009). Gamma irradiation results primarily in apoptotic cell death, with necrosis less 
likely (Baskar et al., 2012). High dose gamma irradiation of a variety of tumour cells has been 
associated with increased immunogenicity due to increased surface MHC-I expression (Reits 
et al., 2006); increased expression of surface MHC class I/II antigens and ICAM-I molecules 
(Chiriva-Internati et al., 2006); and cell surface translocation of calreticulin which promotes 
phagocytosis (Obeid et al., 2007). Radiation dosages in these studies ranged from 10 to 25 Gy 
and the expression of surface molecules and/or antigens increased with the dose. Single gamma 
irradiation doses of up to 80 Gy (Driessens et al., 2004, Zilberberg et al., 2011) have been used 
to induce apoptosis of tumour cells prior to their inclusion in cancer vaccines.   
 
Tumour cell lysates have been described as ideal sources of a variety of TAA’s associated with 
MHC-I and MHC-II molecules (Gonzalez et al., 2014). They are simple to produce and 
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methods include UVB radiation and hyperthermia treatment (Chiang et al., 2015). Sonication 
is another method for cell lysate production and acts by disrupting cell membranes with pulsed 
high frequency sound waves.  
 
Increased immunogenicity of tumour cells is provided not only by inducing necrosis and/or 
apoptosis, but also by in vitro stimulation with cytokines. This can result in the increased 
expression of MHC-I, ICAM-I, ICAM-II and VCAM-I molecules, and possibly other 
molecules required for T cell activation (Guo et al., 1997). One disadvantage is the potential 
for cytokine incubation to up-regulate inhibitory molecules e.g. PDL1 on the tumour cell 
surface (Flies et al., 2016). Finally, the combination of gamma irradiation and cytokine 
incubation of tumour cells prior to their administration as a vaccine has been shown to have an 
additive effect with respect to the up-regulation and expression of cell surface antigen (Santin 
et al., 1996). 
 
Adjuvants enhance the immune response to antigen and are frequently included in cancer 
vaccines due to the poor immunogenicity of tumour cells (Guo et al., 2013). The appropriate 
response elicited by a cancer vaccine is activation of cytotoxic T lymphocytes and IFN-g-
producing type 1 T helper cells (Th1) (Melero et al., 2014). A skewed response toward type 2 
T helper cells (Th2) which generate a primarily humoral immune response is generally 
considered undesirable in cancer immunity. Adjuvants can target immune cells, influence the 
Th1-Th2 response, stimulate cytokine production and may reduce the required number of 
injections (Lefeber et al., 2003). Various adjuvant types e.g. oil emulsions, toll like receptor 
(TLR) agonists, and immune stimulatory complexes (ISCOMs) are often used in combination 
since single adjuvants tend not to result in clinically relevant anti-tumour activity (Melero et 
al., 2014). The interest in TLR agonists for cancer immunotherapy and cancer vaccine 
adjuvants, and the confirmation that devils have functional TLR’s has seen current research 
focus on TLR agonists as useful adjuvants for DFTD vaccines (Patchett et al., 2015). 
 
1.16.3. DFTD vaccine research to date 
 
Immunisation trials have been carried out on a number of captive devils to date. The small 
sample size is a recurrent limiting factor but this has not prevented notable advances in DFTD 
vaccine development. Most important has been the demonstration that induction of an immune 
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response against DFTD cells is possible. This is noteworthy for a tumour characterised by its 
successful immune escape mechanisms.  
 
A trial in 2011 in which two devils were immunised with four monthly doses of irradiated 
DFTD cells and montanide, an oil-based adjuvant, did not produce humoral or cell mediated 
immune responses against DFTD (Brown et al., 2011). However, subsequent trials on a total 
of eight devils using either freeze-thawed, irradiated or sonicated DFTD cells resulted in 
antibody and cytotoxicity responses in most devils (Kreiss et al., 2015). These cell preparations 
included montanide alone or in combination with CpG (a TLR agonist) as adjuvants. It was 
postulated that the inclusion of CpG to activate innate immune cells promoted the immune 
responses.  
 
The humoral immune responses in this study were measured by detecting serum IgG antibody 
using ELISA, flow cytometry and western blots. Cytotoxic responses were assessed with a 
radioactive chromium release assay. It was thought unlikely the observed cytotoxic responses 
were mediated by CD8+ T cells since the DFTD cells in the assay did not express MHC-I. 
However, if IFN-g was produced during the assay culture, this could up-regulate MHC-I 
expression and promote CD8+ T cell activity. An alternative explanation for the cytotoxicity 
was NK killing. Since there were no cytotoxic responses in non-immunised devils, spontaneous 
NK cell activity is unlikely. However, activation of NK cells may have occurred as a result of 
immunisation and translated to in vitro cytotoxic activity.  One devil in the study resisted a 
DFTD challenge after demonstrating an antibody response, although it succumbed to a second 
challenge. The authors suggested other immunisation approaches could include DFTD cell 
modification to up-regulate MHC-I expression, consideration of alternative adjuvants, and 
isolation of tumour associated antigens. 
 
1.16.4. Koala chlamydia vaccine research 
 
As mentioned previously, there are parallels between devil and koala immunology. This applies 
particularly because research in both fields is directed toward developing protective vaccines 
against diseases that are threatening these iconic marsupials. With respect to the vaccine 
development, there are obvious differences between the target pathogens i.e. transmissible 
cancer cells of Schwann cell origin compared to intracellular bacteria which primarily infect 
mucosal tissue. Another disparity is the knowledge base for chlamydia immunobiology which 
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reflects its importance in human health. Even so, a preventative chlamydia vaccine for people 
is still not available. The immune response against chlamydia infection requires both T cell 
(CD4+ Th1 cells in particular) and B cell activity demonstrating that an effective vaccine needs 
to target both the cell mediated and humoral arms of the immune response (Brunham and Rey-
Ladino, 2005, Hafner et al., 2014, Khan et al., 2016). Presumably T cell immunity is of primary 
importance for anti DFTD activity, and the role of humoral immunity is uncertain.  
 
It is perhaps most useful to compare the immunisation protocols and testing of immune 
responses for devils and koalas. This is particularly true because the lack of available 
immunological reagents hampers the assessment of responses in both species. The vaccine 
preparation for koalas has relied on the recombinant chlamydia major membrane outer protein 
(rMOMP) as the antigen. Adjuvants have varied in the trials and include aluminum hydroxide 
gel, TiterMax Gold (which caused abscesses), a combination of poly I:C, polyphosphazene and 
host defence peptide, and Immune stimulating complex (ISC Pfizer/Zoetis) (Carey et al., 2010, 
Khan et al., 2014, Waugh et al., 2015, Waugh et al., 2016). Schedules have comprised a single 
dose, two doses at monthly intervals, and, more often, three doses at monthly intervals. 
Subcutaneous injection has been the usual route of administration but the response obtained by 
the intranasal route was also assessed (Waugh et al., 2015).  
 
Methods to measure the humoral immune response required the preparation of anti-koala IgG. 
Serum IgG antibodies have been detected via ELISA using host specific C. pecorum MOMP 
or whole chlamydia “entire bodies” as antigen. Epitope specificity has been explored with 
PepScan methodology (Waugh et al., 2016). In vitro neutralisation assays are also employed 
(Carey et al., 2010, Waugh et al., 2015). Cell mediated immune responses were addressed by 
assessing total peripheral blood mononuclear cell proliferation, and CD4 proliferation in 
response to stimulation with chlamydia antigen (Waugh et al., 2015, Mangar et al., 2016). A 
chlamydia vaccine trial on 30 free-ranging koalas was carried out in 2013-14 (Waugh et al., 
2016). Despite the differences in target pathogens and availability of some reagents, there is 
considerable scope for aspects of koala immunology/ chlamydia vaccine development and 
devil immunology/ DFTD vaccine development to be applied to each other. 
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1.17. Ecological impacts of a declining devil population 
 
The devil is Tasmania’s top order land predator and as such is a highly interactive keystone 
species. Consequently, its decline is expected to have significant deleterious impacts on 
Tasmania’s ecosystem by advantaging feral predators. Changes in feral cat behaviour and 
possibly their increased abundance have been reported (Fancourt et al., 2015, Hollings et al., 
2014). Devils may have prevented fox incursions in Tasmania from establishing in the past and 
thus protected the state’s native fauna from the devastating effects foxes have had on the 
Australian mainland (Hawkins et al., 2006). Devils are specialised scavengers and the expected 
increase in carrion in the environment due to declining devil numbers could favour alternative 
scavengers (e.g. forest ravens), further disrupting the ecosystem balance (McQuillan, 2009). 
Thus, the devils’ role in maintaining a healthy Tasmanian ecosystem is critical. Declining devil 
populations are already having measurable effects, and the extinction of the species in the wild 
would have profound consequences. 
 
1.18. Final remarks 
 
DFTD is a unique cancer that has developed strategies to avoid the devil’s immune response 
and capitalised on the biting behaviour of devils to allow transmission between individuals. It 
has resulted in the suffering of countless devils and is having serious implications for 
Tasmania’s ecosystem. Nonetheless, DFTD has provided unique opportunities to study 
transmissible cancers, including mechanisms of cancer cell transfer and immune escape. 
Likewise, it has necessitated the advancement of Tasmanian devil immunology. 
 
While there is evidence of compensatory reproductive responses to population decline, and 
suggestion of genetic selection in response to DFTD, the future for the wild devil is not 
guaranteed. According to the literature, prior devil population bottlenecks have not been due 
to disease, and the likelihood of the species recovering from the DFTD epidemic unassisted is 
untested.  As such, attempts to preserve the wild devil population through human intervention 
in the form of well-considered management plans and vaccine development are warranted.  
 
DFTD vaccine research brings together the unusual fields of transmissible cancers and 
marsupial immunology. A deeper understanding of tumour immune escape mechanisms along 
with improved knowledge of a unique species’ immune system is likely to have relevance 
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beyond DFTD and devils. Securing the future of the wild Tasmanian devil and by extension 
the Tasmanian ecosystem is reason enough to pursue the development of a protective DFTD 
vaccine. It is opportune if the results have broader applications. 
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Aims of thesis 
 
Aim 1: To measure the peripheral blood T lymphocyte subset populations and serum 
levels of IgM and IgG in healthy devils, and analyse the effects of age, sex, season and 
DFTD status on each of these. 
 
T lymphocyte subsets and immunoglobulins provide useful indicators of immune competence, 
and have been assessed in the lymphoid organs of healthy devils and those with DFTD. The 
effects of DFTD on haematology and serum biochemistry parameters in the Tasmanian devil 
have been published. However, DFTD’s effects on the immunological components of the 
devil’s peripheral blood require exploration.  
 
Aim 2: To look for the presence of an immune response against DFTD in wild Tasmanian 
devils in the form of serum anti-DFTD IgG antibodies and/or infiltrating T lymphocytes 
in tumour biopsies.  
 
DFTD is an aggressive cancer with most devils dying within 6 to 12 months of clinical signs 
first appearing. The literature suggests that DFTD always escapes the devil’s immune system 
and that death is the inevitable consequence of infection. These assumptions were revisited for 
this aim. Devils that had reportedly undergone tumour regression were included in this study. 
 
Aim 3: To immunise captive devils with irradiated DFTD cells modified to express 
surface MHC-I, and assess the devils’ subsequent immune responses and the 
consequences of a live DFTD cell challenge. 
 
DFTD vaccine development has been underway since 2006.  The conserved morphology of the 
DFTD cell and the devil’s demonstrated ability to mount immune responses against DFTD cell 
preparations make vaccine development a reasonable goal. The epigenetic down-regulation of 
the major histocompatibility complex class I molecule (MHC-I) is considered a principle 
mechanism by which the DFTD cells escape the devil’s immune response. This down-
regulation is reversible and DFTD cells incubated with the cytokine interferon gamma (IFN-g) 
express surface MHC-I. These MHC-I+ve cells are expected to be immunogeneic and provide 
further scope for vaccine development. 
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Aim 4: To assess the immune responses to the immunisation protocol used in Aim 3 on 
19 devils prior to their wild release. To also assess the effects age and sex had on the 
responses. 
 
The state government’s Save the Tasmanian Devil Program’s “wild devil recovery project” 
allowed for the immunisation protocol used in a trial from Aim 3 to be carried out on captive 
held devils prior to their wild release. The relatively large sample size allowed the immune 
responses to be more robustly assessed than had been possible in previous trials. Follow up 
monitoring trips would allow the duration of immune responses to be assessed in devils that 
remained in the vicinity of the release site. 
 
Aim 5: To determine if immune cross-recognition of DFT1 and DFT2 occurs in devils by 
assessing the serum IgG antibody responses to DFT2 in wild and immunised devils that 
had antibody responses to DFT1. 
 
While this thesis was underway a second transmissible cancer affecting Tasmanian devils was 
discovered. This was named DFT2 and bears similar morphological features to DFT1 (the first 
DFTD). However, there are profound differences between the two tumours at the molecular 
level, and genetic analyses confirmed that DFT2 arose independently to DFT1. This aim was 
to explore whether similar antigens occur on the two tumours, allowing for immune cross-
recognition by devils. 
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Chapter 2. General Materials and Methods  
 
 
2. 1. Materials 
 
 
Table 2.1. Reagents (not including antibodies). 
 
Reagent name Supplier Catalogue number 
 
Antibiotic-Antimycotic  
 
Life Technologies 15240-062 
Amniomax 
 
Life Technologies 11269-016 
Bovine serum albumin 
(BSA) 
 
Sigma-Aldrich A7906-100G 
Cell Trace ™ Violet Cell 
Proliferation Kit 
Life Technologies C34557 
Concanavalin A (Con A) 
 
Sigma-Aldrich C 7275 
CpG oligonucleotide 1585 
(CpG 1585) 
 
GeneWorks 1141231 
CpG oligonucleotide 2395 
(CpG 2395) 
 
GeneWorks 1141232 
Diamidino -2-Phenylindole, 
Dihydrochloride (DAPI) 
 
ThermoFisher D1306 
Diaminobenzidine (DAB) 
solution 
 
Dako K3466 
Dimethyl sulfoxide (DMSO) 
 
Sigma-Aldrich D-5879 
Envision Plus System – HRP 
labelled polymer Anti-Mouse 
 
Dako K4001 
Envision Plus System – HRP 
labelled polymer Anti-Rabbit 
 
Dako K4003 
Eosin 
 
Sigma-Aldrich 2853 
Ethanol 
 
Sigma E-7023-1L 
Foetal bovine serum  
(FBS) 
 
Bovogen SFBSF7 
Formalin, 10% neutral 
buffered 
 
Fronine ENNJJ019 
GlutaMAX™ Life technologies 35050-061 
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Reagent name Supplier Catalogue number 
 
Haematoxylin 
 
Sigma-Aldrich 517-28-2 
Hydrochloric acid (HCl) 
 
VWR VWRC20255.290 
Hydrogen Peroxide Sigma-Aldrich 676-3 
 
Interferon gamma (IFN-g) 
recombinant devil 
 
WEHI not a commercial product 
ISCOMATRIX™ CSL Ltd, Victoria, Australia 
 
not a commercial product 
ISOTHESIA® 
Isoflurane  
 
Henry Schein, Northgate, 
Australia 
050031 
Methanol 
 
Merck 4.10232.2500 
Protein block serum free Dako X0909 
 
Phosphate buffered saline 
(PBS) tablet 
 
OXOID BR0014G 
Poly(I:C) 
 
Sigma-Aldrich 42424-50-0 
Propidium iodide (PI) 
 
Sigma-Aldrich P4170 
RNAlater® 
 
Qiagen 1018087 
Roswell Park Memorial 
Institute 1640 medium 
(RPMI) 
 
Life Technologies 11875-093 
Sodium azide 
 (NaN3) 
BDH AnalaR 301112G 
 
Sodium bicarbonate 
(NaHCO3) 
Sigma-Aldrich S5761 
Target Retrieval Solution  Dako 
 
S1699 
TMB  
SureBlue™ TMB Microwell 
Peroxidase Substrate 
 
KPL 52-00-01 
Trypan blue (TB) 
 
Chroma 11661 
 
Tween®20 Sigma P1379 
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Table 2.2. Antibodies used for ELISA, flow cytometry and immunohistochemistry. 
 
Antibody Supplier Catalogue number or  
ID ± concentration if not a 
commercial antibody 
 
IgG 
goat anti-mouse Alexa 
Fluor® 488 
 
ThermoFisher A-11001 
IgG 
goat anti-rabbit Alexa 
Fluor® 647 
 
ThermoFisher A32733 
IgG 
goat anti-mouse Alexa 
Fluor® 647 
 
Life Technologies A21235 
CD3 
polyclonal rabbit anti-human  
 
Dako A0452 
CD4 
monoclonal mouse anti-devil  
 
Walter and Eliza Hall 
Institute 
 
8C9  
3.4 mg/ml 
 
CD4-AF647 
monoclonal mouse anti-devil  
 
Walter and Eliza Hall 
Institute 
 
7H9 
 
CD8 
monoclonal mouse anti-devil  
 
Walter and Eliza Hall 
Institute 
 
10E8  
4 mg/ml 
 
MHC-II 
anti-human HLA-DR  
 
Dako M0746 
CD79b 
rat anti-mouse  
 
AbD Serotec MCA2209 
Periaxin 
rabbit anti-human  
 
Sigma-Aldrich HPA001868 
Beta 2 microglobulin (β2m) 
mouse anti-devil 
Provided by Hannah Siddle 13-34-45 
 
IgG 
monoclonal mouse anti-devil 
 
Walter and Eliza Hall 
Institute 
 
A4D1  
2mg/ml 
 
IgM 
monoclonal mouse anti-devil  
 
Walter and Eliza Hall 
Institute 
 
46-11-8B6  
2 mg/ml 
 
mouse IgG2b isotype 
 
LifeSpan BioScience LS-C149303 
Polyclonal Goat Anti-Mouse 
Immunoglobulins/HRP 
 
Dako P0447 
Polyclonal Goat Anti-Rabbit 
Immunoglobulins/HRP 
Dako P0448 
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Table 2.3. Disposables. 
 
Disposables Supplier Catalogue number 
 
Cell culture cluster, 96 well 
round bottom with lid 
 
Corning 3799 
Centrifuge tube 10 ml 
 
Thermo Fisher LBSCT1003X 
 
Centrifuge tube 15 ml 
 
Corning Inc 430791 
Centrifuge tube 50 ml 
 
Corning Inc 430829 
Clot activating tube 9 ml 
 
Greiner Bio-one 455092 
Costar® Assay Plate, 96 well 
clear, flat bottom 
Corning 9018 
Cryogenive vial 2 ml 
 
Corning 430488 
Lithium heparin tube  
9 ml 
 
Greiner Bio-one 455084 
Microcentrifuge tubes 1.5ml Sigma Aldrich 80-1500 
 
Microscope slides 
Flex IHC 
 
Dako K8020 
Needle 21 G x 1” 
hypodermic 
 
Terumo 2125RL 
Pipette tips 0.1 – 20 µl 
 
Edwards Instruments Co. 1151-965-008 
Pipette tips 02 – 200 µl 
 
Edwards Instruments Co. 1030-260-000 
Pipette tips 50 – 1000 µl 
 
Edwards Instruments Co. 1057-965-018 
Punch biopsy 4 mm Kai Medical 
 
1072022 
Syringe 10ml  
 
Terumo SS+10S 
Syringe 3 ml 
 
Terumo SS+03S 
Syringe 5 ml 
 
Terumo SS+05S 
Tissue culture flask T25 
 
Corning 430639 
Tissue culture flask T75 
 
Corning 430720 
Transfer pipette 3 ml LabServ LBSCNF108 
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Table 2.4. Equipment. 
 
Equipment name 
 
Supplier 
Anaesthetic machine 
Stinger ST 205 
AAS-Advanced Anaesthesia Specialists 
Autoprocessor ASP 200S 
 
Leica 
BD CANTO II flow cytometer 
 
Becton Dickinson 
Centrifuge 
Allegra ® X-12 
Beckman Coulter 
Class II biological safety cabinet 
S@femate 1.2 
 
Bio Cabinets 
Incubator 
Heraeus 
Function Line 
Light microscope 
 
Olympus 
Microscope camera 
 
Leica 
Neubauer chamber (cell counts) 
 
Sigma-Aldrich 
Portable pulse oximeter 
 
VetQuip 
SpectraMax M2 Multi-Mode Microplate 
reader 
Molecular Devices 
Ultrasonic cell disruptor 
 
Misonix Inc. 
Varian Clinac 23-EX linear accelerator 
(Holman Clinic, Royal Hobart Hospital) 
 
Varian Medical Systems Inc. 
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Solutions prepared in the laboratory:  
 
Blocking buffer 
200 ml PBS + 2 ml FBS + 0.2 g BSA + 1 ml 5% azide 
 
Carbonate buffer 
2.1 g NaHCO3 in 250 ml Milli-Q ® water, pH 8.2 
 
Complete Medium (CM)  
RPMI 1640 supplemented with 10% FBS, 1% GlutaMAX™ and 1% Antibiotic-Antimycotic 
  
Con A supernatant (“Con A sup”)  
supernatant of Tasmanian devil PBL’s stimulated with 5 µg/ml Concanavalin A for 48 hours 
in culture medium 
 
FACS buffer  
PBS (prepared from tablets) + 1% BSA + 0.1% NaN3 
 
Freezing medium (2x concentrate)  
20 ml DMSO + 80 ml FBS (i.e. 20% DMSO) 
 
Phosphate Buffered Saline (PBS) 
PBS tablets x 5 in 500 ml Milli-Q ® water, stirred with a magnetic stirrer 
 
Stop solution 
1 Molar HCl 
 
Washing buffer 
500 µl Tween + 1 L PBS 
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2.2. Methods - Laboratory  
 
2.2.1. Immunohistochemistry 
 
Standard haematoxylin and eosin (HE) and immunohistochemical staining were performed on 
three-micrometre paraffin sections from tumour tissues fixed in 10% neutral buffered formalin, 
embedded in paraffin wax and sectioned (3 µm) onto 3-aminotriethoxysilane (Sigma-Aldrich) 
coated slides. HE staining was performed at Pathology South laboratory at the Royal Hobart 
Hospital. 
 
Primary antibodies and their dilutions for immunohistochemistry were as follows:  
anti-devil CD4 (1:50)  
anti-devil CD8 (1:100) 
anti-mouse CD79b (1:400) 
anti- human HLA-DR (MHC-II) (1: 40) 
anti-human CD3 (1:300) 
anti-human periaxin (1:300) 
 
The IHC method used was that described in (Howson et al., 2014). In brief, sections were 
deparaffinized in a histology oven at 60 ºC for 15 minutes followed by two five-minute washes 
in xylene and rehydration through successive graded ethanol solutions and washed for five 
minutes in distilled water. Heat-induced antigen retrieval was carried out in citrate buffer, pH 6 
(Dako, Carpinteria, CA) using an electric pressure cooker at medium heat for ten minutes, 
followed by a 20-minute cooling period at room temperature. The slides were incubated with 
serum-free blocking solution (Dako) for 30 minutes and then incubated with the primary 
antibody for one hour. The slides were then immersed in 3% hydrogen peroxide in phosphate-
buffered saline (PBS) for ten minutes at room temperature to quench endogenous peroxidase 
activity. The anti-mouse or ant-rabbit EnVision System, HRP, (Dako) was used for signal 
detection. Liquid DAB1 Substrate Chromogen System (Dako) was added to each slide and 
incubated for ten minutes. The sections were counterstained with hematoxylin and mounted. 
 
Assessment of the biopsy samples and staining for Chapter 4 was performed by a veterinary 
pathologist, and for Chapter 5 by a pathology registrar (in human pathology).  
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A light microscope (Olympus-BX50) coupled with a camera (Leica-DFC320) was used for 
visualization and acquisition of the images.  
 
2.2.2. Serum separation 
 
Blood samples were collected into clot activating tubes. After a minimum of 30 minutes (to 
allow clot formation) the tubes were centrifuged at 1000 g for 10 minutes. The serum was 
pipetted off and aliquoted and stored at -20 °C (short term) or -80 °C (long term). 
 
2.2.3. Peripheral blood lymphocyte (PBL) isolation 
 
Reagents were warmed to room temperature prior to use, and the following steps carried out 
under sterile conditions. Blood samples collected into lithium heparin tubes were diluted 1:1 
with PBS. Up to 8 ml of the diluted blood was then overlayed on 4 ml Histopaque 1077® in 
15 ml tubes. Tubes were centrifuged at 400 g for 30 minutes, with no brake. The mononuclear 
cells at the interface was pipetted off with a 3 ml transfer pipette. Cells were washed twice in 
RPMI 1640, centrifuged at 200 g for 10 minutes each time. The pellet was resuspended in 
complete medium and a cell count performed on a Neubauer chamber. 
 
2.2.4. Cell culture of established cell lines 
 
Three different DFT1 cell lines (C5065 = strain 3, year of origin 2007; 1426 = strain 2, year of 
origin 2005; and Ed = strain 2, year of origin 2012) were maintained in T75 flasks with 
Complete Medium. 
Two different DFT2 cell lines (Snug/ TD500, year of origin 2014; and TD549, year of origin 
2015) were maintained in T75 flasks with Complete Medium + 20% Amniomax.  
 
All cells were kept at 35 °C in a humidified atmosphere of 5 % CO2 in air. 
 
2.2.5. Up-regulation of surface expression of MHC-I on DFTD cells 
 
DFTD cells were treated with recombinant devil INF-γ (50 ηg/ml added to CM) and incubated 
for 24 hours at 35 °C in a humidified atmosphere of 5% CO2 in air. The MHC-I surface 
expression was confirmed by flow cytometry (see 2.2.7). 
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2.2.6. Cell counts 
 
Counts of tumour cells and peripheral blood lymphocytes were performed with a Neubauer 
Chamber and a light microscope using the 200 or 400 x objective. 10 µl of sample was mixed 
with 10 µl trypan blue and pipetted onto the counting chamber. Cells in the central 25 squares 
were counted. Total cell concentration (TCC) was calculated using the formula: 
 
TCC/ ml = number of cells counted x (25/ number of squares counted) x dilution factor x 104 
 
2.2.7. Flow cytometry 
 
CD4 staining on devil PBL’s 
 
PBL’s were washed and resuspended in FACS buffer at 106 cells/ml. 200 µl of sample was 
incubated with mouse anti-devil CD4 AF647 (1:4,000) for 30 minutes on ice. Cells were 
washed twice, resuspended in DAPI (3 µM) and analysed with the Canto flow cytometer. 
 
To confirm surface expression of β2m (a component of MHC-I) on DFTD cells: 
 
INF-γ treated cells were washed 3 times with FACS buffer before each of the following steps. 
Cells were incubated with mouse anti-devil β2m (1:200) for 30 minutes on ice. Cells were then 
incubated with goat anti-mouse IgG Alexa Fluor® 647 (1:1,000) for 30 minutes on ice. They 
were re-suspended in 200 µl FACS buffer containing 3 µM PI to allow gating of dead cells, 
and analysed by flow cytometry (BD Canto II).   
 
To detect anti DFTD IgG antibody: 
 
DFTD cells were washed 3 times with FACS buffer before each of the following steps. Serum 
samples were diluted 1:50 with FACS buffer and incubated with approximately 
2 x 105 MHC-I+ve DFTD cells/ well and separately with 2 x 105 MHC-I–ve DFTD cells/ well in 
96 well plates for one hour on ice. Cells were then incubated with a monoclonal mouse anti-
devil IgG antibody (1:200) for 30 minutes on ice. Finally, cells were incubated with a 
fluorochrome labelled goat anti-mouse IgG Alexa Fluor® 647 (1:1000) for 30 minutes on ice. 
They were resuspended in 200 µl FACS buffer containing 3 µM PI to allow gating of dead 
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cells, and analysed by flow cytometry (BD Canto II).  Cells labelled with secondary and tertiary 
antibodies only gave no background fluorescence.  The mouse IgG2b isotype (Bioscience) 
controls showed the same MFI as the no-serum controls.  
 
2.2.8. Cytotoxicity assays 
 
DFTD cells from culture were washed twice with PBS (500 g, five minutes), suspended in PBS 
and stained with cell trace violet (CTV) at 2 µl CTV per 106 cells, and incubated for 20 minutes 
at 35 °C in a humidified atmosphere of 5% CO2 in air. The CTV was quenched with 10 ml 
complete medium (CM) for five minutes at 35 °C. A cell count was performed and the cells re-
suspended in CM to a concentration of 105 cells/ml.  
PBL’s were separated (2.2.3), counted and re-suspended in CM at 107 cells/ ml or 5 x 106 
cells/ ml. In a 96 well round-bottomed plate (Corning), 200 µl of the PBL suspension was 
added to wells in row A in triplicate or quadruplicate. 100 µl of CM was added to the wells in 
rows B to G. The PBL suspension was titrated down from row A to row G leaving a final 
volume in each well of 100 µl.  
100 µl of the DFTD cell suspension was then added to each well so that PBL:DFTD ratios 
started at 100:1 in row A, down to 1:1 in row G. (If only 5 x 106 PBL/ ml were available, the 
dilution started at 50 PBL:1 DFTD cell). Row H contained DFTD cells only to measure control 
well cell death. The plate was incubated overnight at 37 °C in a humidified atmosphere of 5% 
CO2 in air. 
The following morning, assays were centrifuged at 1500 rpm for three minutes, the 
supernatants pipetted off and stored at -80 °C, and the cells re-suspended in 200 µl propidium 
iodide (PI) diluted 1:500 with FACS buffer. The plates were then run on the BD Canto for flow 
cytometry analysis. The PBL’s were gated out by selecting the CTV positive cells. The 
percentage of PI positive CTV positive cells (i.e. dead DFTD cells) was recorded. 
Cytotoxicity = (% dead cells - % control well cell death)/(1- % control cell well death) 
Cytotoxicity curves were plotted using GraphPad Prism. 
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2.2.9. Immunisation preparation 
 
C5065 cell line was used for all immunisations 
 
MHC-I up-regulation 
 
For immunisations used in Chapter 5 Trial 1: 
Surface expression of MHC-I was up-regulated on DFTD cells by incubation with 10% 
cytokine rich conditioned medium (“Con A sup”) plus recombinant devil IFN- γ at 1:10,000 
dilution in culture for 24 hours at 35 °C in a humidified atmosphere of 5 % CO2 in air.  
 
For immunisations used in Chapter 5 Trial 2, and Chapter 6: 
MHC-I was up-regulated in DFTD cells by incubation with IFN-g at 1:5,000 dilution in culture 
for 24 hours at 35 °C in a humidified atmosphere of 5 % CO2 in air. 
 
MHC-I expression was confirmed with flow cytometry with mouse anti-devil β2m antibody 
staining (2.2.7). 
 
Sonicated cell vaccine preparation 
 
The MHC-I+ve DFTD cells were counted, suspended in PBS at 2 x 107 cells/ ml, and sonicated 
with four ultra-sonic cycles using 50% power using an ultrasonic cell disruptor – Misonix Inc., 
then aliquotted at 1 ml per cryovial, and stored at -80 °C. 
 
Irradiated cell vaccine preparation 
 
The MHC-I+ve DFTD cells were suspended in CM and placed in 1.8 ml cryovials and irradiated. 
Radiation treatment comprised two doses of 40 Gy of gamma radiation 24 hours apart using a 
Varian Clinac 23-EX linear accelerator – Varian Medical Systems Inc. The cells were kept in 
the crovials at 35 °C in a humidified atmosphere of 5% CO2 in air for the 24 hours in between 
doses. 
Following radiation, the cells were pooled, centrifuged (500 g for 5 minutes), and the pellet 
resuspended in CM. They were counted and 2 x 107 cells in 0.9 ml CM were mixed with 0.9 ml 
of 2 x freezing medium and placed in 1.8 ml cryovials and stored at -80 °C. 
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Adjuvants 
 
The adjuvants added to each vaccine for the trials in Chapters 5 and 6 were: 
50 µl ISCOMATRIX™  
50 µg CpG 1585  
50 µg CpG 2395 
100 µg poly(I:C) 
 
2.2.10. Cytogenetic analysis  
 
This procedure was performed at the Animal Health Laboratory, Prospect, Tasmania, 7250. 
 
Before harvesting cells from culture, 0.1 ml of demecolcine at 10 µg/mL (Sigma-Aldrich) was 
added to each culture and incubated for four hours. The cells were centrifuged for ten minutes 
at 1000 rpm. Supernatant was discarded and the cell pellet was slowly resuspended in 7 ml of 
hypotonic 0.075 M KCl and placed in a water bath at 37 °C for 18 minutes. 2 ml of chilled 
Carnoy’s fixative (3:1 ratio of methanol to acetic acid) was added and the tubes centrifuged for 
ten minutes at 1000 rpm. After removing the supernatant the pellet was gently resuspended in 
Carnoy’s fixative and stored at 4 °C overnight. The following day the cells were spun and 
resuspended in three changes of fresh fixative. The cells were then resuspended in enough 
fixative to form a milky suspension. This suspension was dropped onto clean, frozen 
microscope slides from 10 cm to ensure chromosome spread. Slides were allowed to dry and 
then placed in an oven at 57 °C for three days before banding. G-banding was conducted by 
treating slides with a 0.15 % solution of trypsin for up to 30 seconds before staining with 
Leishmann’s stain for 2½ minutes, then mounting with Leica mounting medium (Leica 
Microsystems) for analysis. 
 
G-banding analysis was performed using a Leica DM 2000 microscope (Leica Microsystems) 
and photographed with a Leica DFC 420 C camera (Leica Microsystems). Karyotypes were 
made using VideoTest Karyo 3.1 (VideoTest). 50 Metaphases were analysed for each sample. 
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2.2.11. Software/ Programmes 
 
GraphPad Prism version 6 for Mac OS X, GraphPad Software, La Jolla, CA, USA, 
www.graphpad.com 
 
Kaluza version 1.5 Flow Cytometry Analysis Software 
 
R statistical software 
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2.3. Methods – Tasmanian devil housing and handling 
 
2.3.1. Animal ethics 
 
The research was carried out in compliance with and with approval from the University of 
Tasmania’s Animal Ethics Committee under permit numbers: 
A0014976; A0014599; A0013685; A0012513 
 
2.3.2. Housing of captive devils 
 
The Tasmanian devils were housed in secured shelters in accordance with the guidelines of the 
Department of Primary Industries, Parks, Water and Environment of Tasmania (DPIPWE). All 
experimental methods were performed in accordance with the University of Tasmania 
guidelines. 
 
2.3.3. Blood collection 
 
From wild and captive devils that could be handled: 
Devils were handled in the sack and between 2 and 5 ml (wild devils) and up to 10 ml (captive 
devils) of blood was collected from the jugular vein with a 21 G hypodermic needle and a 5 or 
10 ml syringe. 
 
From captive devils that couldn’t be handled conscious: 
Devils were anaesthatised as described below. They were placed in ventral recumbancy and 
up to 10 ml blood collected from the jugular vein. 
 
2.3.4. Tumour biopsies 
 
Samples were collected using 4 mm biopsy punches (Kai). Samples were divided and fixed in 
10% neutral buffered formalin and/or RNAlater ®. 
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2.3.5. Tumour fine needle aspirates (FNA’s)  
 
Tumour aspirates were collected with a 21G or 23G hypodermic needle and 5 ml syringe. For 
cytology, these were expressed on to glass microscope slides, air dried and stained with May 
Grunwald-Giemsa stain (Animal Health Laboratory, Prospect, 7250).  
 
Aspirates collected for immunocytochemistry analysis were placed directly into 1ml vials of 
4% paraformaldehyde, and after approximately 10 days (on return from the field) were 
centrifuged and resuspended in phosphate buffered saline for long term storage.  
 
Tumour aspirates for cell culture and karyotype were collected as described above and placed 
directly into 5 ml of transport medium (Complete Medium + 2% Antibiotic-Antimycotic). 
 
2.3.6. General anaesthesia 
 
General anaesthesia was induced with 5% Isoflurane (ISOTHESIA®) reducing to a 
maintenance concentration of 3% via a face mask. A pulse oximeter was clipped to the devil’s 
ear to record heart rate and oxygen saturation. An assistant monitored the anaesthesia 
throughout the procedure. 
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Chapter 3. The effects of DFTD, age, sex and season on peripheral blood T lymphocytes 
and immunoglobulins in Tasmanian devils. 
 
3.1. Introduction 
 
The successful transmission of devil facial tumour disease (DFTD) as an allograft between 
Tasmanian devils raises many immunological questions about the disease, the devil’s immune 
system and their interplay. As appropriate reagents become available these questions are being 
addressed. Peripheral blood T lymphocytes and immunoglobulins provide useful indicators of 
immune competence. These are commonly measured in humans and increasingly assessed in 
other species. The CD4:CD8 ratio has been used to provide an indication of immune 
competence in people and this has been particularly useful for identifying the effect of HIV on 
T cells (Margolick et al., 2006). Likewise, serum immunoglobulin levels can help gauge an 
immune response. Serum total protein is separated into albumin and globulins, with the 
globulin fraction further divided into alpha, beta and gamma globulins (see Appendix 1 for 
protein electrophoresis results of six healthy devils and six devils with DFTD). The gamma 
globulins include the immunoglobulins which are categorised as IgM, IgG, IgA, IgE and IgD. 
 
Immune competence is affected by various parameters including cancer, age, sex and season. 
This has been explored by measuring the effects these parameters have on T lymphocytes and 
immunoglobulin levels in peripheral blood, most widely in humans but also other species 
including domestic pets (Heaton et al., 2002a, Heaton et al., 2002b) and wild animals (Mangar 
et al., 2016, Flies et al., 2015). The development of devil-specific antibodies binding CD4 and 
CD8 in formalin fixed tissue, and IgM and IgG in fresh and fixed tissue has allowed the 
identification of these components in the lymphoid organs of devils (Howson et al., 2014). 
While it is known that devils with DFTD have a lower total lymphocyte count than healthy 
devils (Peck et al., 2016), further study of T lymphocyte subset populations in peripheral blood 
has been hampered by a lack of reagents for fresh blood analysis and the logistical difficulty 
of separating peripheral blood lymphocytes (PBL’s) from samples collected in remote field 
locations. Serum levels of IgM and IgG in healthy and diseased devils are also yet to be 
determined.  
 
This study aimed to measure T lymphocyte subsets and IgM and IgG levels in peripheral blood 
samples collected from a DFTD affected population of wild devils over a 12 month period. As 
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the study was nearing completion, an anti-devil CD4 binding antibody became available for 
flow cytometry. Until then, however, devil specific CD4 and CD8 binding antibodies were 
available only for immunohistochemistry (IHC).  To overcome the limitations of the available 
reagents and PBL separation, a novel method of fixing blood clots in formalin to preserve an 
ample number of PBL’s for IHC staining and subsequent calculation of the T lymphocyte 
subset percentages was used. Indirect ELISA was the method employed for measuring levels 
of serum IgM and IgG. 
 
Here the percentages of peripheral CD4+ and CD8+ T lymphocytes, and the relative levels of 
IgM and IgG found in healthy devils is reported. To determine if these values are altered by 
DFTD was a primary aim of this study and is also shown. The effects of age, sex and season 
on these peripheral blood components in healthy devils is evaluated and how the results 
compare with other mammalian species is discussed. 
 
3.2. Materials and methods 
 
3.2.1. Samples and sample collection 
 
The blood samples were collected from wild devils (n=58) at a study site at West Pencil Pine 
in north west Tasmania (41°31’ S, 145°46’ E). The population is trapped at the same times 
each year to coincide with significant annual events in the devil population: February (summer, 
pre-breeding season); May (autumn, post-breeding season); August (winter, pouch young); and 
November (spring, late lactation) (Hamede et al., 2013). Samples for this study were collected 
over a 12 month period covering each of the four seasons. Devils over two years of age were 
classified as adults, and younger than two years as juveniles. 
 
A diagnosis of DFTD was based on visual assessment of tumour location and appearance 
according to previously described classification methods (Hawkins et al., 2006). Tumour 
biopsies were collected for 17 of the 22 devils diagnosed with DFTD (see Chapter 2.3.4 for 
biopsy procedure). It was not possible to collect tumour samples from the remaining five devils 
due to the location of the tumour e.g. under the tongue or on the hard palate.  
 
Blood (3-5 ml) was collected from the jugular vein with a 21 G needle and 5 ml syringe and 
transferred directly into clot activating tubes. The serum was pipetted off within five hours of 
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collection and the remaining blood clots placed in 10% neutral buffered formalin for between 
three and five days before processing.   
 
3.2.2. Immunohistochemistry and validation experiments  
 
Immunohistochemistry 
 
See Chapter 2.2.1 for IHC staining procedures with haematoxylin and eosin (HE), mouse anti-
devil CD4 and CD8 antibodies, rat anti-mouse CD79b, and anti-human MHC-II. 
 
Validation experiments 
 
This was a novel method and so three validation experiments were performed:  
 
1. White cell identification (morphology) (n=5) 
 
Preservation of cell morphology in the fixed blood clot sections for identification of neutrophils 
and lymphocytes was assessed. The standard method to obtain white blood cell differentials on 
devil blood samples is to perform manual counts on fresh blood smears. To confirm that cell 
identification in the fixed blood clot sections was adequate, blood samples were collected from 
five devils and each divided into EDTA and clot activating tubes. The five EDTA samples 
were sent to the Animal Health Laboratory (AHL), Department for Primary Industries, Parks, 
Water and Environment, Tasmania for manual differentials. These were performed on fresh 
blood smears stained with Diff-Quik (a Romanowsky stain). The blood clots were fixed and 
processed as described above and stained with HE. The number of lymphocytes and neutrophils 
out of 100 white blood cells was counted on these HE stained clots (manual count under 40 x 
objective). This count was repeated two or three times and the average taken. The results 
obtained from the blood smears and the HE stained clots were compared. 
 
2. Flow cytometry compared to IHC method to assess percentages of CD4+ and CD8+ 
lymphocytes on human samples (n=5): 
 
Antibodies binding human CD4 and CD8 are available for use on both fresh (for flow 
cytometry) and fixed (for IHC) human tissue. The conventional method for obtaining 
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percentages of CD4+ and CD8+ lymphocytes in human blood is with flow cytometry. To 
validate the IHC method for obtaining CD4+ and CD8+ lymphocyte percentages in peripheral 
blood, five human blood samples were collected and each divided into EDTA and clot 
activating tubes. The percentages of CD4+ and CD8+ lymphocytes were assessed on the EDTA 
samples by flow cytometry at the NATA accredited Pathology South laboratory at the Royal 
Hobart Hospital. The clots were formalin fixed for sectioning and stained with anti-human CD4 
and CD8 antibodies at the same laboratory. Sections were examined under 40 x objective and 
the number of CD4+ or CD8+ lymphocytes out of 100 lymphocytes was counted for each 
section to acquire the percentage of CD4+ or CD8+ lymphocytes. The counts were repeated 
two or three times and the average taken. CD4+ lymphocytes were distinguished from CD4+ 
monocytes on the basis of morphology. The results obtained by the flow cytometry and IHC 
methods were compared. 
 
3. Flow cytometry compared to IHC method to assess percentage of CD4+ lymphocytes on 
devil samples (n=4) 
 
Towards the end of this study a mouse anti-devil CD4 antibody was developed for flow 
cytometry which allowed a third validation experiment to be performed.  
 
Blood samples were collected from four devils and each divided into EDTA and clot activating 
tubes for processing as described above. Flow cytometry with the anti-devil CD4 antibody was 
performed on PBL’s isolated from the EDTA samples. See Chapter 2 for PBL isolation (2.2.3) 
and flow cytometry staining (2.2.7). Formalin fixed clots were sectioned and stained with anti-
devil CD4 antibody. Sections were examined under 40 x objective and the number of CD4+ 
lymphocytes out of 100 lymphocytes was counted for each section to acquire the percentage 
of CD4+ lymphocytes. This count was repeated two or three times and the average taken. The 
results obtained by the flow cytometry and IHC methods were compared. 
 
3.2.3. Calculation of percentages of CD4+ and CD8+ lymphocytes for the wild devil 
samples 
 
Fixed blood clot sections, each stained with either anti-devil CD4 or CD8 antibody were 
examined under 40 x objective and, as described above, the number of CD4+ or CD8+ 
lymphocytes out of 100 lymphocytes was counted for each section. This count was repeated 
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two or three times and the average taken to give the percentage of CD4+ or CD8+ lymphocytes 
present in each peripheral blood clot. Sections were also stained with the cross-reactive rat anti-
mouse CD79b and anti-human MHC-II to identify B cells and antigen presenting cells (Kreiss 
et al., 2009). See Chapter 2.2.1 for CD79b and MHC-II staining. 
 
3.2.4. Measurement of serum IgM and IgG in wild devils by indirect ELISA 
 
Serum samples were diluted to 1:200,000 in carbonate buffer, and 100 µl of each sample 
pipetted into a single well of a Costar® Assay 96 well plate. The plate was covered in parafilm 
and kept at 4 °C overnight. The following morning, each well was washed with washing buffer 
three times then 200 µl of blocking buffer was added to each well and incubated at room 
temperature for a minimum of two hours. The blocking buffer was discarded and 100 µl of 
diluted IgM or IgG (IgM diluted at 1:500 with blocking buffer; IgG diluted at 1:200 with 
blocking buffer) added to each well and incubated at room temperature for one hour. Each well 
was washed with washing buffer three times. Goat anti-mouse horseradish peroxidase was 
diluted 1:2000 with blocking buffer and 100 µl added to each well for an hour incubation at 
room temperature. Each well was washed with washing buffer three times and TMB 100 µl per 
well was added and left for five to ten minutes depending on colour intensity before adding 
100 µl of stop solution to each well. The plate was read at 450 nm on a SpectraMax Microplate 
reader. The sample results are reported as optical density (OD), and are relative to each other. 
 
3.2.5. Statistics 
 
Arcsine transformation of percentages of all cells (lymphocytes, neutrophils, CD4+ and CD8+ 
lymphocytes) was performed prior to all statistical analyses to normalise the distribution of the 
percentage values.  
Student’s paired t tests were performed for each of the validation experiments. 
A three-way ANOVA followed by Tukey’s posthoc analysis was performed to determine the 
effects of season, age and sex on each of CD4+ and CD8+ percentages, CD4:CD8 ratio, IgM 
and IgG levels, and IgM:IgG ratio in healthy devils.  
Student’s unpaired t tests were performed to compare healthy and diseased devils for each of 
CD4+ and CD8+ percentages, CD4:CD8 ratio, IgM and IgG levels and IgM:IgG ratio. 
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Two-way ANOVAs followed by Sidak’s multiple comparisons tests were performed to 
determine the effects of DFTD and age on CD4+ and CD8+ percentages, CD4:CD8 ratio, IgM 
and IgG levels, and IgM:IgG ratio. 
Arcsine transformation, Student’s t tests and two-way ANOVAs were performed using 
GraphPad Prism version 6; and the three-way ANOVA and Tukey’s posthoc analysis was 
performed using R statistical software. 
 
3.3. Results 
 
3.3.1. Tasmanian devils and blood samples 
 
The number of devils sampled over the 12 month period, and their age, sex and DFTD status 
is summarized in Table 3.1. 
 
Table 3.1. Numbers of devils sampled according to age, sex, DFTD status and season collected. 
 
Total samples 
 
DFTD- DFTD+ 
58 36 22 
 
 Juvenile Adult Male Female 
DFTD- 25 11 17 19 
DFTD+ 6 16 9 13 
total 31 27 26 32 
 
 November 
spring 
February 
summer 
May 
autumn 
August 
winter 
DFTD- 8 10 9 9 
DFTD+ 9 5 5 3 
 D- D+ D- D+ D- D+ D- D+ 
Juvenile 6 4 6 0 5 0 8 2 
Adult 2 5 4 5 4 5 1 1 
Male 4 3 5 3 3 2 5 1 
Female 4 6 5 2 6 3 4 2 
Juvenile male 3 2 4 0 1 0 4 0 
Juvenile 
female 
3 2 2 0 4 0 4 2 
Adult male 1 1 1 3 2 2 1 1 
Adult female 1 4 3 2 2 3 0 0 
 
DFTD- and D- signify healthy devils without DFTD; DFTD+ and D+ are devils with DFTD; juvenile 
devils are < 2years old, adult devils are > 2years old  
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3.3.2. Validation experiments 
 
1. White cell identification /morphology (n=5) 
 
Cell morphology was adequately preserved in HE sections of formalin fixed blood clots to 
allow for identification of lymphocytes and neutrophils (Fig. 3.1a). To determine if this 
identification was reliable, the number of lymphocytes and neutrophils out of 100 cells was 
counted on HE stained fixed clots from blood samples of five devils. Fresh blood smears were 
made from the same five samples, and white blood cell differentials performed on these. 
Student’s paired t tests were carried out to compare the overall results for lymphocytes and 
neutrophils obtained by each method. There was no significant difference between the results 
obtained by the two methods for the percentages of either lymphocytes (p = 0.890) or 
neutrophils (p = 0.144) (Table 3.2). 
 
Table 3.2. Comparison of lymphocyte and neutrophil percentages obtained by two different methods 
for five individual devils. 
 
 %Lymphocytes  %Neutrophils  
Devil Blood smear HE  Blood smear HE  
Barney 24 26 ± 2 68 63 ± 3 
Aslan 35 49 ± 2 52 46 ± 2 
Rose 35 30 ± 1 52 54 ± 2 
Pansy 53 53 ± 2 45 35 ± 2 
Smithy 55 41 ± 2 41 41 ± 3 
 
The percentages of lymphocytes and neutrophils for each of five blood samples were obtained by two 
different methods. Manual white blood cell differentials were performed on fresh blood smears by the 
Animal Health Laboratory which provided the results. Formalin fixed blood clots were stained with HE 
and the number of lymphocytes and neutrophils out of 100 white blood cells then counted. This count 
was repeated 2 or 3 times and the mean ± SD is shown for HE values. HE = haematoxylin and eosin. 
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2. Flow cytometry compared to IHC method to assess percentages of CD4+ and CD8+ 
lymphocytes on human samples (n=5) 
 
Following confirmation that the morphology of formalin fixed neutrophils and lymphocytes 
was adequately preserved to allow their identification on fixed blood clot sections, the next 
validation step was undertaken. This involved comparing results obtained by the conventional 
flow cytometry method to those obtained by the IHC method to measure percentages of CD4+ 
and CD8+ lymphocytes. This was performed on human blood since antibodies binding CD4 
and CD8 for use in both fresh and fixed tissue are available for humans. The fresh blood 
samples were analysed using flow cytometry and the fixed blood clots were sectioned and 
stained for CD4 or CD8. Figure 3.1b, c shows representative staining of CD4+ and CD8+ 
lymphocytes.  
 
For the stained blood clot sections, the number of positive staining lymphocytes out of 100 
total lymphocytes was recorded to provide the percentage of CD4+ or CD8+ lymphocytes. 
Student’s paired t tests were performed to compare the results to those obtained by flow 
cytometry on the same blood samples. Although the IHC results for CD4 and CD8 percentages 
tended to be higher than the flow cytometry results, there was no overall significant difference 
between either the CD4+ (p=0.062) or CD8+ (p=0.061) percentages obtained by either method, 
or for CD4:CD8 ratio (p = 0.510) (Table 3.3). 
 
Table 3.3. Comparison of CD4+ and CD8+ lymphocyte percentages obtained by two different methods 
for five individual humans. 
 
 CD4% CD8% CD4:CD8 ratio 
Human Flow IHC Flow IHC Flow IHC 
A 40 47 ± 1 24 24 ± 2 1.7 2.0 
B 62 65 ± 2 15 18 ± 2 4.1 3.6 
C 43 43 ± 1 26 29 ± 1 1.7 1.5 
D 53 55 ± 2 22 32 ± 1 2.4 1.7 
E 55 57 ± 2 16 25 ± 2 3.4 2.2 
 
The percentages of CD4+ and CD8+ lymphocytes for each of five blood samples were obtained by two 
different methods. Flow cytometry was performed by the hospital pathology laboratory which provided 
the results. Formalin fixed blood clots were stained with IHC with anti CD4 or CD8 antibodies, and the 
number of positive staining lymphocytes out of 100 lymphocytes then counted. This count was repeated 
2 or 3 times and the mean ± SD is shown for IHC values. IHC = immunohistochemistry. 
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(a) 
 
(b) 
 
(c) 
 
 
Figure 3.1. HE and IHC on blood clot sections, haematoxylin is the counterstain. (a) HE of devil blood 
clot showing 2 lymphocytes (e.g. arrow head) and 3 neutrophils (e.g. arrow). (b) CD4 of human blood 
clot section showing 2 positive (brown) staining lymphocytes, 3 negative staining lymphocytes (c) CD8 
of human blood clot showing 2 positive (brown) staining lymphocytes, 5 negative staining lymphocytes. 
All images taken at 63 x objective. 
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3. Flow cytometry compared to IHC method to assess percentage of CD4+ lymphocytes on 
devil samples (n=4) 
 
The final validation experiment was performed when a devil specific antibody binding CD4 
became available toward the end of this study. The same steps that were performed on the 
human samples above were performed on blood samples from four devils to measure the 
percentage of CD4+ lymphocytes. Flow cytometry for CD4 was carried out on PBL’s separated 
from the fresh (EDTA) blood samples for the four devils. Figure 3.2a shows the scatter plot 
and gating strategy for flow cytometry analysis of the PBL’s.  Figure 3.2b shows the clear 
separation of CD4+ and CD4- devil lymphocytes obtained by flow cytometry. Blood clots from 
the same four samples were fixed and sections stained with IHC for CD4 (Fig. 3.2c). The 
number of positive staining lymphocytes out of 100 total lymphocytes for each section was 
recorded to provide the percentage of CD4+ lymphocytes.  
 
A Student’s paired t test was performed to compare the results obtained by flow cytometry and 
IHC on the same blood samples. There was no significant difference for the overall results of 
CD4+ percentages obtained by either method (p = 0.721) (Table 3.4). 
 
Table 3.4. Comparison of CD4+ lymphocyte percentages obtained by two different methods for four 
individual devils. 
 CD4% 
devil Flow IHC 
Batman 37 32 ± 2 
Mars 23 30 ± 2 
Prince 30 32 ± 1 
Surprise 20 20 ± 2 
 
The percentages of CD4+ lymphocytes for each of four blood samples were obtained by two different 
methods. Flow cytometry results are the rounded results obtained from Figure 3.2b. Formalin fixed 
blood clots were stained with IHC with anti-CD4 antibody and the number of positive staining cells out 
of 100 lymphocytes then counted. This count was repeated 2 or 3 times and the mean ± SD is shown 
for IHC values. IHC = immunohistochemistry. 
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               (c)     
 
Figure 3.2. Peripheral blood lymphocyte (PBL) identification, and CD4 staining of fresh and fixed 
devil lymphocytes. (a) Flow plot of devil PBL’s after isolation. The population closest to the x axis i.e. 
with 80.4% of cells, was identified as PBL’s, (b) Flow cytometry histograms showing percentage of 
CD4+ lymphocytes of PBL’s from four individual devils, (c) Immunohistochemistry of devil blood clot 
stained with anti-devil CD4 antibody (brown), haematoxylin is the counterstain. The image shows 2 
CD4+ lymphocytes, 3 negative staining lymphocytes and 6 neutrophils. Image taken at 63 x objective. 
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3.3.3. CD79b and MHC-II IHC staining 
 
Cross-reactive staining of all white cells in the devil blood clots by the rat anti-mouse CD79b 
antibody precluded calculation of the percentages of B lymphocytes in the devils in this study 
(Fig. 3.3a). This is in contrast to the specific staining with anti-devil CD4 (Fig. 3.2c) and anti-
devil CD8 (Fig. 3.3c). Consequently, 11 blood clot sections from devils with DFTD were 
stained with anti-MHC-II antibody. There appeared to be specific staining (Fig. 3.3b) but the 
number of positive cells was too low to quantify. 
 
The validation experiments showed the IHC method to be a reliable way of measuring the 
percentages of CD4+ and CD8+ lymphocytes in the peripheral blood of devils. Although the 
values obtained by flow cytometry and IHC sometimes differed for individuals, the average 
values were not significantly different. It was this average that would be used to assess the 
percentages of lymphocytes in different devil cohorts. 
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(a) 
 
    (b)  
 
(c) 
 
Figure 3.3. IHC of devil blood clots (positive cells are brown), haematoxylin is the counterstain (a) 
anti-mouse CD79b antibody: all cells have positive staining indicating the cross-reactivity of the CD79b 
antibody; (b) anti-human MHC-II antibody staining of a clot from a devil with DFTD: 1 MHC-II+ cell, 
1 negative staining lymphocyte surrounded by neutrophils The large number of neutrophils is typical 
of the stress leukogram seen in devils with DFTD; (c) anti-devil CD8 antibody: 2 CD8+ lymphocytes, 
1 negative staining lymphocyte, 1 granulocyte. Images taken at 63 x objective. 
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3.3.4. Percentages of CD4+ and CD8+ lymphocytes in peripheral blood of healthy 
devils. Effects of age, sex and season. 
 
The percentages of CD4+ and CD8+ lymphocytes for each devil in this study were obtained 
by the novel method of formalin fixing clots from peripheral blood samples, and using IHC to 
stain them with anti-devil CD4 or CD8 antibodies. The percentage of positive staining 
lymphocytes out of 100 total lymphocytes was recorded. Percentages of CD4+ and CD8+ 
lymphocytes were initially evaluated for the 36 healthy devils (those without DFTD). The 
effects that age, sex and season had on these healthy devils were analysed with a three-way 
ANOVA.  
 
Juvenile devils had a significantly higher percentage of CD4+ lymphocytes and lower 
percentage of CD8+ lymphocytes than adults, and consequently a significantly higher 
CD4:CD8 ratio than healthy adults (Fig. 3.4). There was no sex effect on percentages of CD4+ 
or CD8+ lymphocytes. 
 
When the effects of season were analysed the only significant finding was noted for the CD4+ 
lymphocyte values. There was a significant increase in the percentage of CD4+ lymphocytes 
and the CD4:CD8 ratio in autumn (May) and winter (August) compared to spring (November) 
(Fig. 3.5). This seasonal analysis took into account the effects of age and sex. See Table 3.9 
for detailed ANOVA results. 
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Figure 3.4. Effects of age on (a) CD4%, (b) CD8% and (c) CD4:CD8 ratio of healthy devils. Juvenile 
devils are < 2years old, adult devils are > 2years old. Statistical analysis was performed with a three-
way ANOVA. The effects of sex and season are not shown on these graphs. Refer to Table 3.9 for 
detailed ANOVA results.  
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Figure 3.5. Effect of season on (a) CD4%, (b) CD8% and (c) CD4:CD8 ratio of healthy devils. 
Statistical analysis was performed with a three-way ANOVA to produce an overall p value for each 
graph. Post hoc analysis identified which seasons are significantly different from each other and are 
indicated by *. The effects of age and sex are not shown on these graphs. Refer to Table 3.9 for detailed 
ANOVA results.  
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3.3.5. Serum levels of IgM and IgG in peripheral blood of healthy devils. Effects of age, 
sex and season. 
 
The serum levels of IgM and IgG were measured with ELISAs for each devil in the study. The 
values are recorded as optical density (OD) readings and are relative to each other. As with the 
CD4+ and CD8+ lymphocytes, IgM and IgG levels were initially evaluated for the 36 healthy 
devils, and the effects that age, sex and season had on these healthy devils were analysed with 
a three-way ANOVA.  
 
The healthy juvenile devils had significantly lower IgM and IgG levels and a significantly 
higher IgM:IgG ratio than healthy adults (Fig. 3.6). As with the T lymphocyte subsets, sex had 
no effect. 
 
There were no significant seasonal effects found on the immunoglobulin values (Fig. 3.7). As 
with the seasonal analysis of T lymphocyte subsets, the seasonal analysis of IgG and IgM also 
took into account the effects of age and sex. See Table 3.10 for detailed ANOVA results. 
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Figure 3.6. Effect of age on (a) IgM, (b) IgG and (c) IgM:IgG of healthy devils. Juvenile devils are 
< 2 years old, adult devils are > 2 years old.  Statistical analysis was performed with a three-way 
ANOVA. The effects of sex and season are not shown on these graphs. Refer to Table 3.10 for detailed 
ANOVA results.  
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Figure 3.7. Effect of season on (a) IgM, (b) IgG and (c) IgM:IgG of healthy devils. Statistical analysis 
was performed with a three-way ANOVA to produce an overall p value for each graph. The effects of 
age and sex are not shown on these graphs. Refer to Table 3.10 for detailed ANOVA results.  
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3.3.6. The effect of DFTD on percentages of CD4+ and CD8+ lymphocytes in peripheral 
blood of devils 
 
After determining percentages of CD4+ and CD8+ lymphocytes for healthy devils, these were 
then measured in devils with DFTD and the results compared. Values for healthy and diseased 
adult and juvenile devils are shown in Table 3.5. The table presents the average results from 
all devils tested and shows a decrease in CD4 and CD8 percentages for devils with DFTD.   
 
Table 3.5. Percentages of CD4+ and CD8+ lymphocytes in peripheral blood of healthy and diseased 
devils. 
 n CD4% CD8% CD4:CD8 ratio 
DFTD- 36 29.7 ± 7.7 51.6 ± 10.9 0.61 ± 0.21 
DFTD+ 22 14.8 ± 9.6 36.6 ± 17.1 0.41 ± 0.23 
  n    
juvenile DFTD- 25 31.3 ± 6.8 49.1 ± 9.6 0.66 ± 0.20 
DFTD+ 6 14.0 ± 10.1 28.3 ± 13.0 0.50 ± 0.35 
adult DFTD- 11 26.1 ± 8.6 57.2 ±11.9 0.47 ± 0.18 
DFTD+ 16 15.1 ± 9.7 39.7 ± 17.8 0.37 ± 0.16 
 
Results represent mean percentage ± standard deviation for the number (n) of devils. DFTD- signifies 
healthy devils without DFTD; DFTD+ are devils with DFTD; juvenile devils are < 2 years old; adult 
devils are > 2 years old. 
 
To analyse this further, data from individual devils were plotted and statistical analysis 
performed. As shown in Figure 3.8, devils with DFTD had significantly lower percentages of 
CD4+ and CD8+ lymphocytes, and lower CD4:CD8 ratios than healthy devils. The effect of 
both age and DFTD on CD4+ and CD8+ lymphocytes was then explored.  As shown in Figure 
3.9, when age was considered, the percentages of CD4+ and CD8+ lymphocytes were 
significantly higher in healthy devils than devils with DFTD for both age groups. However, 
despite DFTD reducing the CD4:CD8 ratio when all devils were included (Fig. 3.8c), this was 
not evident when age was considered (Fig. 3.9c). Taking age into account, DFTD was 
associated with a reduced percentage of both CD4+ and CD8+ lymphocytes for both age 
groups, but the CD4:CD8 ratio within each age group remained unchanged. 
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Figure 3.8. CD4+ and CD8+ lymphocytes in peripheral blood of healthy devils and devils with DFTD. 
(a) Percentage of CD4+ lymphocytes, (b) Percentage of CD8+ lymphocytes, and (c) CD4:CD8 ratio. 
Healthy devils (DFTD-) and devils with DFTD (DFTD+) were compared. Statistical analysis was 
performed using Student’s unpaired t tests. 
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Figure 3.9. Percentages of (a) CD4+ lymphocytes, (b) CD8+ lymphocytes, and (c) CD4:CD8 ratio 
comparing healthy devils (DFTD-) and devils with DFTD (DFTD+) in juveniles and adults. Juvenile 
devils are < 2 years old, adult devils are > 2 years old. Statistical analysis was performed with a two-
way ANOVA. Only significant p values are shown for age, DFTD status and/or interaction.  Refer to 
Table 3. 12 for detailed ANOVA results.  
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As indicated above, devils with DFTD had lower percentages of CD4+ and CD8+ lymphocytes 
than healthy devils. There were fewer lymphocytes overall in the blood clots from devils with 
DFTD (approximately 9±3 per HPF in healthy devils compared to 5±3 per HPF in devils with 
DFTD). However, the proportion of non-staining lymphocytes was higher in devils with DFTD 
i.e. there were more lymphocytes that were CD4- CD8- in the clots from devils with DFTD 
(Table 3.6). 
 
Table 3.6. Percentages of lymphocytes that are either CD4+, or CD8+, or CD4-CD8- in peripheral 
blood of healthy (DFTD-) and diseased (DFTD+) devils. 
Lymphocytes DFTD- DFTD+ 
CD4+ 29.7 ± 7.7 14.8 ± 9.6 
CD8+ 51.6 ± 10.9 36.6 ± 17.1 
 CD4+ or CD8+  
(i.e. CD4% + CD8%) 
81.3 51.4 
both CD4- and CD8- 
(i.e. CD4-CD8-) 
18.7 48.6 
 
 
3.3.7. The effect of DFTD on serum levels of IgM and IgG in peripheral blood of devils 
 
Analysis of total IgM and IgG was performed by an ELISA and the OD values were compared. 
Devils with DFTD had significantly higher IgM and IgG levels than healthy devils, whereas 
the IgM:IgG ratio was lower in diseased devils (Fig. 3.10).  
 
Age influenced IgM and IgG levels in healthy devils (Fig. 3.6), so once again devils were 
divided into juvenile and adult cohorts.  Age dictated whether a difference in IgM and IgG 
levels were found with diseased devils. Figure 3.11 summarises these results. For relative IgM 
levels, there was no significant difference in either age group (Fig. 3.11a). However, there was 
an interactive effect between age and DFTD status for IgG and the IgM:IgG ratio (Figs 
3.11b,c). Healthy juvenile devils had lower relative IgG levels and a higher IgM:IgG ratio than 
juveniles with DFTD.  There were no significant differences between the healthy and diseased 
adults. A summary of the effects of each parameter (age, sex, season and DFTD status) on the 
T lymphocyte subsets and IgM and IgG levels in peripheral blood is provided in Table 3.7. 
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Figure 3.10. Serum levels of IgM and IgG in healthy devils and devils with DFTD. (a) Relative levels 
of IgM, (b) Relative levels of IgG, (c) IgM:IgG ratio. Healthy devils (DFTD-) and devils with DFTD 
(DFTD+) were compared. Statistical analysis was performed using Student’s unpaired t tests.  
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Figure 3.11. Serum levels of (a) IgM, (b) IgG, and (c) IgM:IgG ratio, comparing healthy devils 
(DFTD-) and devils with DFTD (DFTD+) in juveniles and adults. Juvenile devils are < 2 years old, 
adult devils are > 2 years old. Statistical analysis was performed with a two-way ANOVA. Only 
significant p values are shown for age, DFTD status and/or interaction. Refer to Table 3. 13 for detailed 
ANOVA results.  
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Table 3.7. Summary of the effects of age, sex, season and DFTD parameters on T lymphocyte subset 
populations and serum levels of IgM and IgG in peripheral blood of devils. 
 
Devil cohorts 
compared for 
effects of each 
parameter 
 
CD4% 
 
CD8% 
 
CD4:CD8 
ratio 
 
IgM 
 
IgG 
 
IgM:IgG 
 
AGE 
 
Healthy juvenile 
devils (n=25) 
compared to 
healthy adult 
devils (n=11) 
higher lower higher lower lower higher 
 
SEX 
 
Healthy male 
devils (n=17) 
compared to 
healthy female 
devils (n=19) 
no 
difference 
no 
difference 
no 
difference 
no 
difference 
no 
difference 
no 
difference 
 
SEASON 
 
healthy devils 
spring n=8 
summer n=10 
autumn n=9 
winter n=9 
higher in 
autumn 
and winter 
compared 
to spring 
no 
difference 
higher in 
autumn 
and winter 
compared 
to spring 
no 
difference 
no 
difference 
no 
difference 
 
DFTD 
 
All devils with 
DFTD (n= 22) 
compared to all 
healthy devils 
(n=36) 
lower lower lower higher higher lower 
Juvenile devils 
with DFTD 
(n=6) compared 
to healthy 
juvenile devils 
(n=25) 
lower lower no 
difference 
no 
difference 
higher lower 
Adult devils 
with DFTD 
(n=16) 
compared to 
healthy adult 
devils (n=11) 
lower lower no 
difference 
no 
difference 
no 
difference 
no 
difference 
 
n = number of devils 
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3.3.8. Statistical analysis 
 
Table 3.8. The t and p values for Student’s paired t tests (2 tailed) for the three different validation 
experiments. 
 t p 
devil lymphocytes 0.147 0.890 
devil neutrophils 1.812 0.144 
human CD4 2.565 0.062 
human CD8 2.592 0.061 
human CD4:CD8 0.7228 0.510 
devil CD4 0.393 0.721 
 
 
Table 3.9. A three-way ANOVA for CD4, CD8 and CD4:CD8 ratio comparing effects of season, sex 
and age on healthy devils. 
 
Significance codes: p < 0.001 ‘***’; p < 0.01  ‘**’;  p< 0.05 ‘*’ 
 
Table 3.10. A three-way ANOVA for IgM, IgG and IgM:IgG comparing comparing effects of season, 
sex and age on healthy devils. 
  IgM IgG IgM:IgG 
Parameter Df F p F p F p 
season 3 2.683 0.073 0.567 0.643 0.881 0.467 
sex 1 3.151 0.090 1.86 0.187 0.217 0.646 
age 1 7.731 0.011* 27.636 <0.001*** 25.368 <0.001*** 
season:sex 3 2.823 0.064 2.823 0.064 1.43 0.262 
season:age 3 1.911 0.159 1.911 0.159 0.579 0.635 
sex:age 1 0.838 0.370 0.838 0.370 0.005 0.942 
season:sex:age 2 2.794 0.084 2.794 0.084 0.307 0.739 
residuals 21       
 
Significance codes: p < 0.001 ‘***’; p < 0.01  ‘**’;  p< 0.05 ‘*’ 
  CD4 CD8 CD4:CD8 
Parameter Df F p F p F p 
season 3 6.147 0.004** 2.034 0.14 11.955 <0.001*** 
sex 1 0.137 0.715 0.135 0.717 0.157 0.696 
age 1 6.61 0.018* 4.406 0.048* 16.776 <0.001*** 
season:sex 3 1.295 0.302 1.091 0.375 3.793 0.026* 
season:age 3 2.97 0.055 0.019* 0.996 1.958 0.151 
sex:age 1 2.946 0.101 0.519 0.479 0.92 0.348 
season:sex:age 2 0.312 0.736 0.349 0.709 0.342 0.714 
residuals 21       
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Table 3.11. The t and p values for Student’s unpaired t tests (2 tailed) for effect of DFTD on peripheral 
blood components i.e. comparing CD4, CD8, CD4:CD8 ratio, IgG, IgM, IgM:IgG in healthy devils and 
those with DFTD. 
Peripheral blood components t p 
CD4 6.510 <0.001 *** 
CD8 3.906 <0.001*** 
CD4:CD8 3.109 0.003** 
IgM 2.698 0.009** 
IgG 5.216 <0.001 *** 
IgM:IgG 4.960 <0.001 *** 
 
Significance codes: p < 0.001 ‘***’; p < 0.01  ‘**’;  p< 0.05 ‘*’ 
 
Table 3.12. A two-way ANOVA for CD4, CD8 and CD4:CD8 ratio comparing effects of DFTD and 
age. 
  CD4 CD8 CD4:CD8 
 DF F p F p F p 
Interaction 1 1.644 0.205 0.05875 0.809 0.2897 0.592 
DFTD status 1 31.60 0.001*** 22.51 <0.001*** 3.614 0.063 
age 1 0.7045 0.405 6.440 0.014* 6.419 0.014* 
Residual 54       
 
Significance codes: p < 0.001 ‘***’; p < 0.01  ‘**’;  p< 0.05 ‘*’ 
 
Table 3.13. A two-way ANOVA for IgM, IgG & IgM:IgG comparing effects of DFTD and age. 
  IgM IgG IgM:IgG 
 DF F p F p F p 
Interaction 1 0.3618 0.550 5.971 0.018* 14.12 <0.001*** 
DFTD status 1 3.648 0.063 18.14 <0.001*** 18.64 <0.001*** 
age 1 1.766 0.190 8.251 0.006** 12.81 0.001** 
Residual 54       
 
Significance codes: p < 0.001 ‘***’; p < 0.01  ‘**’;  p< 0.05 ‘*’ 
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3.4. Discussion 
 
The T lymphocyte subsets and immunoglobulins of the peripheral blood provide an indication 
of health as well as insight into how cancer and other parameters influence the immune system. 
This study examined peripheral blood samples collected from a wild population of Tasmanian 
devils and found that DFTD was associated with reduced percentages of T lymphocyte subsets 
and, in juvenile devils, increased serum levels of IgG. It also found that season and/or age 
influenced T lymphocyte subsets and IgM and IgG serum levels in healthy devils. 
 
For this study, a method using formalin fixed blood clots was developed. This overcame the 
difficulties of processing blood samples in the field and the limitations of available reagents. 
This method was used to analyse lymphocyte populations with routine HE and IHC staining. 
While a literature search revealed no previous use of formalin fixed blood clots for T 
lymphocyte subset analysis, they have been used for a variety of other purposes. These include 
identification of circulating canine neoplastic lymphocytes (Finlay and Wyatt, 2015), dengue 
viral antigen (Jessie et al., 2004), and babesia (Torres-Velez et al., 2003). Investigations of 
deep vein thrombosis and pulmonary thromboemboli in animal models (von Bruhl et al., 2012, 
Hand and Chandler, 1962) and sudden death syndrome (associated with blood clots in the 
heart) in chickens (Ononiwu et al., 1979) have also made use of formalin fixed blood clots. 
 
The use and reliability of the formalin fixed blood clot method developed for this study was 
validated by three independent analyses. The first assessed whether cell morphology was 
adequately preserved in the clots to allow neutrophils and lymphocytes to be distinguished 
from each other and counted. The second analysis was performed on human blood samples 
since anti-human CD4 and CD8 antibodies are available for both fresh and fixed human tissue. 
This meant that results obtained by the conventional method for measuring percentages of T 
lymphocytes by flow cytometry could be compared to the IHC method. There was no overall 
significant difference between the results obtained by either method for the same samples. The 
final validation step was performed when, towards the end of this study, an anti-devil CD4 
antibody became available for flow cytometry. The CD4+ T lymphocyte percentages in four 
devil blood samples were obtained by both flow cytometry and IHC staining and were not 
significantly different to each other.  
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The anti CD4+ antibody will bind to monocytes as well as lymphocytes. However, it was 
possible to distinguish monocytes in the sections by their lower levels of CD4 staining and 
their size and nuclear morphology. Monocytes could therefore be excluded from the manual 
count. In addition, since monocytes comprise only 0 - 2% of peripheral blood leucocytes for 
devils (Peck et al., 2015) and 2 – 10% in humans (Curry, 2015), they did not compromise the 
CD4+ T lymphocyte analysis.  
 
All three analyses confirmed that the formalin fixed blood clot method was robust enough to 
evaluate peripheral blood T lymphocyte percentages of devil blood samples that were collected 
in the field. A particular reason for pursuing the method was to determine whether T 
lymphocytes were affected by DFTD. An alternative approach would have been to use blood 
smears. It can, however, be difficult to produce optimal blood smears in the field and there is 
a number of advantages the fixed sections have over smears. These include: no restriction to 
future analyses as occurs with the number of smears made at collection; stability of storage in 
paraffin blocks; fresh sections cut as required and/or as IHC reagents become available; 
formalin fixation and heat antigen retrieval can enhance staining; and, antibodies available for 
IHC may not be applicable to immunocytochemistry. The development of formalin fixed blood 
clots for lymphocyte analysis was a notable finding of this study.  
 
The fixed blood clot method revealed that devils with DFTD had reduced percentages of CD4+ 
and CD8+ T lymphocytes compared to healthy devils. The absolute numbers of CD4+ and 
CD8+ T lymphocytes were not assessed in the present study since total white cell counts 
couldn’t be performed in the field.  However, devils with DFTD are known to have reduced 
total lymphocyte counts compared to healthy devils (Peck et al., 2016) and therefore the lower 
percentages of CD4+ and CD8+ T lymphocytes found in this study imply a reduced total 
number of T lymphocytes. 
 
The lower percentages of peripheral T lymphocytes in devils with DFTD correlates with 
findings from a similar, but much larger (n=365) study on dogs with various cancers. Both 
percentages and absolute counts of lymphocyte subsets were measured (Watabe et al., 2011). 
The study explored how various cancers affected the peripheral blood lymphocyte 
subpopulations of dogs and by extension, their immune status. It found significantly lower 
percentages and absolute numbers of all lymphocyte phenotypes (CD4+ and CD8+ T 
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lymphocytes, and CD21+ B lymphocytes) in dogs with cancer. The conclusion was that 
advanced cancer caused marked immune compromise in these dogs.  
 
The lower percentages of T lymphocyte subsets found in the blood of DFTD affected devils 
was associated with the higher percentage of non-staining (CD4-CD8-) lymphocytes. The 
absence of specific markers prevented identification of these cells. Potential candidates include 
B cells, NK cells, monocytes or NKT cells. The B lymphocyte population could not be 
calculated using the anti-mouse CD79b antibody as this was cross-reactive for all white cells 
in the blood clot sections. Clot sections from devils with DFTD were subsequently stained with 
anti-human MHC-II antibody to determine if the CD4-CD8- cells were B cells and/or antigen 
presenting cells. The MHC-II positive staining cells were too few to quantify implying the non-
staining lymphocytes were not B cells. On a morphological basis, they were unlikely to be 
monocytes. NK cells and/or NKT cells are possibilities, although this seems unlikely given that 
NK cells represent only 8 to 10% of peripheral lymphocytes in humans (Whiteside, 2010). One 
possible explanation for the higher percentage of CD4-CD8- lymphocytes in devils with DFTD 
is provided by Watabe et al whose study found a similar population of non-staining 
lymphocytes in dogs with cancer compared to healthy controls (Watabe et al., 2011). The 
authors suggested that immunosuppressive cytokines secreted by tumours might down-regulate 
expression of CD3 and CD21 molecules. A similar process has been demonstrated in people 
with cancer whereby the density of CD antigen expression (CD3, CD4, CD8 and CD28) on 
lymphocyte populations was lower when compared to healthy donors (Hellstrom et al., 2001). 
Similarly, tuberculosis patients have shown an increased proportion of double negative staining 
T cells (Pinheiro et al., 2012). The lower percentages of CD4+ and CD8+ lymphocytes and 
corresponding increase in non-staining lymphocytes found in devils with DFTD might 
therefore be explained by DFTD-associated cytokines down-regulating expression of CD4 and 
CD8 on lymphocyte populations. The increased percentage of CD4-CD8- lymphocytes was an 
unexpected finding of this study and although there are plausible explanations, the phenotype 
of these cells requires further investigation. 
 
Another unanticipated result of this study was the lower proportion of CD4+ than CD8+ 
lymphocytes found in the peripheral blood of devils. This occurred across all parameters of 
DFTD status, age, sex and season and is the inverse of the usual CD4/CD8 proportions found 
in most eutherian mammals (see Fig. 3.12).  
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Figure 3.12.  Proportion of percentages of CD4+ and CD8+ T lymphocytes found in devils and three 
eutherian mammal species. (Chng et al., 2004, Dean et al., 1991, Itoh et al., 2009). 
 
Humans and most domestic eutherian mammals whose lymphocyte subset populations have 
been calculated e.g. cats, dogs, cattle and horses, have a higher proportion of CD4+ than CD8+ 
T lymphocytes in the peripheral blood and lymphoid organs. This same proportion occurs in 
devil spleen and lymph nodes (Howson et al., 2014). Koalas are the only other marsupial 
species to have their peripheral blood lymphocyte subsets examined and, in common with the 
devils, they have a higher percentage of CD8+ than CD4+ lymphocytes in their peripheral 
 89 
blood (Chandan Mangar pers. comms, August 2016). CD4+ lymphocytes represent 23.8% 
(range 17.3 – 35%) of koala peripheral blood lymphocytes (Mangar et al., 2016) which is 
similar to the 29.7 ± 7.7% identified in devil peripheral blood. It is notable that domestic pigs 
share this same inverse proportion of CD4+ and CD8+ lymphocytes (Saalmuller et al., 1999). 
 
There are at least two differences between eutherian mammals and marsupials regarding their 
T lymphocytes which have been documented and may partially explain the inverse proportion 
identified in devils and koalas. The first relates to regulatory T cells (Tregs), a subset of T 
lymphocytes that dampen the immune response and have a role in preventing autoimmune 
disease (Jiang et al., 2014). Tregs arise in the thymus (tTregs) and in the periphery (pTregs). 
They are CD4 positive thus contributing to the total CD4+ T cell count. The conserved 
noncoding sequence 1 (CNS1) is essential for pTreg cell generation, and CNS1 is present in 
eutherian mammals but absent in monotremes and marsupials (Samstein et al., 2012). 
Eutherian mammals require pTregs to protect against maternal-foetal conflict and allow for 
prolonged in utero foetal development. Indeed, abortion is associated with women who have a 
pTreg deficiency (Sasaki et al., 2004). Marsupial young spend only a brief period of time in 
the placenta (21 days for devils) and undergo the majority of their development in the maternal 
pouch. Although there are no reagents available to identify and confirm the absence of pTregs 
in the peripheral blood of marsupials, the short gestation period and the genetic evidence 
described above suggest they are not present. The lack of CD4+ Tregs in the peripheral blood 
of devils might provide some explanation for the reduced percentage of CD4+ T lymphocytes. 
However, Tregs in the peripheral blood of humans account for 5 to 10% of total CD4+ cells 
(Boye et al., 2010) and thus the lack of pTregs doesn’t entirely explain the inverse proportion. 
 
A second difference found in the marsupial T cell population is the existence of a unique T cell 
receptor, TCRµ (µ for marsupial) (Parra et al., 2007). It is uncertain whether these cells are 
CD4 or CD8 positive, however there is evidence they are co-expressing the g chain i.e. are gµ 
T cells. The µ chain shares an ancestry with d and these cells may therefore have characteristics 
of the gd cell phenotype (Rob Miller pers. comms, February 2016). In humans CD4 and CD8 
molecules are uncommon on gd T cells (Deniger et al., 2014) and therefore cells expressing 
TCRµ might be negative for CD4 and/or CD8. It seems too speculative at this stage to consider 
if these cells account for the CD4-CD8- cells associated with DFTD that were identified in this 
study.  While these differences don’t provide a direct explanation for the inverse proportion of 
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CD4/CD8 lymphocytes found in devils, it can be said they exemplify that differences between 
species, and between marsupials and eutherians, exist.  
 
Of course, many similarities are found between the immune systems of eutherian and marsupial 
species and this was true when assessing the effect age had on T lymphocyte subsets. Juvenile 
devils had higher mean CD4+ and lower mean CD8+ percentages than adults. These findings 
correlate with various studies on dogs and cats that have addressed age-associated changes to 
the immune system. A decrease in the percentage of CD4+ T lymphocytes, and an increase in 
that of CD8+ T lymphocytes was associated with increasing age in healthy dogs across a 
number of studies (Watabe et al., 2011, HogenEsch et al., 2004, Heaton et al., 2002a, Greeley 
et al., 1996). Similar results have been found in cats (Heaton et al., 2002b). The first report of 
age related variation in immunity in a wild mammal population was on a group of Soay sheep 
where T lymphocyte subsets were measured (Nussey et al., 2012). While the CD8+ lymphocyte 
proportion increased with age, the proportion of CD4+ lymphocytes in Soay sheep also 
increased (although naïve CD4 cells (CD45RA+) decreased). 
 
The age-associated percentage increase of CD8+ lymphocytes found across species, including 
devils, might be explained by the T cell clonal expansions (TCEs) that occur with aging. Large 
TCEs are almost always CD8+, are most strongly associated with age, and impact on immune 
responsiveness due to loss of T cell receptor diversity. As such, the CD8+ TCE’s are believed 
to contribute to the “immunodeficiency of senescence” (Messaoudi et al., 2004). Likewise, the 
reduced population of naïve T lymphocytes and increase in memory T cells explain the age 
associated decrease in CD4+ and CD8+ mediated responses (Linton and Dorshkind, 2004).  
 
Seasonal effects on immune function are most commonly explained by adrenal corticosteroids 
which dampen immune function and T cell activity. Their increased secretion in winter and 
decrease in summer link them to the circannual change in immune function (Fares, 2013). This 
study found a significant seasonal effect on the percentage of CD4+ T lymphocytes in healthy 
devils with an increase in autumn/ winter compared to spring/ summer. These (CD4+) findings 
correlate with at least two human studies (Termorshuizen et al., 2002, Paglieroni and Holland, 
1994) and tie in with seasonal changes found in adult male devils whereby stress leukograms 
(reduced total lymphocyte and increased total neutrophil counts) and reduced body weights 
occurred in the post-mating season of autumn (Peck et al., 2015).  
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Tasmanian devils with DFTD had higher levels of both IgM and IgG which correlates with 
results from a previous study that showed devils with DFTD had higher globulin levels than 
healthy devils (Peck et al., 2016). Electrophoresis results for serum samples from 12 devils 
showed the gamma globulin proportion to be similar for healthy and diseased devils (Appendix 
1). The alpha 1 globulin component was notably higher in devils with DFTD, and there was a 
tendency for the beta 1 and beta 2 fractions to be elevated in devils with DFTD when compared 
to healthy devils. IgA, IgM and sometimes IgG can be found in the beta fraction (O'Connell et 
al., 2005). It was reported by Peck et al that when age was considered alongside DFTD, the 
globulin levels for adults with DFTD and healthy adults were the same (Peck et al., 2016). 
Likewise, when age was factored in to the assessment of DFTD’s effect on IgM and IgG levels, 
the increased IgG levels associated with DFTD were only found in juvenile devils. There was 
no effect on IgM. It therefore appears that the major effect of DFTD with respect to the 
immunoglobulins analysed is restricted to increasing IgG levels in juvenile devils and a 
corresponding reduction in their IgM:IgG ratio. A large proportion of DFTs are ulcerated 
(74%) and/or necrotic (73%) (Loh et al., 2006) and this may allow for bacterial infection of the 
tumours (Peck et al., 2016). Increased pathogen exposure associated with DFTD might 
therefore account for the increased globulins. These results contrasted somewhat to those of a 
recent study which found DFTD was associated with a lower IgM:IgG ratio, independent of 
age (Ujvari et al., 2016). The authors suggested the IgM:IgG ratio in devils may play a role in 
devil susceptibility to DFTD. That study had a smaller sample size (n=23) than the one 
described in this thesis, and used mRNA rather than protein for analysis. A longitudinal study 
would allow further exploration of the IgM:IgG association with DFTD.  
 
With respect to healthy devils, serum levels of IgM and in particular IgG were significantly 
increased in adult devils. These findings correlate with a previous report showing that the 
serum globulin range for healthy adult devils (29-46 g/L) was higher than the range for healthy 
juveniles (22-41 g/L) (Peck et al., 2015). The same explanation suggested above might account 
for these differences i.e. cumulative antibody responses to increased pathogen exposure which 
occurs over time. Humans also show increasing IgM and IgG levels with age (up to middle 
age) (Jazayeri et al., 2013, Gonzalez-Quintela et al., 2008). Similarly, a study comparing IgM 
and IgG serum levels in captive and wild hyenas found significantly higher serum levels of 
both in wild hyenas (Flies et al., 2015). Although the study didn’t compare hyena ages, the 
increased exposure to pathogens experienced by the wild cohort was the explanation proposed 
for the differences. This ties in with the devil findings in so far as increased exposure occurs 
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with age. In addition, it is expected the naïve juvenile immune systems would have relatively 
less IgG since IgG is class switching i.e. is made in response to antigen stimulation and thus 
increases with exposure to insults and infection as occurs with aging.  
 
In conclusion, this study showed that DFTD altered some of the immune components of the 
peripheral blood of devils. The most consistent finding in both adult and juvenile devils with 
DFTD was a reduction in the CD4+ and CD8+ lymphocyte populations. This could interfere 
with cell mediated immune responses and allow the progression of DFTD. The effect of DFTD 
on immunoglobulin levels was restricted to juvenile devils which had an increase in IgG levels. 
This might be explained by increased pathogen exposure secondary to DFTD rather than a 
direct result of DFTD. This study also showed how devils’ peripheral blood lymphocytes and 
immunoglobulins compared to those of other species. These were influenced in a similar 
fashion by the parameters of age and season. One notable difference however was the 
proportion of CD4/CD8 lymphocytes in devils which was the inverse of most eutherian 
mammals. Although similarities across species clearly exist, demonstrated differences should 
not be dismissed. Such differences may have consequences for the mechanisms which regulate 
the development and expression of immune responses to disease, including cancer and should 
be considered when exploring the interplay between DFTD and the devil’s immune system. 
  
 93 
 
 
 
 
Chapter 4 
 
 
 
Demonstration of immune responses against devil 
facial tumour disease in wild Tasmanian devils 
 
   
 94 
Chapter 4. Demonstration of immune responses against devil facial tumour disease in 
wild Tasmanian devils ........................................................................................................... 95 
4.1. Introduction ................................................................................................................... 95 
4.2. Materials and methods .................................................................................................. 96 
4.2.1. Individual devils and sample collection ................................................................. 96 
4.2.2. DFTD assessment .................................................................................................. 98 
4.3. Results ......................................................................................................................... 101 
4.4. Discussion ................................................................................................................... 106 
 
  
 95 
Chapter 4. Demonstration of immune responses against devil facial tumour disease in 
wild Tasmanian devils 
 
4.1. Introduction 
 
Devil facial tumour disease (DFTD) is a recently emerged transmissible cancer threatening the 
Tasmanian devil with extinction in the wild (Hawkins et al., 2008). It is transmitted when 
susceptible and infected individuals bite each other and is considered invariably fatal, with 
most animals dying within 6 to12 months of the tumour first appearing (Hamede et al., 2012). 
The literature reports that no protective immune response has been observed (Siddle and 
Kaufman, 2015). 
 
The disease is transmitted as an allograft (Pearse and Swift, 2006) and three explanations were 
initially suggested to explain the lack of immune rejection: the limited genetic diversity of the 
species; the unknown competency of the devil’s immune system; and the immune evasion 
mechanisms of the tumour (Woods et al., 2015). All research to date addressing these 
possibilities suggests it is the successful immune evasion strategies employed by the tumour 
cells that are primarily responsible for the transmission of DFTD (Woods et al., 2015, Siddle 
and Kaufman, 2013, Siddle et al., 2013). 
 
Current DFTD research suggests that a major mechanism of immune escape is down-regulation 
of the major histocompatibility complex class I molecule (MHC-I) (Siddle et al., 2013). MHC-I 
cell surface expression occurs on all nucleated cells and allows the immune system to recognise 
foreign or infected cells. Some cancers fail to express surface MHC-I, a mechanism which 
contributes to evasion of the host’s T cell response. The only other naturally occurring 
transmissible cancer to affect a mammalian species is canine transmissible venereal tumour 
(CTVT) in domestic dogs. CTVT also demonstrates MHC-I down-regulation in its progressive 
phase (Hsiao et al., 2002).  However, after three to four months of tumour growth, there is 
increased surface MHC-I expression resulting in a host alloresponse. This is demonstrated by 
host antibody production and T lymphocyte infiltration of the tumour resulting in tumour 
stabilisation or regression and immunological memory. MHC-I expression of CTVT is 
associated with the presence of inflammatory cytokines (Hsiao et al., 2002, Cohen, 1972). 
Likewise DFTD’s down-regulation of surface MHC-I can be reversed in vitro by treatment of 
DFTD cells with the inflammatory cytokine interferon gamma (IFN-γ) (Siddle et al., 2013). 
 96 
 
Down-regulation of MHC-I provides an explanation for DFTD transmission and is believed to 
be responsible for the lack of a T cell mediated immune response against the tumour. The long-
standing assumptions are that DFTD always escapes the devils’ immune system, and that the 
disease is invariably fatal. These assumptions were re-examined in this study by analysing 
serum and tumour samples from a population of wild devils to detect the presence of 
anti-DFTD immune responses. 
 
4.2. Materials and methods 
 
4.2.1. Individual devils and sample collection 
 
The samples used in this study were collected between 2008 and 2014 from a closely monitored 
population at West Pencil Pine in north western Tasmania. Blood samples were collected from 
a total of 52 devils. Ages ranged from one to six years, with 34 females and 18 males (Table 
4.1). Tumour samples were collected from a total of 20 devils. Tumour sample collection was 
dependent on size and location of the tumour, and was not always possible in a field setting. 
Tumour size was measured by recording length, width and depth with 15 cm caliMax calipers. 
See Chapter 2.3.3 and 2.3.4 for blood and biopsy collection, and 2.3.5 for fine needle aspirate 
collection for subsequent cytology, karyotyping or immunocytochemistry.  
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Table 4.1. Summary of serum samples collected and analysed from Tasmanian devils from West Pencil 
Pine.  
  
Age (years) 1 2 3 4 5 6 Total 
Number of devils 16 15 11 4 4 2 52 
DFTD+ (including those with regressed 
tumours) 
5 10 11 3 3 2 34 
DFTD- 11 5 0 1 1 0 18 
Females 8 8 10 3 4 1 34 
Males 8 7 1 1 0 1 18 
Females DFTD+ 2 6 10 2 3 1 24 
Males DFTD+ 3 4 1 1 0 1 10 
Number of devils that had only 1 serum 
sample analysed 
5 2 0 0 0 0 7 
Number of devils that had multiple serum 
samples analysed 
11 13 11 4 4 2 45 
Number of devils that had serum taken 
prior and subsequent to becoming 
DFTD+ (including those with regressed 
tumours) 
0 4 7 2 2 2 17 
Number of devils that had their final 
serum sample taken at time of first 
clinical signs 
3 6 4 1 0 0 14 
Number of DFTD- devils that had 
multiple serum samples analysed 
8 4 0 1 1 0 14 
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Blood was collected from a further 20 devils from a DFTD free island to use as the negative 
control serum (Table 4.2). The serum samples had been collected > 6 months after release of 
the devils on to the island. The adult (> 1 year old) females had higher levels of background 
IgG antibody than the other cohorts so their sera were used as the negative control for the wild 
devils from West Pencil Pine.  
 
Table 4.2. Summary of samples collected and analysed from Tasmanian devils from Maria Island 
(DFTD free island) used as the negative control serum.  
 1 year old Adult (> 1 year old) 
Males 5 5 
Females 5 5 
 
 
4.2.2. DFTD assessment 
 
In cases where histopathological samples were not taken, fine needle aspirate (FNA) collection 
and either cytological examination (one devil), cell culture and karyotype (six devils), or 
immunocytochemistry (ICC) (five devils, two of which also had biopsies collected) were taken 
from cutaneous or oral raised nodular or ulcerated lesions. The results of these methods 
supported DFTD identification. For the remaining 14 devils, visual assessment of tumour 
location and appearance according to previously described classification methods (Hawkins et 
al., 2006) supported DFTD identification. Table 4.3 summarises the techniques used to identify 
DFTD for each devil in this study. See Chapter 2.2.10 for karyotype method. 
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Table 4.3. Summary of techniques used to identify DFTD in the 34 DFTD+ devils. 
 
Diagnostic technique No. of DFTD cases Veterinary pathologist 
report/ periaxin positive 
Visual diagnosis 14 / 
 
Histopathology (biopsy) 11 (including TD3’s 
DFT1 recurrence) 
11 
Cytology: May Grunwald-Giemsa stain 1 1 
 
Cytology: immunocytochemistry 5 (2 of these also had 
biopsies from which a 
histology diagnosis was 
made) 
5 
Cell culture & karyotype 6 6 
 
“/” indicates not performed 
 
Histopathology and immunohistochemistry interpretation 
 
A diagnosis of DFTD was made based on clinical findings supported by histopathological 
examination of tumour biopsies for ten devils. Histopathology was assessed by a veterinary 
pathologist. Confirmation of DFTD by HE stained sections was based on histopathologic 
findings consistent with Loh et al (Loh et al., 2006). Immunohistochemistry (CD3 and MHC-II) 
was performed on the nine tumour biopsies available for this study. See Chapter 2.2.1 for the 
IHC staining procedure. Assessment of tumour infiltrating lymphocytes in anti-CD3 antibody 
stained sections was performed by a veterinary pathologist and based on the method outlined 
by Zhang et al (Zhang et al., 2003) and reviewed by Gooden et al (Gooden et al., 2011). A 
similar method for counting the number of infiltrating positive MHC-II cells was performed.  
 
Immunocytochemistry  
 
Immunocytochemistry (ICC) was performed by Alison Caldwell, Southampton on five tumour 
fine needle aspirates (FNA’s). The samples were stained for periaxin, a positive marker for 
DFTD cells (Tovar et al., 2011), and for β2microglobulin (β2m), a component of the MHC-I 
molecule. 
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From each FNA sample, 100 µl was seeded onto poly-L-lysine (Sigma P4707) coated slides.  
Slides were incubated for 60 minutes at room temperature.  Excess cell suspension was 
aspirated and slides placed in PBS for 10 minutes.  Cells were incubated in ice-cold methanol 
for 10 minutes and air-dried, before incubation in blocking buffer (10 % goat sera in PBS) for 
30 minutes to minimize any non-specific absorption of antibodies. Cells were incubated in anti-
devil β2m antibody at 20 µg/ml and periaxin in blocking buffer for 30 minutes.  Cells were 
washed twice in PBS for 10 minutes and then 5 minutes.  The secondary antibodies (goat anti-
mouse Alexa Fluor® 488 and goat anti-rabbit Alexa Fluor® 647) were diluted 1:1000 in PBS 
and cells were incubated for 30 minutes.  Cells were washed three times in PBS for 5 minutes.  
Slides were mounted with DAPI mounting media (Fluoroshield™ with DAPI, Sigma). 
 
Serum antibody detection 
 
Indirect immunofluorescence and flow cytometry to measure serum anti-DFTD IgG antibody 
levels was performed on the serum samples against un-manipulated DFTD cells (i.e. cells not 
expressing MHC-I, referred to as MHC-I-ve DFTD cells); and cells treated with IFN-γ to up-
regulate MHC-I expression i.e. MHC-I+ve DFTD cells. For 45 of the individual devils, multiple 
serum samples collected over an extended period were analysed. Sera from a translocated 
population of captive born devils living in wild conditions on a DFTD-free island were used 
as the negative control. See Chapter 2 for MHC-I up-regulation (2.2.5) and flow cytometry 
(2.2.7) procedures. Antibody levels were recorded as median fluorescence intensity (MFI). 
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4.3. Results 
 
This study aimed to identify an immune response against DFTD by examining serum and 
tumour samples from a population of wild devils. Of the 52 devils, 46 had no detectable serum 
IgG antibody against either MHC-I+ve or MHC-I-ve DFTD cells. The remaining six devils 
(referred to here as TD1 through to TD6) had serum IgG antibody against MHC-I+ve DFTD 
cells, but not MHC-I–ve cells. Only one of these six devils had clinical signs of DFTD at initial 
sample collection. The remaining five devils developed DFTD at some stage during sample 
collection (Table 4.4). DFTD assessment was made in TD1, TD2 and TD3 by visual 
examination; in TD4 by cytology of the FNA; in TD5 by histopathology; and in TD6 by ICC 
of the FNAs. 
 
Multiple serum samples from each of the six devils were analysed and for each devil the earliest 
sample had the same MFI as the negative control.  After these devils showed clinical signs of 
DFTD, they developed anti-DFTD antibodies (Fig. 4.1). Remarkably, DFTD regression 
occurred in four of the six devils that had seroconverted (TD1, TD2, TD3 and TD4). When 
each devil was retrapped between 4 and 15 months after DFTD was first noted, their tumours 
were no longer visible and anti-DFTD antibodies were detected. TD1 and TD2 were not 
retrapped more than three months after the regression was observed. TD3 remained disease-
free for two years following tumour regression but at the age of five years, a tumour biopsy 
confirmed recurrence of DFTD. Serum antibodies persisted in TD3 at this time and tumour-
infiltrating MHC-II+ cells and CD3+ T lymphocytes were present in the biopsy (Table 4.5). 
TD4 remained disease free for three years to the age of six years, beyond which it was not 
retrapped (six years is considered the maximum lifespan for a wild devil). 
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Table 4.4. DFTD and antibody (Ab) status of 6 Tasmanian devils exhibiting anti-DFTD responses  
 
 
Serum Ab column: “/” no serum sample collected, “negative” same as MFI control, “medium” 2 - 4 x 
MFI control, “high” > 4 x MFI control) 
YOB = year of birth 
 
  
Devil ID. YOB sex date DFTD status serum Ab's Comments 
 
TD1 2006 F Nov 08- May 11 
Jul-11 
Nov-11 
Feb-12 
D- 
D+ 
D- 
D- 
negative 
/ 
 medium 
medium 
 
 
tumour regressed 
 
(not retrapped after Feb 12) 
TD2 2006 F Feb 09- Feb 11 
May-11 
Nov-11 
D- 
D+ 
D- 
negative 
 medium 
high 
  
 
tumour regressed 
(not retrapped after Nov 11) 
TD3 2009 F Feb-11 
Feb-12 
May-12 
Feb-14 
May-14 
D- 
D+ 
D- 
D- 
D+ 
negative 
negative 
/ 
 high 
 high 
 
 
 
tumour regressed 
disease free for 2 years 
DFTD, T lymphocytes in biopsy 
(not retrapped after May 14) 
TD4 2008 M Jul-11 
Aug-12 
Nov-13 
May-14 
D- 
D+ 
D-   
D- 
negative  
/ 
 medium 
 high 
 
 
tumour regressed 
 
still disease free 
(not retrapped after Aug 15) 
TD5 2008 F Feb 09-Nov 10 
Feb-11 
May-11 
D- 
D+ 
D+ 
negative 
 negative 
 high 
  
  
T lymphocytes in biopsy 
(not retrapped after May 11) 
TD6 2010 M Nov-13 
Feb-14 
D+ 
D+ 
negative 
 high 
 
MHC+ve DFTD cells in FNA 
(not retrapped after Feb 14) 
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Figure 4.1. Flow cytometric analysis of anti-DFTD antibody responses. (a to f) IgG serum antibody 
results of TD1 to TD6 against MHC-I+ve DFTD cells compared to negative control. In brackets are the 
dates each devil was first observed with DFTD (D+) and when the tumour was no longer present (D-); 
(g) representative results from 3 of the 46 devils that had no serum antibody; (h) negative results of 
TD3 for serum IgG against MHC-I-ve DFTD cells, representative of TD1 to 6. Control = serum from 
wild devil from DFTD-free island. 
 
 
  
(a) (b) (c)
(d) (e) (f)
(g) (h)
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Table 4.5. Immunohistochemistry for DFTD biopsies. Columns show number of positive staining 
cells per high powered field (HPF) counted. 
 
Animal ID CD3+ tumour infiltrating 
T cells/ HPF ± SD 
MHCII+ tumour infiltrating 
cells/ HPF ± SD 
TD 416 0 / 
TD 417 1± 1 / 
TD 421 0 / 
TD 433 0 / 
TD 439 0 / 
TD 455 0 / 
TD 473 0 / 
TD 3 4±2 4± 2 
TD 5 20± 2 18±2 
 
NB All biopsies came from devils which also had serum samples assessed for anti-DFTD antibody. 
Only TD3 and TD5 had serum antibody against DFT1 cells.  
10 high powered fields (HPF) counted for all tumours except for TD3 (7 x HPF) and TD5 (3 x HPF) 
because these were the only areas for the tumours. 
“/” signifies not performed 
 
 
Tumour regression for TD5 and TD6 was not observed, however their tumour samples showed 
interesting features. At the time of TD5’s seroconversion, the biopsy had tumour infiltration of 
MHC-II and CD3 positive cells (Fig. 4.2e,f,h,i; Table 4.5). TD6 had tumour FNA’s and serum 
collected when first trapped and again three months later. Cells from the initial FNA were 
periaxin positive and faintly positive for β2m (Fig. 4.2j and k), however three months later, 
coinciding with seroconversion, the periaxin positive cells were strongly positive for β2m 
indicating MHC-I expression by the DFTD cells (Fig. 4.2l). Neither TD5 nor TD6 were 
retrapped following seroconversion. In contrast to TD3, TD5 and TD6, the tumour samples 
from devils without serum antibody did not show significant tumour infiltration of immune 
cells or β2m staining. 
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Figure 4.2. Evidence for immune cell infiltration of DFTD or MHC-I expression of DFTD cells. (a to i) 
IHC staining of DFTD tumour biopsies. Top and middle rows taken at 20x magnification, scale bar 
indicates 100 µm. Bottom row taken at 100x magnification, scale bar indicates 20 µm. Positive cells 
for each marker are brown; haematoxylin (blue) is the counter stain. (a,d,g) periaxin, marker for DFTD 
cells; (b,e,h) CD3, marker for T lymphocytes; (c,f,i) MHCII, marker for antigen presenting cells; (a 
to c) typical DFTD biopsy with no evidence of immune response; (d to f) tumour biopsy from TD5 
showing infiltration of CD3 and MHCII positive cells throughout the tumour; (h & i) immune cells 
infiltrating DFTD cell clusters. (j to l) ICC of DFTD cells with periaxin (red), and β2m (green) to 
identify MHC-I surface expression: (j) DFTD cells from culture; (k) DFTD FNA from TD6 collected 
in Nov 2013; (l) DFTD FNA from TD6 collected in Feb 2012. (ICC images taken at 20x 
magnification) 
c
d e f
g h i
j k l
a b
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4.4. Discussion 
 
The immune escape mechanisms of DFTD play a significant role in its successful transmission 
and tumour development. While anti-DFTD immune responses have been induced in captive 
devils by immunising with killed DFTD cell preparations (Kreiss et al., 2015), no convincing 
evidence for immune responses against DFTD had been identified in wild devils. This study 
reports the first evidence of anti-DFTD immune responses occurring in wild Tasmanian devils 
exposed to DFTD. 
 
The serum antibodies directed against IFN-γ treated DFTD cells (MHC-I+ve) found in six devils 
may have resulted from an initial immune response against the primary tumour and subsequent 
IFN-γ release. This may have up-regulated MHC-I expression on the DFTD cells, resulting in 
an immune response against these modified cells. The results presented here indicate that this 
response is initiated by infiltrating T lymphocytes, which although rare, have been documented 
in at least one case of DFTD and associated with tumour cell surface expression of MHC-I 
(Siddle et al., 2013). What caused the initial immune response in these six devils is not clear. 
However, the increase in MHC-I expression on DFTD cells potentially provided a mechanism 
for T cell mediated killing of tumour cells and ultimately tumour stabilisation or regression. 
Antibody production, in the form of IgG, provides confirmatory evidence that an anti-DFTD 
immune response had been generated. The IgG antibodies could facilitate tumour cell killing 
via antibody dependent cell mediated cytotoxicity.  
 
It is not certain which epitopes on the MHC-I+ve DFTD cells are recognized by the serum 
antibodies found in these six devils. Possible candidates are:  the MHC-I molecule; the peptide 
presented by the MHC-I molecule; and/or other molecules that are also up-regulated by 
cytokine incubation but not necessarily associated with MHC-I. Identification of these epitopes 
will require further analysis, for example by western blotting. 
 
Cell mediated immunity, specifically T cell, has a primary role in tumour immunity. There is 
however evidence for antibody production correlating with anti-tumour activity in human cases 
of breast and pancreatic cancer as well as in CTVT in dogs (Blixt et al., 2011, Hamanaka et al., 
2003, Cohen, 1972). Although there are significant differences between CTVT and DFTD, 
they share characteristics of transmissibility and MHC-I down-regulation. Indeed, the 
development of IgG antibodies against DFTD cells may parallel what is believed to occur in 
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CTVT cases: after the canine tumour has established there are increased numbers of MHC-I+ve 
CTVT cells discernable by immunohistochemistry and immunocytochemistry, and the 
development of serum IgG antibodies against CTVT cells occurs (Hsiao et al., 2002, Cohen, 
1972). The experimentally induced CTVT’s tend to regress (Hsiao et al., 2002) whereas the 
naturally occurring tumours seem to remain in equilibrium as locally invasive tumours with 
metastases being uncommon (Das and Das, 2000). It is probable that this equilibrium or 
regression occurs as a result of the increased MHC-I expression of the tumour cells. The 
consecutive tumour FNA’s taken from TD6 showed increased intensity of β2m surface staining 
indicative of increased MHC-I expression on the DFTD cells. Up-regulation of MHC-I, along 
with seroconversion occurring at that time, indicates that DFTD and CTVT may share 
additional characteristics of disease progression.  
 
While there has been no observed reduction in the demographic effect of DFTD in the local 
population of this study, this evidence indicates that DFTD does not always escape detection 
by the immune system, and death may not be the inevitable outcome of infection. The naturally 
occurring immune responses against DFTD may enable identification of significant tumour 
antigens and thus advance DFTD vaccine development. If there is a heritable component to the 
immune response, over time selection should favour those individuals that are able to recognize 
the tumour, with increased survival and therefore lifetime reproductive output leading to 
increased representation of these devil lineages and increased survival of wild populations. 
 
In summary, this study demonstrated a naturally occurring immune response against DFTD in 
this population of wild devils. The presence of anti-DFTD antibodies in the four devils with 
tumour regression is indicative of immune-mediated regression. The findings highlight the 
value of monitoring disease at the individual level where ongoing microevolutionary changes 
can be detected and permit evaluation of their impact on the disease trajectory and epidemic 
outcome at a population level. 
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Chapter 5. Immune mediated regression of devil facial tumour disease following 
immunotherapy in immunised devils 
 
 
5.1. Introduction 
 
The development of a DFTD vaccine would provide an extremely useful conservation tool for 
efforts aimed at preventing extinction of the wild Tasmanian devil. Research toward this goal 
has been underway since 2006. There are many factors which make this a reasonable objective: 
the highly conserved morphology and genotype of DFTD (Woods et al., 2007); the ability of 
devils to produce both cytotoxicity and antibody responses against xenogeneic cancer cells 
(Brown et al., 2011); the demonstration that mice injected with DFTD cells produce an immune 
response against the cells and do not develop tumours (Pinfold et al., 2014); and finally, the 
results from preliminary DFTD immunisation trials on devils which showed that devils can 
produce humoral and cellular immune responses against DFTD cells (Kreiss et al., 2015).  
 
A subsequent study demonstrated that immune mediated regression of an experimentally 
induced devil facial tumour is possible (paper submitted). The devil in the study was 
immunised with DFTD cells. She was then challenged with live DFTD cells and developed a 
tumour. This tumour regressed following the administration of various immunotherapies 
including a subcutaneous injection of live DFTD cells treated to express surface MHC-I (i.e. 
MHC-I+ve DFTD cells). It was hypothesised that this injection of MHC-I+ve DFTD cells was 
primarily responsible for the tumour regression.   
 
This current study initially sought to establish whether anti-DFTD tumour responses could be 
induced by inactivated MHC-I+ve DFTD cells. Immunisation with these cells resulted in 
antibody responses against DFTD.  It also delayed but was not sufficient to prevent 
experimental tumour engraftment in all the devils. This provided the opportunity to repeat the 
immunotherapy used in the previous study i.e. administration of live MHC-I+ve DFTD cells. 
Once again, this resulted in immune mediated tumour regression. This study had two outcomes. 
It demonstrated that inactivated MHC-I+ve DFTD cells as the antigenic basis of an 
immunisation protocol will elicit antibody responses against DFTD.  It also confirmed that 
DFTD tumours can undergo immune mediated regression in vivo. 
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5.2. Materials and methods 
 
5.2.1. Tasmanian devils and biological sample collection 
 
The Tasmanian devils were housed according to conditions described in Chapter 2.3.2. The 
first immunisation trial (Trial 1) used two devils. Trial 2 used a total of four devils: two for 
immunisation, one as an adjuvant-only control, and one as the non-immunised control for the 
live DFTD cell challenge. The age, sex and origin of the devils in each of the trials is 
summarized in Table 5.1. 
 
Table 5.1. Age, sex and origin of the devils in each of the trials. 
Devil Age (years) 
at the start of 
the trial 
Sex Origin Trial 
Badger 7 Female Wild born 1 
Maydim 6 Female Wild born 1 
Tip 6 Male Captive born 2 
Stinky 7 Female Captive born 2 
Phil 5 Male Wild born 2 
Adjuvant control 
Merrick 5 Male Captive born 2 
Non-immunised 
control for live 
challenge 
 
The two devils in Trial 1 did not require anaesthesia for immunisation or blood collection. 
These procedures along with live cell challenge and therapy on the four devils in Trial 2 were 
performed under general anaesthesia according to Chapter 2.3.6. 
 
Up to 10 ml of blood was obtained from the jugular vein, with up to 4 ml placed into clot 
activating tubes for serum analysis, and the remainder into lithium heparin anticoagulant tubes 
for separation of peripheral blood lymphocytes (PBL’s) for cytotoxicity assays. See Chapter 2 
for blood collection (2.3.3), and serum and PBL separation (2.2.2 and 2.2.3). 
 
Tumour biopsies were collected using sterile 4 mm disposable biopsy punches (Kai Medical). 
Biopsies were divided with a scalpel blade and one portion placed into 1 ml 10% neutral 
buffered formalin and the other into 1 ml RNAlater. 
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5.2.2. Cell culture and preparation of DFTD cells for immunisation and challenge 
	
The immunisation protocols for Trial 1 and Trial 2 are summarized in Table 5.2. See Chapter 
2 for full details on cell culture (2.2.4) and immunisation preparation (2.2.9). 
 
Table 5.2. Immunisation protocols for Trials 1 and 2. 
Time Trial 1 
(two devils) 
Trial 2 
(two devils and one adjuvant-
only control*) 
 
Week 0 3 x 107 MHC-I+ve DFTD cells 
sonicated 
2 x 106 MHC-I+ve DFTD cells 
irradiated 
Week 2 / 2 x 106 MHC-I+ve DFTD cells 
irradiated 
 
Week 4 3 x 107 MHC-I+ve DFTD cells 
sonicated 
2 x 106 MHC-I+ve DFTD cells 
irradiated 
 
Week 8 2 x 106 MHC-I+ve DFTD cells 
irradiated 
2 x 107 MHC-I+ve DFTD cells 
sonicated 
 
Week 12 2 x 106 MHC-I+ve DFTD cells 
irradiated 
 
/ 
1st Booster 4 months 
after last immunisation 
 
2 x 106 MHC-I+ve DFTD cells 
irradiated 
(both devils) 
 
/ 
1st Booster 6 months 
after last immunisation 
 
/ 2 x 106 MHC-I+ve DFTD cells 
irradiated 
both devils 
2nd Booster 7 months 
after previous booster 
 
2 x 106 MHC-I+ve DFTD cells 
irradiated 
(one devil only) 
 
/ 
 
Final cell suspensions were in 1ml PBS and the following adjuvants added to each immunisation: 
ISCOMATRIX 50 µl; polyI:C 100 µg; CpG 1585 50 µg and CpG 2395 50 µg.  
*The adjuvants were added to 1 ml PBS for the adjuvant-only control devil. 
“/” indicates not performed 
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Live tumour challenge: 
 
One immunised devil (Maydim) was challenged with a single dose of 25,000 live DFTD cells 
(cell line C5065) resuspended in 0.25 ml of PBS injected subcutaneously into the rump. Two 
immunised devils (Tip and Stinky) and the non-immunised control (Merrick) were challenged 
with 100,000 live DFTD cells in 1 ml of PBS into the left-hand side of the rump and 25,000 
live DFTD cells into the right-hand side of the rump. The areas of injection were shaved for 
easier visualization and to mark the location. The devils were examined monthly under 
anaesthesia for evidence and measurement of tumours. 
 
5.2.3. Immune response analysis  
 
See Chapter 2 for the flow cytometry procedure to detect serum antibodies (2.2.7), and the 
cytotoxicity assay method (2.2.8) to identify cell mediated immune responses.  For flow 
cytometry analysis, the median fluorescence intensity ratio (MFIR) was used to classify the 
antibody responses. The MFIR is the median fluorescence intensity (MFI) of DFTD cells 
labelled with immune serum divided by the MFI of DFTD cells labelled with pre-immune 
serum. The responses were considered:  
Negative:  MFIR  < 1.5 times the pre-immune response     
Low:  MFIR 1.5 to 2 times the pre-immune response     
Medium: MFIR 2 to 4 times the pre-immune response      
High:  MFIR  > 4 times the pre-immune response  
 
Tumour biopsies were processed and stained via immunohistochemistry with anti-human CD3, 
anti-human periaxin, anti-devil CD4 and anti-devil CD8. See Chapter 2.2.1 for  histology and 
immunohistochemistry methods. 
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5.3. Results 
 
Four devils were immunised in two separate trials (Trials 1 and 2) using MHC-I+ve DFTD cells 
inactivated either by sonication or gamma radiation, plus adjuvants. All devils received four 
immunisations in their primary course followed by boosters. The protocols of the two trials 
differed in the interval between immunisations and the order that sonicated or irradiated cells 
were given. The aim was to determine if immunisation with non-viable MHC-I+ve DFTD cells 
would produce a measurable immune response that would protect the devils against a live 
DFTD cell challenge. In Trial 2, one devil (Phil) was used as an adjuvant-only control and one 
devil (Merrick) as a non-immunised control for the live challenge. There were no adverse 
reactions identified to the immunisations. 
  
For the devils in Trial 2, an attempt was made to assess cell mediated immune responses to the 
immunisations with a flow cytometry based cytotoxicity assay. The reliability of this assay was 
uncertain and so emphasis was placed on the DFTD-specific IgG antibody levels in devil serum 
to evaluate the immune responses after the immunisations in each protocol. Antibody responses 
were evaluated against interferon gamma (IFN-g) treated (MHC-I+ve) and untreated (MHC-I-ve) 
DFTD cells.  
 
Three of the immunised devils and the non-immunised control devil were later challenged with 
live DFTD cells. Tumours developed in two of the immunised devils and the control devil and 
immunotherapy was administered. Tumour biopsies were taken before and after 
immunotherapy, and evaluated for immune cell infiltration by immunohistochemistry. The 
tumour rejection and anti-DFTD antibody responses that occurred in the two immunised devils 
were recorded. 
 
5.3.1. Trial 1  
 
Protocol 
 
Two devils (Maydim and Badger) were given a primary course of four immunisations at 
monthly intervals. The first two immunisations were sonicated DFTD cells that had been 
treated with IFN-g to up-regulate MHC-I. The third and fourth immunisations were irradiated, 
IFN-g treated DFTD cells. Boosters with irradiated MHC-I+ve DFTD cells were given after four 
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months (both devils) and again after another seven months (one devil, Maydim). All 
immunisations/boosters included the adjuvants ISCOMATRIX™, Poly I:C and CpG. 
 
Responses to immunisation 
 
Both Maydim and Badger developed moderate antibody responses against IFN-g treated 
MHC-I+ve and untreated DFTD cells (Figs 5.1a,b). Maydim was given two booster injections 
of irradiated MHC-I+ve DFTD cells at four and eleven months after the last immunisation but 
these did not appear to increase the antibody levels.  
 
Response to live DFTD cell challenge 
 
Badger was euthanized for age-related health reasons soon after her booster and wasn’t 
challenged with live DFTD cells. After the second booster, Maydim was challenged with a 
single injection of 25,000 live DFTD cells on the rump. No tumour had developed after six 
months at which point she was euthanased for age-related health reasons. Medium to high 
antibody responses against both IFN-g treated and untreated DFTD cells were detected after 
the live tumour cell challenge and similar levels identified in the post-mortem sample (Fig. 
5.1c).  
 
Trial 1 conclusion 
 
This trial showed that inactivated MHC-I+ve DFTD cells when used in combination with 
adjuvants could elicit antibody responses against DFTD cells. It suggested that an 
immunisation protocol could delay and possibly prevent experimental DFTD tumour 
engraftment. 
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Figure 5.1. Trial 1 antibody response in Maydim and Badger after immunisation. (a) Maydim 
developed medium to high antibody responses against both MHC-I+ve and MHC-I-ve DFTD cells after 
immunisation with sonicated and irradiated MHC-I+ve DFTD cells, and a booster with irradiated 
MHC-I+ve DFTD cells. (b) Badger produced medium to high levels of antibodies against both MHC-
I+ve and MHC-I-ve DFTD cells following the same immunisation protocol as Maydim. Badger was 
euthanased before DFTD tumour cell challenge. (c) For Maydim, antibody levels were maintained after 
challenge with live MHC-I+ve DFTD cells and persisted until post-mortem 189 days later. No tumour 
development was detected after challenge. 
 
 
  
MHC-I (-) MHC-I (+)
(a)
(b)
Pre immune
Post immunisation with sonicated cells
Post immunisation with irradiated cells
Post booster
(c)
Fluorescence intensity
Pre immune
Post challenge
Post mortem
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5.3.2. Trial 2 
 
Protocol 
 
The second trial attempted to shorten the immunisation protocol by giving three irradiated 
MHC-I+ve DFTD cell preparations at fortnightly intervals. Two devils (Tip and Stinky) 
received this protocol. Only a minimal antibody response resulted in Tip, so a fourth 
immunisation (sonicated MHC-I+ve DFTD cells) was given to both devils one month after the 
third. A booster with irradiated MHC-I+ve DFTD cells was given six months later.  All 
immunisations/boosters were in combination with ISCOMATRIX™, Poly I:C and CpG 
adjuvants. 
 
Responses to immunisation 
 
Tip did not produce antibodies after receiving irradiated cells, but medium antibody responses 
against both IFN-g treated and untreated DFTD cells were evident after receiving the sonicated 
IFN-g treated DFTD cells. The booster did not increase the antibody response (Fig. 5.2a). 
Stinky produced medium/high antibody responses against both IFN-g treated and untreated 
DFTD cells after receiving the irradiated IFN-g treated DFTD cells. The antibody response 
increased after the fourth immunisation with sonicated IFN-g treated DFTD cells (Fig. 5.2b). 
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Figure 5.2. Trial 2 antibody responses in Tip and Stinky after immunisation (a) Tip: Antibody responses 
against DFTD cells were not detected after immunisation with irradiated MHC-I+ve DFTD cells. 
Immunisation with sonicated MHC-I+ve DFTD cells induced medium levels of antibodies against both 
MHC-I-ve and MHC-I+ve DFTD cells. A booster with irradiated MHC-I+ve  DFTD cells did not increase 
the antibody levels. (b) Stinky: Medium levels of antibody against both MHC-I+ve and MHC-I-ve  cells 
were observed after immunisation with irradiated MHC-I+ve cells. Antibody levels increased after 
immunisation with sonicated MHC-I+ve DFTD cells. Booster with irradiated cells did not alter the level 
of antibody. 
 
  
MHC-I (-) MHC-I (+)
(a)
(b)
Pre immune
Post immunisation with irradiated cells
Post immunisation with sonicated cells
Post booster
Fluorescence intensity
a) Tip
b) Stinky
c) Figure	5.2
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Cytotoxicity assays were performed for both devils after each immunisation, and for the 
adjuvant-only control devil (Fig. 5.3). The cytotoxicity assay results were deemed unreliable 
if spontaneous cell death in the control wells was > 30%. There was evidence for cytotoxicity 
for all three devils prior to immunisation. Cytotoxicity appears to be the highest two weeks 
following the first immunisation, but this also occurred with the control devil. After the third 
immunisation, all three devils showed cytotoxicity results similar to their pre-immune samples.  
 
 
Figure 5.3. Cytotoxicity curves for (a) Tip, (b) Stinky and (c) Phil (adjuvant-only control) showing 
killing of DFTD cells (y axis) by different ratios of PBLs (x axis).  
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Live DFTD cell challenge, immunotherapy and responses 
 
Both Stinky and Tip were challenged 28 days after the booster with 25,000 live DFTD cells on 
the right hand side (RHS) of the rump and 100,000 live DFTD cells on the left hand side (LHS) 
of the rump. The higher dose was used to exclude the possibility that tumour development 
required more than 25,000 cells. 
 
DFTD tumours developed at both inoculation sites 90 days after the challenge in Tip, and at 
both inoculation sites 120 days after challenge in Stinky. Immunohistochemistry of the LHS 
tumours of both devils revealed limited immune cell infiltration (Figs 5.4a, 5.5a). When these 
tumours reached between 20 cm3 and 30 cm3 in volume the devils were subcutaneously injected 
in the interscapular region with 108 live IFN-g treated MHC-I+ve DFTD cells.  
 
Following immunotherapy, the original tumours in both devils increased in size then one week 
later both tumours began to regress. A month after the immunotherapy, biopsies of the LHS 
tumour (Tip) and LHS and RHS tumours (Stinky), revealed moderate numbers of MHC-II+ 
cells at the periphery of the tumour and some cells within the tumour. A large number of CD3+ 
cells showed a similar distribution to the MHC-II+ cells, with CD8+ cells more abundant than 
CD4+ cells (Figs 5.4b, 5.5b). 
 
Antibody levels against both IFN-g treated (MHC-I+ve) and untreated (MHC-I-ve) DFTD cells 
in both devils increased following immunotherapy (Figs 5.6 a,b). In both devils neither the 
LHS or RHS tumours were palpable 70 days after treatment commenced. For Stinky, the live 
MHC-I+ve DFTD cells that were used for immunotherapy developed into a small tumour. This 
tumour did not increase in volume after it had reached 10 cm3. MHC-II+ and CD3+ cells could 
be found throughout the tumour.   
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Figure 5.4. Tip. Immunohistochemistry of tumours following challenge with live DFTD cells, and after 
immunotherapy with live MHC-I+ve DFTD cells. (a) DFTD tumours developed at both sides (left hand 
side – LHS, and right hand side - RHS of the rump). Representative histology of a biopsy from the LHS 
tumour taken 14 weeks after challenge shows very poor immune cell infiltration. Standard 
haematoxylin and eosin (HE) staining and immunohistochemical labelling using anti-periaxin (PRX) 
antibody and anti-MHC-II and anti-CD3 antibodies. Scale bar, 50 µm. (b) Following immunotherapy, 
tumour regression correlated with strong immune infiltration of MHC-II+ cells and CD3+ cells with 
CD8+ cells more abundant than CD4+ cells. Biopsy taken 4 weeks after therapy. Scale bar, 50 µm. 
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Figure 5.5. Stinky. Immunohistochemistry of tumours following challenge with live DFTD cells, and 
after immunotherapy with live MHC-I+ve DFTD cells. (a) DFTD tumours developed at both sides (left 
hand side – LHS, and right hand side - RHS of the rump) of challenge with no evidence of immune cell 
infiltration in a biopsy of the LHS tumour taken 20 weeks after challenge. Standard haematoxylin and 
eosin (HE) staining and immunohistochemical labelling using anti-periaxin (PRX) antibody and anti-
MHC-II and anti-CD3 antibodies. Scale bar, 50 µm. (b) Tumour regression correlated with strong 
immune infiltration of MHC-II+ cells and a similar distribution of CD3+ cells. CD8+ cells were more 
abundant than CD4+ cells. Biopsy taken 4 weeks after the immunotherapy. Scale bar, 50 µm. 
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Figure 5.6. Antibody responses following immunotherapy. (a) Tip. Low to medium antibody responses 
against IFN-g treated (MHC-I+ve) and untreated DFTD cells were evident after immunotherapy, (b) 
Stinky. Medium to high antibody responses against IFN-g treated (MHC-I+ve) DFTD cells and untreated 
DFTD cells were evident after immunotherapy. 
 
 
Adjuvant-only control devil 
 
During Trial 2, Phil received five injections of the adjuvant components only (i.e. excluding 
DFTD cells) and did not produce detectable anti-DFTD antibodies (Fig. 5.7a). As with Tip and 
Stinky, cytotoxicity assays were performed after each adjuvant injection i.e. cytotoxicity assays 
were performed on all three devils at the same time so that post immunisation assay results for 
Tip and Stinky could be compared to their pre-immune results but also to Phil, the adjuvant-
only control (Fig. 5.3). This devil was not challenged with live DFTD cells. 
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Figure 5.7. Antibody responses of (a) adjuvant-only devil (Phil) and (b) non-immunised control 
(Merrick) showing no antibody against DFTD cells after the intervention in either devil. 
 
Non-immunised control devil  
 
Merrick was not immunised and did not receive adjuvant. He was challenged with live DFTD 
cells in the same manner as Stinky and Tip and after 40 days, tumours were palpable on both 
the LHS and RHS of the rump. The tumours continued to grow, with no indication of immune 
cell infiltration (Fig. 5.8a). 
 
When the tumour reached approximately 10 cm3 in volume, the devil was subcutaneously 
injected in the interscapular region with 108 live IFN-g treated MHC-I+ve DFTD cells. A tumour 
developed at the immunotherapy site. Biopsies taken 28 days after the immunotherapy showed 
well established and encapsulated tumours. A few foci of MHC-II+ cells appeared in the 
periphery of the tumours with very few within the tumour. Very few CD3+ (either CD4 and/or 
CD8) T cells were found within or surrounding the tumour (Fig. 5.8b) and there was no 
evidence for antibody production (Fig. 5.7b). Due to the progression of tumour size, this devil 
was euthanased.  
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Figure 5.8. Merrick. Immunohistochemistry of tumours following challenge with live DFTD cells, and 
after immunotherapy with live MHC-I+ve DFTD cells.  (a) DFTD tumours developed at both sides (left 
hand side – LHS, and right hand side - RHS of the rump) of the challenge. A biopsy of the LHS tumour 
taken 10 weeks after challenge shows scattered MHC-II+ cells within the tumour and very occasional 
CD3+ cells. Standard haematoxylin and eosin (HE) staining and immunohistochemical labelling using 
anti-periaxin (PRX) antibody and anti-MHC-II and anti-CD3 antibodies. Scale bar, 50 µm. (b) Biopsy 
of the LHS tumour taken 4 weeks after therapy. PRX shows well established DFTD tumours with 
virtually no immune cell infiltration. Scale bar, 50 µm.  
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Trial 2 conclusion 
 
The protocol used in this second trial was able to delay DFTD engraftment and the subsequent 
immunotherapy induced tumour regression. 
 
5.4. Discussion 
 
The effect of DFTD on the wild devil population has been devastating with declines of up to 
90% in some locations (McCallum et al., 2007). A vaccine to protect against DFTD could help 
ensure the survival of the species in the wild. An effective vaccine must induce an immune 
response against the cancer cells and show evidence of efficacy in vivo. This study showed that 
DFTD cancer cells can be targeted in vivo by the Tasmanian devil’s immune system. This was 
done by using sonicated and irradiated MHC-I+ve DFTD cells as the antigenic basis for two 
immunisation trials. The protocols in each trial differed slightly but both resulted in specific 
antibodies against MHC-I+ve and MHC-I-ve DFTD cells in all four devils.  This suggests that 
immunisation with sonicated and irradiated MHC-I+ve DFTD cells in the presence of multiple 
adjuvants promotes anti-DFTD responses.  
 
The immunisation strategy may have protected one devil (Maydim, Trial 1) from DFTD 
development following challenge with the tumour cells. The DFTD tumours that developed in 
two immunised devils (Tip and Stinky, Trial 2) were delayed in onset compared to the tumour 
in the non-immunised control. Both these devils had antibodies to untreated (MHC-I-ve) and 
treated (MHC-I+ve) DFTD cells. It is logical that a protective a vaccine should induce an 
antibody response against MHC-I-ve DFTD cells since these cells reflect the lack of surface 
MHC-I on wild-type tumour cells. However, a role for antibody recognizing MHC-I+ve DFTD 
cells was implied in wild devils that had histories of tumour regression (Chapter 4). It has been 
hypothesised that once an immune response is initiated, production of inflammatory cytokines 
e.g. IFN-g within the tumour is likely to up-regulate MHC-I expression, allowing 
allorecognition to occur (Chapter 4) (Siddle et al., 2013). 
 
Cell mediated immune responses to the immunisations in the devils from Trial 2 were based 
on a flow cytometry cytotoxicity assay. This was used because the chromium based assay used 
in previous trials (Kreiss et al., 2015) was no longer available. In this trial, cytotoxicity curves 
were evident in pre-immune samples which was not consistent with the chromium based assay 
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results (Kreiss et al., 2015, Brown et al., 2011). Similarly, the adjuvant-only devil produced 
cytotoxic responses. This meant any cytotoxicity demonstrated by the immunised devils could 
not be confidently attributed to the immunisations. Other factors that may have contributed to 
cell death include overcrowding and other experimental conditions such as target cell fragility. 
Although cell mediated immune responses to the immunisations could not be reliably 
demonstrated, these were subsequently shown in tumours that developed after live challenge.  
 
The development of DFTD tumours in two of the immunised devils that were subsequently 
challenged with live DFTD cells provided an opportunity to treat these devils with 
immunotherapy and evaluate an anti-tumour immune response in vivo. The immunotherapy 
given to these devils was a therapy administered in 2012 to a devil with a similar history i.e. 
that devil had been immunised with DFTD cell preparations and challenged with live tumour 
cells which resulted in tumour development. The devils were injected with live DFTD cells 
that had been cultured in vitro with IFN-γ to up-regulate MHC-I. This particular therapy took 
advantage of the potential strong allogeneic responses induced by MHC incompatibilities. 
Following tumour growth and subsequent to immunotherapy, infiltration of CD4+ and CD8+ 
cells occurred in the tumours in both Stinky and Tip, and in the 2012 devil’s tumour. This co-
incided with tumour regression. In contrast, the tumour in the non-immunised control devil 
continued to grow with no evidence of a cell mediated or antibody response. It is worth noting 
here that the only antibody response of the 2012 devil occurred subsequent to the 
immunotherapy.  This devil developed high levels of antibody against MHC-I+ve but none 
against MHC-I-ve DFTD cells. In short, these three cases provided the first monitored 
observations of DFTD tumour regression.  
 
The different protocols in Trials 1 and 2 of this study may have influenced the antibody 
responses and the outcomes of the live challenge, although the small sample size makes this 
speculative. The protocols varied in the order that sonicated or irradiated cells were given, and 
in the timing between immunisations. The rationale for using irradiated cells was to present 
whole cells, albeit modified, to the immune system. Irradiated cells given at fortnightly 
intervals did not promote a robust immune response in the two devils in Trial 2. Both devils 
developed a higher antibody response following immunisation with sonicated cells one month 
later. Whether it is useful to “prime” the immune system with a larger number (2 x 107 in this 
study) of sonicated cells that present both intracellular and cell surface antigens to the immune 
system, before delivering the whole cells, is suggested by this study but not clear given the 
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small sample size. A shorter immunisation protocol would of course be more practical, but 
results from this study suggest the longer protocol from Trial 1 is more effective.  
 
There were two key conclusions drawn from this study. Firstly, that inactivated MHC-I+ve 
DFTD cells used as the antigenic basis for DFTD immunisations resulted in antibody responses 
against DFTD in all four devils. The DFTD cells used as the antigenic basis for the 
immunisations in both trials in this study were treated with inflammatory cytokines to up-
regulate expression of surface MHC-I. The cells in some of the immunisations were 
subsequently treated with gamma radiation. The primary purpose of the radiation was to make 
the cells non-viable, but radiation can also increase the immunogenicity of the cells. This has 
been demonstrated with radiation resulting in the increased expression of surface MHC class 
I/II antigens and ICAM-I molecules (Chiriva-Internati et al., 2006), and cell surface 
translocation of calreticulin which promotes phagocytosis (Obeid, Panaretakis et al. 2007). 
 
The combination of cytokine incubation and gamma radiation has been shown to have an 
additive effect with respect to the up-regulation and expression of cell surface antigen (Santin 
et al., 1996). Aside from MHC-I, it is currently unknown which antigenic molecules on the 
DFTD cell surface might have increased expression following manipulation. Further studies 
should identify up-regulated antigenic molecules, but presumably the end result of the cytokine 
stimulation and radiation is a more immunogeneic cell. The caveat is that inhibitory molecules 
can also be up-regulated with manipulation. This has been demonstrated with the increased 
expression of PD-L1 on tumour cells (Flies et al., 2016) in response to IFN-g exposure. 
 
Along with cell manipulation, the combination of adjuvants used in these immunisations most 
probably contributed to the immune response. ISCOMATRIXTM is a proprietary saponin based 
adjuvant known to elicit a broad antibody response. In combination with TLR agonists it can 
induce regression of established solid tumours (Silva et al., 2015). The TLR agonists used in 
these DFTD immunisations were CPG-1585 and CPG-2395 (both TLR9 agonists), and Poly 
I:C (a TLR3 agonist). It is likely this adjuvant combination engaged multiple signalling 
pathways that support adaptive cellular immune responses in the Tasmanian devil. 
 
The other conclusion drawn from this study was that tumour regression was associated with 
prior immunisation with DFTD cells, and was immune mediated. The regression was observed 
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after the administration of live IFN-γ treated DFTD cells and this correlated with the cellular 
immune response observed at the tumour engraftment site. Proliferating DFTD tumour cells 
expressing MHC-I provide tumour antigens for presentation and the prior immunisation may 
allow presentation to memory cells, enabling more DFTD-specific T cells to be activated. 
There was a rise in antibody levels to DFTD cells following the immunotherapy. Remission 
correlated with T cell and MHC-II+ cell (potentially dendritic cell) infiltration into the DFTD 
tumour indicative of immune mediated regression. Likewise, increased levels of IgG anti-
DFTD antibodies followed immunotherapy in the immunised devils. As IgG antibodies are T 
cell dependent, this provides further evidence for a T cell anti-tumour immune response. This 
was distinct from the non-immunised control devil that had no signs of remission with no 
indication of immune cell infiltration into the tumour.  
 
These results highlight the feasibility of developing a vaccine to counter devil facial tumour 
disease. The immune system of the Tasmanian devil is able to mount specific humoral and 
cellular responses to facilitate the rejection of established tumours. DFTD cells cultured in 
IFN-g up-regulate MHC-I and by incorporating preparations of these cells with adjuvants that 
target TLRs, immune responses against the tumour cells are consistently produced. The 
immunisations alone in this study did not completely prevent tumour engraftment, indicating 
the need for stronger protective immune responses. This will require further research into the 
mechanisms involved in DFTD rejection. Likewise, identifying DFTD’s immune escape 
strategies will highlight opportunities for blocking them. Pursuing these research avenues will 
improve the likelihood of effecting immune control of DFTD. 
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Chapter 6. DFTD immunisation trial on Tasmanian devils prior to their wild release 
 
6.1. Introduction 
 
Devil facial tumour disease (DFTD) immunisation trials on small numbers of captive devils 
have been carried out since 2006. These trials have provided key insights to the devils’ immune 
responses against DFTD (Chapter 5), (Kreiss et al., 2015). However, their limitations include 
small sample sizes and senescent individuals. There is also uncertainty surrounding how well 
the experimental DFTD challenge replicates a natural challenge with respect to the number of 
DFTD cells used and their mode of delivery.  
 
The opportunity to address these limitations arose with the implementation of the Save the 
Tasmanian Devil Program’s (STDP) “wild devil recovery” project. The project’s aim is to “trial 
various release methodologies to determine the most effective and successful way to release 
captive or semi-wild devils into the wild” (Samantha Fox pers. comms October 2016). It 
involves the release of devils from the STDP’s captive insurance and DFTD-free Maria island 
populations to augment local wild devil populations that have been decimated by DFTD. The 
first wild release took place in September 2015 in Narawntapu National Park (NNP) in 
Tasmania’s north. Since the devils chosen for release were held in free range enclosures for 
several months prior to the release date, there was the opportunity to use them in a DFTD 
immunisation trial. None of the devils had any exposure to DFTD prior to the trial. 
 
The selection of the immunisation protocol for this trial was based on results of the two pilot 
trials (Chapter 5) that used MHC-I+ve DFTD cells as the antigenic basis for the immunisations 
i.e. DFTD cells that had been manipulated in vitro to express the major histocompatibility 
complex class I molecule (MHC-I) on the cell surface. The protocol from Trial 1 (Chapter 5) 
was chosen over the Trial 2 protocol because it had resulted in higher anti-DFTD IgG antibody 
responses. Also, there was no tumour development for six months after experimental challenge 
in one devil in Trial 1 compared to tumour development in both devils in Trial 2. 
 
There were 20 devils released into NNP in September 2015 and 19 of those were available for 
immunisation prior to their release. The sample size was therefore six times greater than any 
previous DFTD immunisation trial. The number of devils, their range of ages and fairly even 
ratio of sexes allowed for a more robust assessment of anti-DFTD immune responses than had 
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previously been possible. Along with measuring serum anti-DFTD IgG antibodies in each of 
the 19 devils, an attempt was made to assess the cytotoxic responses after immunisation. 
 
Post release monitoring trips at NNP were carried out by the STDP at varying intervals for 
seven months following release. Serum samples were collected from the immunised devils that 
were trapped during these trips to assess changes to their antibody levels over time. The 
possibility that the devils would be exposed to DFTD following their release into NNP meant 
assessment of the protectiveness of the immunisation protocol might be possible. 
 
 
6.2. Materials and methods 
 
6.2.1. Tasmanian devils 
 
There was a total of 19 devils, 11 males and 8 females, of varying ages in the immunisation 
trial (Table 6.1). All the devils had been selected from the captive insurance population (i.e. 
none were from Maria Island). 
 
Table 6.1. Summary of age and sex of devils in the immunisation trial. 
 
 1 year 2 years 3 years 4 years 5 years total 
Male 4 0 0 7 0 11 
Female 1 1 2 3 1 8 
 
 
6.2.2. Devil enclosures, trapping and blood sample collection 
 
The devils were kept in free range enclosure (FREs) for at least eight months prior to their 
release. Male devils were kept in an 11 hectare FRE near Launceston, and females in a similar 
sized FRE near Bicheno. The devils were trapped fortnightly during the primary three month 
immunisation course. For the four months prior to the booster immunisation, the devils were 
monitored weekly with camera traps by STDP staff.  
 
There were 15 traps set in each FRE the afternoon before procedures were performed (body 
weight, physical examination, blood collection and immunisation if required). The traps were 
baited with possum or lamb flaps and checked the following morning. Each trapped devil was 
transferred into a hessian sack and the handling and procedures were carried out by two 
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veterinarians. General anaesthesia was given in the rare event of not being able to handle the 
devil in the sack. Devils were released into the FRE immediately following the procedure.  
 
Blood sample collection and general anaesthesia are described in Chapter 2.3.3 and 2.3.6. 
Blood was collected at each visit for serum and where possible, in lithium heparin tubes for 
peripheral blood lymphocyte (PBL) isolation.  
 
Not all devils were trapped on each trip. Due to this, and to the juvenile (one year old) devils 
(n=5) coming later into the trial, there were some differences in the immunisation protocol 
given, and the blood samples available. 
 
6.2.3. Vaccine protocol and preparation 
 
The full immunisation protocol was the same used in Trial 1 carried out on captive devils as 
described in Chapter 5.2.2 and is summarised in Table 6.2. 
 
Table 6.2. Complete immunisation protocol. 
Primary course (4 immunisations given at monthly intervals)* 
Date of each immunisation Composition of immunisations 
1st  (Feb 2015) 2 x 107 MHC-I+ve sonicated cells 
2nd  (March 2015) 2 x 107 MHC-I+ve sonicated cells 
3rd  (April 2015) 2 x 106 MHC-I+ve irradiated cells 
4th  (May 2015) 2 x 106 MHC-I+ve irradiated cells 
Booster immunisations * 
Date of each booster Composition of booster immunisations 
1st (Sep 2015) pre-release 2 x 106 MHC-I+ve irradiated cells 
2nd (Feb 2016) post-release 2 x 106 MHC-I+ve irradiated cells 
 
*The combination of adjuvants used in each immunisation and booster was ISCOMATRIX™, Poly I:C, 
CpG 1585 and CpG 2395 
 
One day of travel was required prior to the administration of the immunisations. On the 
morning of the travel day, sonicated preparations were taken from -80 °C, thawed and 
adjuvants added. Irradiated cell preparations were thawed, washed twice (with PBS, 500 g for 
5 minutes), counted and resuspended in 1 ml PBS at 2 x 106 cells per dose, and adjuvants added. 
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The immunisations were kept on ice or at 4 °C for 24 hours prior to administration. 
Immunisations were given as a subcutaneous injection between the devils’ scapulae. The 
immunisation preparation is described in full in Chapter 2.2.9. 
 
6.2.4. Serum and PBL transport and isolation 
 
Following collection, blood samples in clot activating tubes were placed in a polystyrene box 
with ice bricks, and samples in lithium heparin tubes were kept at ambient temperature. On 
return to the laboratory the same afternoon, serum and PBL’s were separated as described in 
Chapter 2.2.2 and 2.2.3. 
 
6.2.5. Serum antibody detection 
 
Indirect immunofluorescence and flow cytometry to measure serum anti-DFTD IgG antibody 
levels was performed on the serum samples against un-manipulated DFTD cells (i.e. cells not 
expressing MHC-I, referred to as MHC-I-ve DFTD cells) and INF-γ treated MHC-I+ve DFTD 
cells. See Chapter 2 for MHC-I up-regulation (2.2.5) and flow cytometry (2.2.7) procedures. 
The median fluorescence intensity ratio (MFIR) was used to classify the antibody responses. 
The MFI is the median fluorescence intensity (MFI) of DFTD cells labelled with immune 
serum divided by the MFI of DFTD cells labelled with pre-immune serum. This ratio accounts 
for any background serum IgG present prior to the immunisations, as well as inevitable 
variations between flow cytometry experiments. 
 
6.2.6. Cytotoxicity assays 
 
Cytotoxicity assays to assess the killing ability of PBL’s against MHC-I-ve DFTD cells were 
set up on the evening of blood collection. The assays were kept at 37 °C overnight, and the 
following morning the plates were centrifuged (350 g for 3 minutes). The supernatant was 
collected and stored at -80 °C. The cell pellets were resuspended with 200 µl of a 1:500 dilution 
of propidium iodide, and the plates run through the flow cytometer to count the number of dead 
DFTD cells. See Chapter 2.2.8 for the cytotoxicity assay procedure and analysis. 
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6.2.7. Devil release into NNP and post-release monitoring 
 
The STDP released 20 devils in total, including the 19 from the immunisation trial into NNP 
on 25/09/15.  Monitoring trips were carried out at 2, 6, 12 and 20 weeks post release i.e. 
October, November and December 2015, and February 2016. The STDP’s annual monitoring 
NNP trip took place in April 2016. Serum was collected from the immunised devils that were 
trapped during the monitoring trips. A booster immunisation was given to devils that were 
trapped in February 2016 to coincide with the mating period when most biting injuries occur 
and risk of DFTD transmission is highest (Hamede et al., 2008). 
 
6.2.8. Statistical analysis 
 
One-way ANOVAs (Figs 6.2, 6.3, 6.6) were performed to compare overall anti-DFTD IgG 
antibody responses at different time periods.  
A four-way repeated-measures ANOVA comparing sex, age and protocol over time was 
performed to compare antibody responses at three time points i.e. at the end of the primary 
immunisation course, on the day of the booster, and two weeks after the booster (for Fig. 6.4). 
Tukey’s post hoc analyses were performed. 
One-way ANOVAs were performed using GraphPad Prism version 6 for Mac OS X, GraphPad 
Software, La Jolla, CA, USA, www.graphpad.com 
The four-way ANOVA and Tukey’s posthoc analysis were performed using R statistical 
software. 
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6.3. Results 
 
6.3.1. Immunisation protocols  
 
The primary immunisation protocol each devil received was dependent on trapping success, 
and on when the devils came into the trial (the five juveniles were late entries). Table 6.3 
summarises the immunisation protocols and the number of devils that received each protocol. 
All the devils received a booster immunisation four months after the primary course. Table 6.4 
identifies the name, sex and age of the individual devils that received each protocol. 
 
Table 6.3. Description of immunisation protocols and the number of devils that received each 
protocol. 
 
Protocol Protocol description* No. of devils 
 
 
A 
4 immunisations at 4 week intervals: 
 
1st and 2nd: sonicated cells 
3rd and 4th: irradiated cells 
 
6 
 
B 
4 immunisations at 4 or 6 week intervals**: 
 
1st and 2nd: sonicated cells 
3rd and 4th: irradiated cells 
 
6 
 
C 
3 immunisations at 4 week intervals: 
 
1st and 2nd: sonicated cells 
3rd: irradiated cells 
 
3 
(including 2 juveniles) 
 
D 
2 immunisations at 2 or 4 week intervals: 
 
1st: sonicated cells 
2nd: irradiated cells 
 
4 
(including 3 juveniles) 
 
* See Table 6.2 for complete description of immunisation composition 
** Two male devils (Cory and Jackson) had their 2nd immunisations 6 weeks after the 1st. There were 4 
week intervals between their 2nd and 3rd, and their 3rd and 4th immunisations. 
Four female devils (Cindy, Irry, Isla and Janice) had 4 week intervals between their 1st and 2nd, and 2nd 
and 3rd immunisations. The 4th immunisation was given 6 weeks after the 3rd immunisation. 
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Table 6.4. Sex and age of individual devils and the immunisation protocol each received. 
 
Males Females 
Immunisation 
protocol 
Name Age (years) 
in 2015 
Immunisation 
protocol 
Name Age (years) 
in 2015 
A Beau 4 A Andrea 4 
A Bruce 4 A Heidi 3 
A Floyd 4 A Mystique 3 
B Cory 4 B Cindy 5 
B Jackson 4 B Irry 2 
C Boots 4 B Isla 4 
C Gendry 1 B Janice 4 
C Jorah 1 D Lysa 1 
D Chilli 1    
D Chouffe 1    
D Monty 4    
 
Immunisation protocols A-D are described in Table 6.3. 
 
6.3.2. Anti-DFTD IgG antibody responses prior to wild release 
 
The anti-DFTD IgG antibody responses were assessed separately against MHC-I-ve and 
MHC-I+ve DFTD cells. There were no significant differences between results for either cell 
type (p value between 0.176 and 0.758, data not shown), so the results presented here are for 
responses against MHC-I-ve DFTD cells only. These responses were classified as negative, low, 
medium or high depending on the MFIR, where Negative = MFIR < 1.5 times the pre-immune 
response; Low = MFIR 1.5 to 2 times the pre-immune response; Medium = MFIR 2 to 4 times 
the pre-immune response; High = MFIR > 4 times the pre-immune response. Figure 6.1 shows 
example flow plots for low, medium and high responders. 
 
At the end of the primary immunisation course, nine devils had medium/high responses, and 
only two devils had negative responses. Antibody levels in most devils dropped over the four 
months prior to the booster. The booster resulted in increased antibody levels in all devils, 
however in the adult male devils, the antibodies didn’t reach the levels found after the primary 
immunisation course. In contrast, the booster resulted in all the female devils having antibody 
levels that were equal to or higher than their levels achieved after the primary course (Table 
6.5). 
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Figure 6.1. Representative flow plots of IgG antibody responses to untreated (MHC-I-ve) DFTD cells 
two weeks post booster (coloured line) compared to pre-immune (grey line) for (a) low, (b) medium 
and (c) high responders. 
Negative = MFIR < 1.5 times the pre-immune response; Low = MFIR 1.5 to 2 times the pre-immune 
response; Medium = MFIR 2 to 4 times the pre-immune response; High = MFIR > 4 times the pre-
immune response. (MFIR = median fluorescence intensity ratio). 
  
(a)
(b)
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Table 6.5. Serum anti-DFTD IgG antibody levels (MFIR) for each devil at three different time points. 
 
Response 2 weeks after primary 
course 
n=17 
Response on day of booster 
n=19 
Response 2 weeks after booster 
n=19 
Medium – 
High 
n = 9 
 
Low 
n = 6 
Negative 
n = 2 
Medium 
- High 
n = 4 
Low 
n = 8 
Negative 
n = 7 
Medium - 
High 
n = 12 
Low 
n=3 
Negative 
n = 4 
Andrea 
5.1 
Beau 
1.8 
Janice* 
1.3 
Andrea 
3 
Bruce 
1.7 
Beau 
0.7 
Andrea 
5 
Cory 
1.9 
Beau 
1.3 
Bruce 
3.6 
 
Boots 
1.6 
 
Monty 
1.0 
Gendry 
2.6 
 
Cindy 
1.6 
 
Boots 
1.2 
Bruce 
2.1 
Floyd 
1.7 
Boots 
1.4 
Cory 
2.3 
Cindy* 
1.9 
 
Chilli** Irry 
4.6 
Chilli 
1.9 
Cory 
1.2 
Chilli 
3 
Janice 
1.9 
Jackson 
1.4 
Gendry 
3.7 
 
Floyd 
1.8 
Chouffe** Lysa 
3.8 
Chouffe 
2 
Floyd 
1.3 
Chouffe 
3 
 Monty 
1.1 
Heidi 
2.1 
Jackson 
1.7 
  Isla 
1.6 
Heidi 
1.4 
Cindy 
3.2 
  
Irry* 
2.9 
Isla* 
2 
  Janice 
1.5 
Jackson 
1.2 
Gendry 
3.2 
  
Jorah 
5 
   Jorah 
2 
Monty 
1.0 
Irry 
5 
  
Lysa 
6 
   Mystique 
1.8 
 Heidi 
2.1 
  
Mystique 
3.4 
     Isla 
2.1 
  
      Jorah 
2.7 
  
      Lysa 
6.6 
  
      Mystique 
4.1 
  
 
Females are in red, males in black. 
The number in each cell is the MFIR; Negative = MFIR < 1.5 times the pre-immune response; Low = 
MFIR 1.5 to 2 times the pre-immune response; Medium = MFIR 2 to 4 times the pre-immune response; 
High = MFIR > 4 times the pre-immune response. (MFIR = median fluorescence intensity ratio). 
* These devils had Protocol B i.e. 4 immunisations, however their last serum sample for the primary 
course was collected on the day of their 4th immunisation which was 6 weeks after their 3rd 
immunisation. 
** No serum sample available after primary course. 
 
 
  
 141 
Antibody responses after each of the immunisations given in the primary course were also 
recorded. Figure 6.2 shows the responses for devils that received four immunisations in the 
primary course i.e. Protocol A or B, for which serum samples were available at each time point. 
Antibody levels were significantly higher after the second and third immunisations compared 
to after the first.  
 
 
 
Figure 6.2. Serum anti-DFTD IgG levels (MFIR) of devils that had four immunisations in their primary 
course i.e. protocol A or B, Table 6.3. Only those devils for which sera samples were available at all 
time points are included. Statistical analysis was performed with a one-way ANOVA (with repeated 
measures) to produce an overall p value. Post hoc analysis identified which time points had significantly 
different MFIR’s from each other and are indicated by *. NB pre-immune MFIR for each devil is equal 
to 1 and is therefore not shown. 
 
 
Antibody levels of all devils at three time points (two weeks after primary course, on the day 
of the booster, and two weeks after the booster) were then compared. The levels on average 
were lowest on the day of the booster i.e. four months after the primary course. Although the 
average antibody level rose after the booster, this was not a statistically significant increase 
(Figure 6.3). 
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Figure 6.3. Serum anti-DFTD IgG antibody levels (MFIR) in devils for each of the three time points: 
end of primary immunisation course, day of booster (4 months later) and 2 weeks post booster. 
Statistical analysis was performed with a one-way ANOVA (with repeated measures) to produce an 
overall p value. Post hoc analysis identified which time points had significantly different MFIR’s from 
each other as indicated by *. (MFIR = median fluorescence intensity ratio). 
 
 
 
6.3.3. Effects of protocol, age and sex on antibody responses measured at three time 
points 
  
The effects of protocol, age, and sex on the antibody responses measured at three time points 
(two weeks after primary course, on the day of the booster and two weeks after the booster) 
were assessed with a four-way ANOVA. The primary immunisation protocol (i.e. two, three 
or four immunisations) did not make a significant difference to the antibody responses (Fig. 
6.4a). However, both age and sex were found to have significant effects on the antibody 
responses (Figs 6.4b,c). Juveniles had higher responses on average than adults, and females 
had higher responses than males. 
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Figure 6.4. Serum anti-DFTD IgG antibody levels (MFIR) showing effect of (a) protocol, (b) age, and 
(c) sex.  The three different time points (two weeks after primary course, on the day of the booster and 
two weeks after the booster) are not shown separately on each graph. Instead, the MFIR for each devil 
at each time point has been plotted on each graph. Protocol A = 4 immunisations at 4 week intervals, 
B = 4 immunisations at 4 or 6 week intervals, C = 3 immunisations at 4 week intervals, D = 2 
immunisations at 2 or 4 week intervals.  The p values were obtained with the four-way ANOVA 
analysis. See Table 6.8 for detailed ANOVA results. 
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6.3.4. Cytotoxicity assays 
 
Cytotoxicity assays were performed fortnightly on the devils for which blood samples were 
available since not all devils were trapped each fortnight. The cytotoxicity assay results were 
deemed unreliable if spontaneous cell death in the control wells was > 30%. The control well 
cell death for the pre-immune assays of the male devils was 46.2% so only results for female 
devils comparing pre-immune samples to post immunisation samples are shown. Pre-
immunisation cytotoxicity varied between devils, ranging from 25 to 40% at the highest 
effector to target cell ratio of 100:1. This level of killing was higher than in some of the post 
immunisation samples (Fig. 6.5).  
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Figure 6.5. Cytotoxicity curves for five female devils showing killing of DFTD cells (y axis) by 
different ratios of PBLs to DFTD cells (x axis). Post immunisation cytotoxicity (coloured lines) is 
compared to the pre-immunisation cytotoxicity (black line). 
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6.3.5. Anti-DFTD IgG antibody responses after wild release 
 
Following the release into NNP, monitoring trips were run at 2, 6, 12 and 20 weeks i.e. October, 
November, December 2015 and February 2016. The annual monitoring trapping trip for NNP 
took place in April 2016. Table 6.6 shows the dates that the trial devils were re-trapped on 
these trips. 
 
 
Table 6.6. Post release trapping and sampling. 
 
Post release monitoring trip Number of immunised devils 
re-trapped and serum 
collected 
Individual devils 
2 weeks 
October 2015 
6 Cindy, Heidi, Isla 
Beau, Boots, Bruce 
 
6 weeks 
November 2015 
4 Heidi 
Beau, Boots, Bruce 
 
12 weeks 
December 2015 
3 Beau, Bruce, Cory 
(Boots to vet but no serum)* 
 
20 weeks 
booster given 
Feb 2015 
 
1 (+1 at AHL) 
 
Boots – booster at AHL, 
blood collected 2 weeks later 
Beau -booster 
7 months 
April 2016 
 
1 Beau 
 
* Boots had a non-healing bite wound on his rump so received veterinary treatment and was housed at 
the Animal Health Laboratory (AHL) for recovery. He was re-released into NNP in March 2016. 
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Serum anti-DFTD IgG antibody was measured for each sample collected on the post-release 
trips (Fig. 6.6). Statistical analysis could only be performed on samples from the three devils 
that were consistently trapped. The change in antibody levels was not significant over the two 
month period post release. There was however a trend for antibody levels to decrease over 
time. Only one devil (Beau, a four year old male) was trapped on each of the post release 
monitoring trips. He received a booster immunisation in February 2016 after which his 
antibody levels increased. Only one other devil (Boots), also a four year old male, was given a 
second booster immunisation in February. In contrast to Beau, Boots’ response after this 
second booster wasn’t as high as his response after the first (data not shown). NB Boots was 
undergoing veterinary care at this time. 
 
 
           
 
 
 
Figure 6.6. Serum anti-DFTD IgG antibody levels (MFIR) of devils collected post release compared 
to their post booster response in September 2015. The graph shows serum antibody levels of devils 
trapped on each of the post-release trips. Only 3 individual devils were trapped in both October and 
November and a one-way ANOVA analysis (with repeated measures) was performed, p = 0.418.  
(MFIR = median fluorescence intensity ratio). 
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6.3.6. Statistical analysis  
 
One-way ANOVAs were performed to compare the antibody responses of devils during the 
primary immunisations course; at three time points during the immunisations before release; 
and of the individual devils which were trapped on both the October and November post release 
trips (Table 6.7). 
 
 
Table 6.7. One-way ANOVA results for data analysed in figures 6.2, 6.3 and 6.6. 
 
One-way ANOVA F p 
Antibody responses during primary immunisation course 
(Figure 6.2) 
8.317 0.024 
Antibody responses at 3 time points before release 
(Figure 6.3) 
4.314 0.029 
Antibody responses at post release time points 
(Figure 6.6) 
1.060 0.418 
 
 
 
A four-way repeated-measures ANOVA comparing sex, age and protocol over time was 
performed to compare responses at three time points i.e. at the end of the primary course, on 
day of booster, and two weeks after the booster (Table 6.8). 
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Table 6.8. Results of four-way ANOVA comparing effects of sex, age and immunisation protocol at 3 
time points 
 
Error: ID    
 Df F value Pr (>F) 
sex 1 6.609 0.028 
age 1 12.417 0.005 
protocol 3 0.682 0.583 
sex:age 1 0.348 0.569 
sex:protocol 1 0.234 0.639 
Residuals 10   
    
Error: within    
 Df F value Pr (>F) 
    
sex:time 1 3.811 0.061 
age:time 1 0 0.984 
protocol:time 3 0.82 0.494 
sex:age:time 1 1.364 0.253 
sex:protocol:time 1 0.163 0.69 
age:protocol:time 1 1.279 0.268 
Residuals 27   
 
 
 
6.4. Discussion 
 
This DFTD immunisation trial was carried out on the first cohort of devils released to the wild 
by the STDP’s “wild devil recovery” project. The collaboration brought together two “firsts” 
for management attempts to prevent the extinction of devils in the wild i.e. DFTD 
immunisation and population augmentation. The immunisation trial was carried out on a much 
larger number of devils than had previously been possible allowing for a comparatively robust 
assessment of immune responses.  
 
There are other examples of vaccinating captive bred and/or wild populations of endangered 
species against fatal diseases e.g. black footed ferrets against plague and canine distemper virus 
(Marinari and Kreeger, 2006) (Service, 2013), kakapo against erysipelas (Gartrell et al., 2005); 
and Ethiopian wolves against rabies (Randall et al., 2004, Sillero-Zubiri et al., 2016). An 
experimental chlamydia vaccine trial has also been carried out on a wild population of koalas 
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in south east Queensland (Waugh et al., 2016). This DFTD immunisation trial shared aspects 
of these examples i.e. it focused on an endangered species facing a primary threat of disease 
which might be addressed by vaccination. Vaccine development is necessary to meet the 
ambitious long term objective of releasing devils with immunity to DFTD into the wild to 
augment local wild devil populations that have been decimated by the disease. 
  
The potential exposure of released devils to DFTD meant that the benefit of this immunisation 
trial extended beyond vaccine development. Addressing the original threatening process in a 
release environment is considered requisite for successful reintroductions of individuals from 
captive bred populations of a threatened species (Caughley and Gunn, 1996). Despite the 
unproven efficacy of the immunisation protocol, an advantage of this trial was its merit as an 
attempt to mitigate the DFTD threat to the devils once released. 
 
The biggest advantage of this trial with respect to DFTD vaccine development was the sample 
size of 19 devils.  Previous immunisation studies were limited to two to four devils. The 
comparatively large sample size of this trial allowed for greater confidence in the assessment 
of anti-DFTD immune responses. It also allowed for the effects of age, sex and varying 
immunisation protocols to be assessed. Previous immunisation trials on captive devils have 
demonstrated that an immune response against DFTD is achievable. However, the 
representation of results with respect to the wider devil population has been uncertain due to 
the small sample sizes. The high number of responders in this trial suggests most devils are 
capable of producing an immune response against DFTD which is encouraging for vaccine 
development. 
  
The four devils that had a low to negative antibody response following the booster were all 
adult males. This was illustrated by the analysis of results for the effects of age and sex on 
responses. The five juvenile devils showed on average, higher antibody responses than the 
adult devils. This was despite the juveniles receiving a shorter primary immunisation course 
(i.e. fewer doses) than the majority of adults. Female devils had higher antibody responses than 
males. This is in keeping with evidence that sex affects immune responses via a combination 
of genetic, hormonal and environmental factors (Klein and Flanagan, 2016). In general, human 
studies show females to have heightened immunity to pathogens, and a tendency toward higher 
responses to bacterial and viral vaccines than males. 
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Compared to conventional immunisation protocols against microbial pathogens, this DFTD 
immunisation protocol was long, taking seven months as it included a booster prior to the 
release date. Not all devils received the entire primary immunisation course, and although the 
number of devils receiving each different protocol was small, the results suggested that a 
reduced number of immunisations in the primary course did not affect the post booster antibody 
response. Clearly a shorter immunisation protocol would be more practical and these results 
suggest that similar antibody responses would be achieved with fewer immunisations.  
 
There were three notable limitations to this trial. The first was the inability to reliably measure 
the cell mediated immune response to the immunsiations. With the chromium release assay 
used in previous trials (Brown et al., 2011, Kreiss et al., 2015) no longer available, a flow 
cytometry based assay was employed. The cytotoxicity curves seen in the pre-immune sample 
assays meant any cytotoxicity demonstrated after immunisation could not be confidently 
attributed to the immunisations. Likewise, the similarity of the curves for each devil on each 
day the assays were performed suggested the experimental conditions plus or minus the 
individual devil responses played a notable role in the results. Similar concerns were noted for 
the cytotoxicity assay results from Chapter 5. Realizing the cell death measured in the assays 
from this study may not provide definitive information regarding cell mediated immune 
response to the immunisations, the assay supernatants were stored at -80 °C.  This would allow 
for post hoc analysis such as the presence of IFN-g once a sensitive anti-devil IFN-g antibody 
becomes available. 
 
The other limitations were associated with the low post-release trapping success of immunised 
devils. The low recapture rate was partly due to the devils’ likely dispersal beyond the trap 
lines, but also due to deaths from road traffic accidents. As a result, it was not possible to assess 
extended duration of antibody responses for the majority of devils. The other consequence of 
the low re-trapping rate was the inability to assess the protectiveness of the immunisation 
protocol. While a natural DFTD challenge would provide the gold standard test for immunity, 
the small size of the incumbent devil population in NNP (n=18) and the low DFTD prevalence 
(15%) (Samantha Fox pers. comms 2016) meant the probability of the released devils coming 
into contact with diseased devils was low. Likewise, although the incubation period of DFTD 
is uncertain, it seems unlikely devils would be showing clinical signs of DFTD in April 2016 
(the final monitoring trip) even if they had been susceptible and exposed post-release. 
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Despite the limitations, this trial signifies a notable advance in DFTD vaccine research. 
Although it remains unknown what protection the immunisation protocol provided against a 
natural DFTD challenge, the serum antibodies detected in the majority of devils in response to 
the immunisations suggest that development of an effective DFTD vaccine is a realistic 
expectation. A vaccine would be a valuable conservation tool to secure the future of the wild 
devil population. There are suggestions that responses to DFTD are occurring in the wild. 
Natural immune responses against DFTD have been found in a small percentage of wild devils 
(Chapter 4). There is also evidence that gene selection associated with DFTD has occurred in 
certain populations (Epstein et al., 2016). However, there has not been a measurable reduction 
of the DFTD effect on these populations. DFTD has resulted in dramatic devil population 
decline to the point where the species is functionally extinct in certain locations (Hollings et 
al., 2015). Evolution is by definition a slow process, and so even assuming adequate anti-DFTD 
responses are evolving, the ecological impacts of a decimated devil population are profound 
and relying on evolution alone for population recovery at this stage seems risky. A protective 
DFTD vaccine would aid in a timelier restoration of a functional devil population while helping 
to ensure the genetic diversity of the species. 
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Chapter 7. Immune recognition of DFT2 
 
7.1. Introduction 
 
Until 2015, the only clonally transmissible cancers observed in nature were Tasmanian devil 
facial tumor disease (DFTD) and canine transmissible venereal tumor (CTVT). That only two 
such cancers had ever been documented underscored the belief that transmissible cancer 
lineages in nature are rare and the likelihood of discovering new clones, highly improbable. 
However, in 2015, the leukaemia-like disseminated neoplasia in soft- shell clams was identified 
as a transmissible cancer (Metzger et al., 2015). In the following year, we published research 
confirming a second transmissible cancer affecting Tasmanian devils (Pye et al., 2016). This 
cancer was named devil facial tumour 2 (DFT2) in recognition of the gross similarities it shares 
with the first cancer, now referred to as DFT1. The original DFTD nomenclature is 
consequently now regarded as an umbrella term to include both tumours. 
 
The tumours associated with DFT2 are macroscopically indistinguishable from DFT1 tumours. 
However, they have marked histological and cytogenetic differences. DFT2 has a Y 
chromosome in direct contrast to the two X chromosomes in DFT1 (Murchison et al., 2012). 
We found DFT2 has different alleles compared to both its hosts and DFT1 at microsatellite, 
structural variant and major histocompatibility complex (MHC) loci. These results indicated 
that DFT2 is a second independent transmissible cancer affecting the Tasmanian devil (Pye et 
al., 2016).   
 
Exploring the immune escape mechanisms of DFT1 has been central to understanding how 
these foreign tumour cells establish in individuals without eliciting an alloresponse. The down-
regulation of the major histocompatibility complex class I molecule (MHC-I) on the tumour 
cell surface is recognized as a principle mechanism for DFT1’s immune evasion (Siddle et al., 
2013). The immune escape mechanisms of DFT2 are yet to be identified. 
 
The discovery of a second transmissible cancer affecting Tasmanian devils has raised many 
questions about the cancer itself, but also regarding the devil’s susceptibility to such cancers. 
In light of recent evidence for immune recognition of DFT1 in both wild and immunised devils 
(Chapters 4, 5 and 6), one immediate concern was whether immune cross-recognition of DFT1 
and DFT2 could occur. To explore this, serum samples from three cohorts of devils were tested 
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for IgG antibody binding to DFT2 cells. The first cohort consisted of wild devils with clinical 
signs of DFT1 or DFT2 or, in one case, both tumour types. This group had no previous 
demonstration of serum antibodies against either DFT1 or DFT2. The second cohort was a 
group of wild devils with demonstrated anti-DFT1 IgG antibodies (Chapter 4). The third cohort 
was a group of devils immunised with DFT1 preparations that had developed serum IgG 
antibodies against DFT1 (Chapters 5 and 6). In accordance with previous experiments on DFT1 
cells, each serum sample was tested against un-manipulated, cultured DFT2 cells, and also 
against interferon gamma (IFN-g) treated DFT2 cells. The expression of beta 2 microglobulin 
(b2m), a component of the MHC-I molecule and thus an indication of surface MHC-I 
expression, was assessed for both untreated and IFN-g treated DFT2 cells. The DFT2 antibody 
responses for each serum sample were compared to the responses against DFT1 cells. 
 
7.2. Materials and methods 
 
7.2.1. Cell culture 
 
This study used two different DFT2 cell lines: Snug/TD500, collected and established in 
culture in October 2014; and TD549, collected and established in culture in December 2015. 
Tumour cells from the devils “Snug/TD500” and “TD549” were collected by fine needle 
aspirate from tumours during necropsies, which were carried out immediately after the devils 
were euthanased. The aspirates were collected with 21 G needles and 5 ml syringes and the 
cells placed directly into 5 ml of transport medium. Within a few hours of collection, the 
tumour cells were centrifuged (500 g for 5 minutes), resuspended in 5 ml Amniomax cell 
culture medium, placed in T25 flasks and incubated at 35 °C with 5% CO2 in air. 
 
Once the tumour cells were established in culture and proliferating, a sample was sent to the 
Animal Health Laboratory, Mount Pleasant for cytogenetic analysis as described in Chapter 
2.2.10. Both Snug/TD500 and TD549 were confirmed as DFT2 by karyotype. The cell cultures 
were maintained in “super complete” medium i.e. complete medium with 20% Amniomax. 
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7.2.2. Serum samples from Tasmanian devils 
 
Serum samples from 18 devils were tested for specific antibody binding to the two DFT2 cell 
lines using flow cytometry. Devils were divided into three groups according to their histories 
(Table 7.1):  
 
Group 1. (n=6) Wild devils with clinical signs and histological confirmation of DFT1 and/or 
DFT2. Serum was collected at only one time point for each of these devils. 
Group 2. (n=6) Wild devils from West Pencil Pine in north west Tasmania that had previously 
demonstrated antibody responses against MHC-I+ve DFT1 cells. For each of these devils there 
were pre and post seroconversion serum samples that were tested. 
Group 3. (n=6) Devils immunised with MHC-I+ve DFT1 cell preparations that developed 
antibody responses against both MHC-I-ve and MHC-I+ve DFT1 cells. The pre-immune and post 
immunisation serum samples for each of these devils were tested. 
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Table 7.1. Details of devils and serum samples. 
 
 
Group 1. Wild devils with DFT1 and/or DFT2 
 
Name/ ID Estimated 
YOB 
Sex Location DFT1 
or 
DFT2 
or both 
Serum date 
TD550 2014 M Snug DFT1 
and 
DFT2 
Jan 2016 
TD549 2012 M Woodbridge DFT2 Dec 2015 
TD467 2011 M Cygnet DFT2 March 2014 
TD500 2011 M Snug DFT2 Oct 2014 
Savuti 2011 F WPP* DFT1 Nov 2013 
Winky 2013 M Bronte DFT1 May 2015 
 
Group 2. Wild devils from WPP* with antibodies against MHC-I+ve DFT1 cells 
 
Name 
 
Chapter 4 
ID 
Estimated 
YOB 
Sex Pre seroconversion 
serum date 
Date of seroconversion 
Gengibre TD1 2006 F Nov 2009 Nov 2011 
Esquivel TD2 2006 F May 2009 Nov 2011 
Nairobi TD3 2009 F Feb 2011 Feb 2014 
Trujillo TD4 2008 M July 2011 May 2014 
Oryx TD5 2008 F Nov 2010 May 2011 
Falestinya TD6 2010 M Nov 2013 (DFT1+) Feb 2014 
 
Group 3. Devils immunised in trials (Chapters 5 and 6) with subsequent antibody 
development against both MHC-I-ve and MHC-I+ve DFT1 cells 
 
Name 
 
Referred 
to in 
chapter 5 
or 6 
YOB Sex Pre-immmune serum 
date 
Post immunisation 
serum date 
Badger 5 2008 F 28/03/13 03/07/13 
Stinky 5 2007 F 12/02/14 13/05/15 
Tip 5 2008 M 12/02/14 13/04/15 
Lysa 6 2014 F 09/04/15 17/09/15 
Chilli 6 2014 M 04/05/15 15/09/15 
Andrea 6 2011 F 12/02/15 17/09/15 
 
* WPP = West Pencil Pine, north west Tasmania 
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7.2.3. Flow cytometry 
 
Indirect immunofluorescence and flow cytometry to measure serum anti-DFT2 IgG antibody 
levels was performed on all the serum samples against both Snug/TD500 and TD549 cell lines. 
Serum samples were tested with the untreated cell lines and also with IFN-g treated cells. 
MHC-I surface expression was assessed on both untreated and treated cells with anti-
beta 2 microglobulin (b2m) with flow cytometry. See Chapter 2 for MHC-I up-regulation 
(2.2.5) and flow cytometry (2.2.7) methods.  The median fluorescence intensity ratio (MFIR) 
was used to classify the antibody responses. The MFIR is the median fluorescence intensity 
(MFI) of DFTD cells labelled with immune serum divided by the MFI of DFTD cells labelled 
with pre-immune serum. The MFIR for the WPP and immunised devils was calculated by 
dividing the MFI at time of seroconversion by the “negative”/pre-immune serum MFI. This 
accounted for background serum IgG present, as well as inevitable variations between flow 
cytometry experiments. There was no such “constant” for the DFTD-affected wild devils in 
group 1 since only one serum sample was available for each. Therefore, the serum sample of 
one of these devils (TD550) was used as the constant i.e. the MFI of each of the serum samples 
of the devils in this cohort were divided by the MFI of TD550’s serum sample (therefore 
TD550’s MFIR = 1). 
 
7.2.4. Statistical analyses 
 
Student’s paired t tests were performed to compare antibody responses for each group of devils 
against untreated and IFN-g treated DFT1 and DFT2 cells. 
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7. 3. Results  
 
7.3.1. Surface expression of MHC-I by DFT2 cells  
 
Cell surface expression of MHC-I was assessed by staining DFT2 cells with b2m antibody both 
before and after the cells were incubated for 24 hours with IFN-g. The results were compared 
to DFT1 cells. The IFN-g treated DFT1 cells were positive for b2m, whereas the untreated cells 
were negative (Fig 7.1a). DFT2 cells showed some positive staining for  b2m prior to treatment 
but this was dramatically increased after the IFN-g incubation (Fig 7.1b). 
 
 
 
Figure 7.1. MHC-I expression, as indicated by b2m surface staining, of untreated (untx) and IFN-g 
treated (IFNg tx) (a) DFT1 cells and (b) DFT2 cells. The control samples are without the b2m antibody. 
 
 
 
7.3.2. Serum IgG antibody responses against untreated and IFN-g treated DFT2 cells  
 
Serum samples from 18 devils, divided into three groups according to their histories, were 
tested for specific antibody binding to DFT2 cells with flow cytometry. The samples described 
in 7.2.2 were assessed for IgG antibody binding to untreated DFT2 cells and also to IFN-g 
treated DFT2 cells. The results reported are for serum samples tested on the Snug/TD500 cell 
line (representative of both DFT2 cell lines tested). The antibody responses to DFT2 for each 
serum sample were then compared to those measured on DFT1 cells. All antibody responses 
are reported as mean fluorescence intensity ratio (MFIR). 
 
(a) (b)
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Group 1.  Wild devils with DFTD  
 
Serum samples from six wild devils (two with DFT1, three with DFT2, and one devil with both 
DFT1 and DFT2) were assessed for serum antibodies to cells of both DFT1 and DFT2. None 
of these devils had serum antibodies to untreated or IFN-g treated DFT1 or DFT2 cells. 
Responses are shown for the devils with DFT2 against DFT2 cells in Figure 7.2.  
 
 
 
Figure 7.2. Group 1. IgG antibody responses of the three wild devils with DFT2 (TD467, TD500, 
TD549), and TD550 which had DFT1 and DFT2 against (a) untreated (untx) DFT2 cells, (b) 
IFN-g treated DFT2 cells. 
 
 
 
Group 2. Wild devils with antibodies against MHC-I+ve DFT1 
 
In Chapter 4 it was shown that six wild devils had antibody responses to IFN-g treated (i.e. 
MHC-I+ve) DFT1 cells. These devils didn’t have antibody responses against MHC-I-ve DFT1 
cells. Serum samples from these devils were tested with untreated and IFN-g treated DFT2 
cells. For the untreated DFT2 cells, four devils (7.3a-d) had no antibody response in keeping 
with their DFT1 responses. However, two devils (Fig 7.3e,f) showed antibody responses to 
untreated DFT2 cells. All these devils had antibody that could bind to IFN-g treated DFT2 cells 
(Figure 7.4). 
  
(a) (b)
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Figure 7.3. Group 2. IgG antibody responses against untreated (untx) DFT2 cells found in six wild 
devils with antibodies against MHC+ve DFT1 cells. Devils shown in (a) to (d) had no antibody response 
whereas those in (e) and (f) had antibody recognizing untreated DFT2 cells. 
 
 
  
(c) (d)
(e) (f)
(a) (b)
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Figure 7.4. Group 2. IgG antibody responses against IFN-g treated DFT2 cells found in six wild devils 
with antibodies against MHC-I+ve DFT1 cells. All devils shown in (a) to (f) had antibody recognizing 
IFN-g treated DFT2 cells. 
  
(c) (d)
(e) (f)
(a) (b)
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Group 3.  Captive devils immunised with MHC-I+ve DFT1 cell preparations 
 
DFTD (DFT1) immunisation trials have resulted in devils producing antibodies able to bind to 
both MHC-I-ve and MHC-I+ve DFT1 cells. Serum samples from six devils from the trials 
described in Chapters 5 and 6 were tested to assess whether they had similar antibody responses 
to DFT2. There were three devils selected from the pilot trials described in Chapter 5, and three 
selected from the field trial described in Chapter 6. All the devils except for one showed 
antibody responses to untreated DFT2 cells (Fig 7.5). All the devils had antibody responses to 
IFN-g treated DFT2 cells (Fig 7.6). 
 
Comparison of antibody responses to DFT1 and DFT2  
 
The differences between the antibody responses to DFT1 and DFT2 cell lines were then 
analysed with Student’s paired t tests for each group of devils i.e. wild devils with DFTD; wild 
devils with previous demonstration of anti-DFT1 responses; and immunised devils (Figure 
7.7). The only significant difference between responses for either tumour type for any of the 
three groups of devils was found in the wild devils that had demonstrated antibodies to 
MHC-I+ve DFT1 cells. While they all showed robust antibody responses to IFN-g-treated DFT2 
cells, the average MFIR was 4.6 compared to an average MFIR of 7 for antibodies against 
MHC-I+ve DFT1 cells. 
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Figure 7.5. Group 3. IgG antibody responses to untreated (untx) DFT2 cells found in six devils 
immunised against DFT1. Only the devil in (c) failed to show an antibody response to untreated DFT2 
cells. This devil had a low antibody response against untreated DFT1 cells (Chapter 5). 
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Figure 7.6. Group 3. IgG antibody responses to IFN-g treated DFT2 cells found in six devils immunised 
against DFT1. All devils shown in (a) to (f) had antibody recognizing the treated DFT2 cells. 
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Figure 7.7. Summary of responses of all devils to untreated (untx) and IFN-g treated DFT1 and DFT2 
cells. (a), (c) and (e) are untreated cells; (b), (d) and (f) are treated cells; (a) and (b) are wild devils with 
DFTD; (c) and (d) are wild devils with previously demonstrated immune responses against MHC-I+ve 
DFT1 cells; (e) and (f) are immunised devils. P values are the results of Student’s paired t tests. 
The wild devils with DFTD (a,b) had no antibody responses to untreated or IFN-g treated DFT1 or 
DFT2 cells. The wild devils with antibody responses to treated DFT1 cells (c, d) had antibodies to 
treated DFT2 cells. These devils on average had no response to untreated DFT1 cells, and a low but not 
significantly different response to untreated DFT2 cells. The immunised devils (e, f) overall had 
antibodies to both untreated and treated DFT1 and DFT2 cells. MFIR  = median fluorescence intensity 
ratio, as measure of antibody response. 
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7.3.3. Statistics analysis 
 
Table 7.2. The t and p values for Student’s paired t tests (2 tailed) comparing three different groups of 
devils’ antibody responses to untreated (untx) and IFN-g treated DFTD cells. 
 Group 1 
Wild devils with 
DFTD 
Group  2 
Wild devils with 
antibodies to DFT1 
Group 3 
Immunised devils 
Cell type t p t p t p 
untx  DFTD cells 1.501 0.194 1.234 0.272 1.138 0.307 
IFN-g  treated 
DFTD cells 
1.638 0.162 3.197 0.024 0.983 0.371 
 
 
7.4. Discussion 
 
Until recently it had been thought that transmissible cancers are extremely rare. Prior to 2015, 
only two such cancers had ever been observed in nature, DFTD in Tasmanian devils and CTVT 
in domestic dogs. That number doubled in 2015 with the discovery that leukaemia in soft shell 
clams is transmitted between individuals, and that a second transmissible tumour is affecting 
the devil. In 2016, a further four transmissible cancers were reported in shell fish including one 
cancer that had crossed species (Metzger et al., 2016). These authors concluded that 
transmissible cancers may be more common in nature than was first appreciated. Although we 
found the two cancers affecting the devil to be very different at the molecular level, DFT1 and 
DFT2 are grossly similar, with both causing tumours in the oral mucosa and/or facial skin (Pye 
et al., 2016).  This study aimed to determine if there is common antigenicity between the 
tumour cell types.  
 
None of the six wild devils in Group 1 with clinical signs of DFTD (DFT1, DFT2, or both) had 
serum antibody against either tumour type. This was not unexpected given that the previous 
study described in Chapter 4 found anti-DFT1 immune responses in only 10% of wild devils 
from a particular population.  
 
The six wild devils with anti-DFT1 responses in Group 2 either had histories of DFT1 tumour 
regression, or tumours with evidence of immune cell infiltration or MHC-I expression. All six 
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of these devils showed detectable antibody binding to IFN-g treated DFT2 cells. However, this 
was not as high as that against treated DFT1 cells.  This suggests either these devils have a 
lower antibody titre for DFT2, or there are fewer specific target antigens on DFT2 cells.  None 
of these devils had shown a significant response to MHC-I-ve DFT1 cells but two of them 
seemed to have antibodies to untreated DFT2 cells. These were at lower levels than their 
antibodies to IFN-g treated DFT2 cells, and didn’t contribute to an overall significant difference 
between the responses to untreated DFT1 or DFT2 cells in this cohort of devils. It is interesting 
to note that neither of the devils with antibodies to untreated DFT2 cells had a history of 
observed tumour regression. This is in contrast to the other four devils. It is possible these two 
devils had autoantibodies recognising antigens on the untreated DFT2 cell surface, or the 
degree of MHC expression on these untreated DFT2 cells is responsible for the antibody 
response. However, further analysis of DFT2 cells with serum from a larger number of wild 
devils (as was carried out in Chapter 4) should be performed before drawing conclusions about 
these differing responses. 
 
Devils immunised with MHC-I+ve DFT1 cell preparations developed antibodies against both 
MHC-I–ve and MHC-I+ve DFT1 cells (Chapters 5 and 6). These devils show similar antibody 
responses against both untreated and IFN-g treated DFT2 cells. The only immunised devil not 
to show serum antibodies for untreated DFT2 cells was “Tip”. This devil underwent tumour 
regression following immunotherapy, and had a low antibody response against untreated DFT1 
cells as shown in Chapter 5. He did however have antibodies recognizing both IFN-g treated 
DFT1 and DFT2 cells. In this respect his response was similar to the four wild devils that had 
histories of DFT1 tumour regression and antibodies that only recognized IFN-g treated cells. 
The overall results from this cohort of devils suggest that immunising devils with DFT1 cell 
preparations will produce immune responses against both tumour types. Assuming the 
antibody responses provide some correlation with protectiveness against DFTD, this bodes 
well for a single vaccine protecting against both tumours. However, it might be more 
efficacious to include DFT2 in the vaccination protocol to ensure coverage. 
 
The MHC-I expression of DFT2 in situ is yet to be clarified but is already proving an intriguing 
aspect of DFT2 research. It is well established that DFT1 cells, at least in culture, have down-
regulated surface expression of MHC-I (Siddle et al., 2013). Experiments have shown that at 
least a proportion of untreated DFT2 cells show some positive staining for b2m when compared 
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to untreated DFT1 cells. This suggests some surface expression of MHC-I in the un-
manipulated DFT2 cells, at least in culture. As occurs with DFT1 cells, this surface MHC-I 
expression is dramatically elevated when the DFT2 cells are treated with IFN-g. It has been 
confirmed that DFT2 has a different MHC-I genotype from DFT1 (Pye et al., 2016). 
 
It would be curious if foreign cells expressing surface MHC-I do not elicit an alloresponse in 
devils. Despite low genetic diversity, devils have demonstrated immune rejection of allografts 
(Kreiss et al., 2011). One possible explanation for the lack of response against the MHC-I 
molecules expressed on DFT2 cells is that these are non-classical MHC-I (Hannah Siddle, pers. 
comms 2015). Non-classical MHC-I molecules can be over-expressed by malignant cells and 
inhibit the cytolytic activity of various effector cells (Kochan et al., 2013) thus providing a 
mechanism of immune escape for neoplastic cells. The particular responses of the wild devils 
with DFTD seroconversion suggests that classical MHC-I expression is a target for naturally 
occurring immune recognition of DFTD.   
 
The serum antibody results reported here suggest there is common antigenicity between DFT1 
and DFT2 cells. Further analysis of the serum antibodies using western blotting and 2D gel 
electrophoresis may aid in identifying the common antigens between the two tumours. 
Antibodies from the seroconverted wild devils may also help determine the significance of 
MHC-I in the immune responses against DFTD. 
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Chapter 8. Final discussion 
 
8.1. The Tasmanian devil, DFTD and vaccine development 
 
The Tasmanian devil (Sarcophilus harrisii) has been listed as an endangered species due to an 
aggressive, transmissible and fatal cancer known as devil facial tumour disease (DFTD) 
(Hawkins et al., 2008). The devil is the world’s largest extant carnivorous marsupial and unique 
to Australia’s island state of Tasmania. DFTD is a contagious cancer, passed between devils 
by biting. Transmissible cancers are rare events whereby the tumour cells are the sole 
aetiological agent. They require a means to infect new hosts, as well mechanisms to evade the 
host’s immune system. Until 2015, the only other transmissible cancer known to exist was 
canine transmissible venereal tumour (CTVT), an ancient tumour affecting domestic dogs 
(Murgia et al., 2006). Another six transmissible cancers have since been reported, with five 
occurring in shellfish, and one in Tasmanian devils (Metzger et al., 2015, Metzger et al., 2016, 
Pye et al., 2016).  
 
The extinction in the wild of the Tasmanian devil would have profound impacts. It is an 
internationally recognised species with an iconic status that inhabits a unique ecological niche. 
As devil populations decline this niche is at risk of being filled by feral cats and potentially 
foxes, the consequences of which would prove disastrous for native species (Hollings et al., 
2014, Hawkins et al., 2006). Although no local devil population extinctions have been 
recorded, the devil has been described as functionally extinct in certain parts of the state 
(Hollings et al., 2015). There is evidence suggesting that DFTD is influencing genetic selection  
(Epstein et al., 2016), but there is no sign yet that the effect of DFTD is abating. Consequently, 
human intervention in the form of carefully thought out management plans may be necessary 
to restore a genetically diverse wild devil population. This would include the development of 
a protective vaccine against DFTD.  
 
Research towards the goal of vaccine development has been in progress since 2006. Clearly it 
is a long term and challenging commitment. The aims of this thesis were formed within the 
context of DFTD vaccine development, and studies were carried out on wild and captive devil 
populations. The wild devil population provides great scope for exploring DFTD, the devil’s 
immune system and how the two interact. Such knowledge, in particular how it relates to 
natural conditions, is essential for vaccine development. Part of this thesis made use of field 
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studies on wild devils to inform on the “normal” devil immune system with respect to T 
lymphocytes and immunoglobulins, and how these are affected by DFTD. This included 
identifying specific immune responses against DFTD in the wild devils. 
 
The captive devil population has proven extremely useful for vaccine research, particularly in 
respect to the implementation of immunisation trials.  The advantages of working with captive 
devils include their assured non-exposure to DFTD due to strict quarantine conditions, and the 
guaranteed follow up of individual devils. Previous DFTD immunisation trials on small 
numbers of captive devils, usually two or three individuals per trial, have yielded encouraging 
preliminary results. In particular, they have shown that devils are capable of mounting both 
humoral and cell mediated immune responses against DFTD (Kreiss et al., 2015). The limited 
number of individual devils available for trials has meant uncertainty regarding how the wider 
devil population is represented. Nonetheless notable results in this thesis arose from the small 
immunisation trials described in Chapter 5. There was evidence of an immune response 
consistently generated against MHC-I+ve DFTD cells. More importantly, there was convincing 
evidence for immune mediated tumour regression in immunised devils with DFTD following 
immunotherapy. These results serendipitously coincided with the initial stages of the Save the 
Tasmanian Devil Program’s (STDP) “wild devil recovery” project. The devils earmarked for 
the first wild release were made available for immunisation trials prior to their release. This 
provided the opportunity to address sample size restrictions for the first time. Consequently, 
this thesis included the implementation of a field immunisation trial.  
 
Lastly, the discovery of a second transmissible cancer affecting Tasmanian devils has raised 
many questions regarding transmissible cancers: their prevalence, their immune escape 
mechanisms, and the susceptibility of devils to such cancers. An immediate question for those 
involved in DFTD vaccine research was whether immune cross-recognition of the tumours 
could occur. The final aim of this thesis was to identify antibody responses against DFT2 in 
both wild and immunised captive devils. 
 
 
8.2. Effects of DFTD on the immune response of the Tasmanian devil 
 
In general, malignant cancers compromise the immune response of the host (Whiteside, 2006, 
Whiteside, 2010). This is particularly relevant at the tumour site whereby the tumour 
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microenvironment is characterized by a variety of immunosuppressive factors e.g. TGF-ß and 
IL10; and suppressor cell populations e.g. T regulatory cells (Whiteside, 2006). At a systemic 
level, the circulating T lymphocytes of patients with malignancies have been shown to be 
functionally compromised (Hellstrom et al., 2001). Since T cell function is critical for anti-
tumour activity, it follows that a dysfunctional population facilitates tumour progression.  
 
DFTD is an aggressive malignant cancer, with death usually resulting within  6 to 12 months 
of the tumour’s first appearance (Hawkins et al., 2006). It is therefore logical to assume that it 
impacts on the devil’s immune system, including the T lymphocyte population. Knowledge of 
the make-up and activity of T cell populations in healthy and diseased devils is necessary for 
understanding the interaction between the devil’s immune system and DFTD. Advances in this 
area continue within the confines of limited reagents for investigation. DFTD has previously 
been shown not to affect lymphocyte proliferation in vitro (Kreiss et al., 2008). The distribution 
and abundance of CD4+ and CD8+ T cells in lymphoid tissue of heathy devils and devils with 
DFTD has also been documented (Howson et al., 2014). One of the aims of this thesis was to 
address the T lymphocyte populations in peripheral blood of wild devils, and to ascertain the 
effect of DFTD on these circulating cells. This would indicate whether immunocompromise is 
a consequence of DFTD. 
 
A primary finding was that DFTD is associated with reduced percentages of CD4+ and CD8+ 
lymphocytes in the peripheral blood. This was accompanied by an increased percentage of 
CD4-CD8- lymphocytes. The identification and activity of these ‘double-negative’ T cells 
remains undetermined. It was hypothesized in Chapter 3 that immunosuppressive cytokines 
released by the tumour cells might cause reduced expression of the CD4 and CD8 molecules. 
Peripheral T lymphocytes from patients with advanced cancer have demonstrated low 
expression of CD3, CD4 and CD8 molecules in comparison to lymphocytes from healthy 
donors (Hellstrom et al., 2001). Proliferation and cytokine release was diminished in these 
cancer patients’ lymphocytes. The function of the ‘double negative’ T lymphocytes in devils 
with DFTD could also be compromised as CD4 and CD8 are important molecules involved in 
antigen presentation and T cell activation. A reduced density of these molecules would impair 
T cell activation and result in reduced T cell immunity, and conceivably promote the 
progression of DFTD. 
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The novel method described in this thesis to identify and quantify the peripheral blood CD4+ 
and CD8+ T lymphocytes in devils was particularly useful for the field situation. Preservation 
of the blood clots was quick, requiring no special equipment and only buffered formalin for 
fixation. Storage and transport of the fixed clots was at ambient temperature, and there was no 
time limit in which to analyse the samples. While the tests used to validate the method showed 
it was useful for quantifying the average percentages of lymphocytes for devils in a particular 
cohort, it wasn’t accurate enough to confidently quantify the percentages in an individual. 
Further validation of the method will be possible with the availability of more reagents, in 
particular an anti-devil CD8 antibody for use in fresh blood. Despite the limitations of the 
method, there was a clear finding that DFTD reduces the normal T lymphocyte population.  
 
Most of the literature discusses immunocompromise of the cancer patient in terms of reduced 
lymphocyte counts and lymphocyte function (Whiteside, 2006, Kim et al., 2007). The humoral 
immune response is examined more specifically with respect to antibodies against tumour 
associated antigens (Reuschenbach et al., 2009, Dudas et al., 2010). Detection of antibodies 
against DFTD in wild devils was an important part of this thesis, but the effect of DFTD on 
total serum IgG and IgM levels was also explored. The increased serum levels of IgM and IgG 
noted in this study could be explained by increased exposure to pathogens in general. Both IgM 
and IgG were at higher levels in healthy adults than healthy juveniles. This is typical of other 
species and considered a normal consequence of maturity (Schreiber et al., 1992). DFTD was 
found to affect the IgM:IgG ratio in a study that examined serum mRNA (Ujvari et al., 2016). 
However, the study described in this thesis found differences for IgG and the IgM:IgG ratio 
between healthy and diseased devils only in the juvenile cohort. This points to the complexity 
of factors, including environment and age, involved in the effect of cancer on various immune 
parameters. 
 
The immunoglobulin results reported in this thesis suggest the devils with DFTD still have a 
functional humoral immune response. The T lymphocyte populations however, are adversely 
affected by DFTD in line with the effects of malignant cancers on other species. This has 
implications for immunotherapy which requires a functional immune system to be effective. 
However, the effects of cancer on T cells are not necessarily irreversible. Restoration of 
lymphocyte function as measured by proliferation and cytokine release has been demonstrated 
in vitro with lymphocytes collected from patients with malignancies (Hellstrom et al., 2001). 
In addition, cytokine therapy has restored normal signaling in CD8+ T lymphocytes of patients 
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with malignant melanoma (Whiteside, 2006). Recognizing how the immune system is altered 
in devils naturally infected with DFTD informs on which responses are influenced by DFTD 
infection and, by extension, which pathways, for example cytokine release, might be important 
for DFTD rejection.  
 
8.3. Immune responses against DFTD, and the role of MHC-I expression 
 
The demonstration of immune responses against DFTD in wild devils described in Chapter 4 
was a major finding of this thesis. It provided the first evidence that the devil’s immune system 
can respond to DFTD and that death is not the inevitable outcome of DFTD infection. DFTD 
antibodies were present in all six of the wild devils with a response. A cell mediated immune 
response in the form of CD3+ and MHC-II+ infiltrating cells in tumour biopsies was evident 
in two devils. The tumour cells from a third devil showed MHC-I surface expression at the 
time of that devil’s seroconversion. 
 
The serum antibodies identified in these wild devils were against MHC-I+ve DFTD cells, but 
not MHC-I-ve cells. This suggests that MHC-I expression by DFTD cells is necessary to activate 
an anti-DFTD immune response. It is not clear what provides the initial trigger for MHC-I 
expression in the tumour cells. It is likely, however, that this trigger is a primary immune 
response that results in cytokine release by T helper cells and macrophages that are drawn to 
the tumour microenvironment. Since incubating DFTD cells with inflammatory cytokines in 
vitro results in the cells’ dramatic up-regulation of MHC-I surface expression, it is reasonable 
to assume the same occurs in vivo. The cytokine release should have a cascade effect with 
increasing numbers of MHC-I+ve DFTD cells attracting more cytotoxic lymphocytes resulting 
in killing of tumour cells and ultimately tumour stabilization or regression. The simultaneous 
seroconversion is explained by presentation of tumour peptides on the MHC-II molecules of 
antigen presenting cells to T helper cells, and the subsequent proliferation of B cells and 
antibody production. The antibodies could play a functional role in the anti-tumour response 
by antibody dependent cell mediated cytotoxicity (ADCC). This process has previously been 
reported in devils whereby the cytotoxicity against xenogeneic tumour cells demonstrated in 
vitro was attributed to natural killer (NK) cells acting in an antibody dependent manner (Brown 
et al., 2011). 
The importance of the serum antibody response for DFTD rejection is further supported by 
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results from the immunised captive devils that underwent regression of their experimentally 
induced tumours, described in Chapter 5. These devils had an increase in their serum antibody 
levels to MHC-I+ve DFTD cells following immunotherapy with live DFTD cells expressing 
MHC-I. This coincided with tumour regression. Even more distinctive was the seroconversion 
in the devil from the 2012 trial referred to in Chapter 5. This devil didn’t have a measurable 
antibody response following immunisations. However, after tumour development and 
subsequent immunotherapy she developed a high level of serum antibodies to MHC-I+ve DFTD 
cells, but no response to MHC-I-ve cells. Once again, this coincided with complete tumour 
regression.  
The most likely explanation for DFTD’s avoidance of allorecognition is the lack of MHC-I 
expression on the tumour cells (Siddle and Kaufman, 2013). This results in a failure to activate 
MHC-I restricted cytotoxic T cells and tumour development is unhindered. Despite indirect 
evidence for devil NK cells (Brown et al., 2011), it is unknown why these cells fail to target 
the transmitted i.e. MHC-I-ve DFTD cells.  Anti-inflammatory cytokines such as TGF-ß inhibit 
the function of NK cells (Jakowlew, 2006) and unpublished data suggests these inhibitory 
cytokines are present in the DFTD microenvironment (Howson, 2011). This provides a 
potential explanation for the lack of NK cell activity. Likewise, some tumour cells don’t 
express the requisite ligands for NK cell function (Cheng et al., 2013). The lack of NK cell 
activity might be reversed after an inflammatory response such as the one described above. 
The evidence from the wild and captive devils argues that if DFTD cells can express MHC-I, 
a response against the DFTD tumour cells will be activated. 
 A noteworthy parallel is that the role for MHC-I expression and antibody responses in canine 
transmissible venereal tumour (CTVT) rejection has been demonstrated. During the 
progressive phase of experimentally induced tumours, there is minimal surface expression of 
MHC-I on the CTVT cell surface. After 4 months, MHC-I expression is significantly increased 
and coincides with tumour regression. Both cell mediated and humoral responses occur during 
this regressive phase (Hsiao et al., 2008, Hsiao et al., 2002). Antibody dependent cell mediated 
cytotoxicity is enabled by the anti-CTVT IgG antibodies (Cohen, 1980). The development of 
allotypic antibodies in the serum of dogs following CTVT rejection suggests that tumour 
rejection involves the canine MHC system (Epstein and Bennett, 1974). 
The evidence for the role of MHC-I expression for the development of immune responses 
against DFTD led to the next part of the study. This was an immunisation trial on 19 captive 
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devils prior to their wild release as the first stage of the STDP’s “wild devil recovery” project. 
The use of DFTD cells expressing MHC-I as the antigenic basis for the immunisation trial 
described in Chapter 6 resulted in antibody responses against both MHC-I+ve and MHC-I-ve 
DFTD cells in the majority of devils. It is expected that cells expressing MHC-I are more 
immunogeneic than MHC-I-ve cells due to presentation of cellular antigen by the MHC-I 
molecule. The adjuvants used in the immunisations are likely to have further enhanced the 
immune response to the cell preparations since multiple signalling pathways were targeted by 
the combination of TLR agonists and ISCOMATRIX™. MHC-I+ve and MHC-I-ve DFTD cells 
are likely to have antigens in common providing an explanation for the generation of antibody 
responses against both cell types in the immunised devils. Whether these responses translated 
to protection from a natural DFTD challenge currently remains untested. It may be possible to 
extend the trapping range beyond Narawntapu National Park in 2017 and locate some of the 
released devils that dispersed outside the park. This may provide an indication of the duration 
of immune responses and protectiveness of the immunisations. 
 
8.4. Identification of DFTD epitopes for future vaccine development and immune 
response measurement 
 
The above discussion highlights the apparent importance of MHC-I expression for immune 
recognition of DFTD. At this stage, however, the only certainty is that serum antibodies in 
devils with histories of tumour rejection are recognizing epitopes on DFTD cells that have been 
incubated with IFN-g. Antibodies to MHC-I+ve cells could be recognizing: the MHC-I 
molecule; the peptide presented by the MHC-I molecule; and/or other molecules that are also 
up-regulated by cytokine incubation but not necessarily associated with MHC-I. The other 
consideration is that immunised devils develop antibodies against MHC-I-ve DFTD cells. Given 
these cells reflect the wild type tumour cells which lack MHC-I expression, it is logical that 
protection from a natural DFTD challenge also requires recognition of MHC-I-ve DFTD cells. 
This theory however has not been properly tested. 
 
It will take dedicated research to determine which DFTD epitopes are recognized by the serum 
antibodies from individual devils, and to what extent there is commonality. It is reasonable to 
assume that the serum antibodies identified in devils with tumour regression have functional 
relevance and/or prognostic value rather than simply denoting exposure or immunopathology.  
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Identification of DFTD epitopes recognized by serum antibodies from these devils has practical 
applications. It will allow for development of an epitope based vaccine as opposed to the whole 
cell preparation in current use. While advantages of whole cell vaccines were described in the 
literature review (Chapter 1.16.2), a vaccine comprised of target epitopes in combination with 
adjuvants could prove an effective approach. At the very least it would eliminate the risk of 
tumour inoculation as a result of the whole cell preparation.  
 
The parallels between devil immunology / DFTD vaccine development and koala immunology/ 
chlamydia vaccine development were discussed in Chapter 1.16.4. The chlamydia vaccine 
trialled in koalas has relied on the chlamydia recombinant major outer membrane protein 
(rMOMP) as the antigen, rather than incorporating the whole chlamydia organism. The 
rMOMP, in combination with similar adjuvants to those used in DFTD immunisation trials, 
has resulted in seemingly protective humoral and cell mediated immune responses in koalas 
(Waugh et al., 2016). It remains to be seen whether an epitope-only DFTD vaccine will be 
effective in the devils.  
 
The chlamydia rMOMP has also been instrumental in measuring the koalas’ responses to the 
immunisations, and this is the other area to which identification of DFTD epitopes will 
contribute. Flow cytometry is the method currently used for antibody response measurement 
in devils. It identifies the presence of serum antibody to any epitope on the entire tumour cell 
surface. This method can’t detect whether each devil has antibodies recognizing the same 
epitopes. The isolation of DFTD cell surface epitopes with immune serum from devils with 
histories of tumour regression should determine if these devils have anti-DFTD antibodies in 
common. Presumably these antibodies and the epitopes they recognize will be keys to DFTD 
immune recognition and rejection. As with koala vaccine research, these specific epitopes 
could then be used to assess antibody responses to immunisation trials. They could also be used 
to screen wild devil serum samples to assess the prevalence of naturally occurring immune 
responses. Cell mediated immune responses could also be tested with the epitopes e.g. by 
measuring lymphocyte proliferation in response to epitope stimulation. 
 
8.5. DFT2 and final remarks 
 
The final chapter of this thesis was based on DFT2, a second transmissible cancer affecting the 
devils that was discovered while this thesis was underway. While DFT1 and DFT2 are 
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indistinguishable at the macroscopic level, they have marked histological, cytogenetic and 
genetic differences, including distinct MHC-I genotypes (Pye et al., 2016). All analyses to date 
indicate that DFT2 is a transmissible cancer independent of DFT1. The confirmation of a 
second transmissible cancer affecting an already endangered species is troubling. However, 
DFT2 has been limited to the Channel peninsula in south east Tasmania with only 13 confirmed 
cases at the time of writing.  It is currently open to speculation whether the Tasmanian devil is 
particularly susceptible to such events, whether there is an exogenous component, or whether 
it is pure chance that two independent transmissible cancers have appeared in the species within 
a relatively short time frame. The reporting of five transmissible cancers in clams (Metzger et 
al., 2015, Metzger et al., 2016) around the same time as the DFT2 discovery has prompted the 
question of whether transmissible cancers are more common in nature than has previously been 
assumed. 
 
There remains much to find out about DFT2: its cellular origin; its immune escape 
mechanisms; and how it compares with DFT1. Despite the concerns DFT2 presents for the 
survival of the species, research into this new transmissible cancer will contribute to an 
understanding of immune escape and cancer evolution.  On a more immediate and practical 
level, preliminary results presented here suggest that if the devils can mount an immune 
response against DFT1 this should translate as a response against DFT2. There was cross-
recognition of DFT2 by all devils, wild and immunised, that had demonstrated antibodies 
against DFT1 cells. All of these devils had antibodies that recognized IFN-g treated DFT2 cells, 
but only a proportion also had antibodies recognizing the unmanipulated DFT2 cells. DFT2’s 
in vitro expression of MHC-I is distinct from that of DFT1. As discussed in Chapter 7, 
unmanipulated DFT2 cells show some level of MHC-I expression. This might be non-classical 
MHC-I which would help explain the lack of allorecognition of DFT2 tumours (Hannah Siddle, 
pers. comms 2015). It is clear that when DFT2 cells are incubated with the inflammatory 
cytokine IFN-g, the MHC-I expression is dramatically increased. This provides further 
evidence for the role of MHC-I expression in immune recognition of DFTD. 
 
The immune cross-recognition of DFT1 and DFT2 is encouraging especially in the light of 
recent evidence for immune responses against DFT1 in wild devils (Chapter 4), possible gene 
selection in reaction to DFT1 (Epstein et al., 2016), and promising results from DFT1 
immunisation trials (Chapters 5 and 6). These are exciting developments and should be 
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acknowledged as such. Yet without evidence for the effects of DFTD abating, it is too soon for 
complacency. At an individual level, hundreds of devils continue to succumb to DFTD and die 
of starvation or metastatic disease. At a population scale, the future of the wild Tasmanian devil 
is not guaranteed. The challenges are complex, but the development of a protective vaccine 
against DFTD would prevent the suffering of countless individuals, help secure a genetically 
diverse wild devil population, and contribute to maintaining the unique Tasmanian ecosystem. 
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Appendix 1 
 
Protein electrophoresis 
 
Table 1. Devil serum samples.  
 
Sex 
DFTD- DFTD+ 
Devil name Age (years) Devil name Age (years) 
control  
(captive, male) 
Prince 4 / / 
male Wheery 1 Tylden 2 
Libano 2 Enfield 2 
Trujillo 6 Tiwanaku 2 
female Hoppity Hare 1 Maui 1 
Kialla 2 Savuti 2 
Chiricoca 4 Nungwi 3 
 
The control devil was a captive devil, the others were wild devils from West Pencil Pine. 
 
 
Table 2. Total protein, albumin and globulin ranges for healthy and DFTD+ devils. 
DFTD status Total protein g/L Albumin g/L Globulin g/L A:G 
DFTD- 59 - 68 32 - 40 24 - 32 1.09 - 1.50 
DFTD+ 57 - 67 25 - 35 29 - 36 0.86 - 1.10 
control 
(DFTD-) 
67 35 32 1.09 
 
 
 
Table 3.  Globulin fraction ranges for healthy and DFTD+ devils. 
DFTD status Alpha 1 g/L Alpha 2 g/L Beta 1 g/L Beta 2 g/L Gamma g/L 
DFTD- 1.7 – 2.6 2.6 – 6.5 6.5 – 7.5 2 – 3.7 8.9 – 19.9 
DFTD+ 6.4 – 9.0 2.0 – 4.6 7.4 – 9.6 3.4 – 5.1 12.7 – 17.4 
Control 
(DFTD-) 
2.7 5.4 6.0 3.8 14.7 
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Figure 1. Electropherograms of healthy (DFTD-) male devils (a) control devil, 4 years old, (b) and (c) 
wild devils, both 2 years old, (d) wild devil, 6 years old. 
 
  
(a) (b)
(c) (d)
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Figure 2. Electropherograms of healthy (DFTD-) wild female devils (a) 1 year old, (b) 2 years old, (c) 
4 years old 
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Figure 3. Electropherograms of DFTD+ wild male devils (a) 1 year old, (b) 2 years old, (c) 4 years 
old 
 
(a) (b)
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Figure 4. Electropherograms of DFTD+ wild female devils (a) 1 year old, (b) 2 years old, (c) 3 years 
old. 
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C reactive protein (CRP):  
 
Although there were differences in CRP levels between the healthy and diseased devils, it is 
unlikely the actual values are significant. Active inflammation in domestic dogs is > 10 mg/L 
and the reliability of the test decreases with low values (< 5 mg/L) so the current method for 
CRP evaluation in dogs does not appear transferrable to devils.  
 
Table 4.  CRP ranges for healthy (DFTD-) and DFTD+ devils. 
DFTD status mg/L 
Healthy (DFTD-) 0 to 0.58 
DFTD+ 0.79 to 4.91 
Control 
(DFTD-) 
0.86 
where 0 value indicates below detection level or the test. 
 
METHODS 
 
Devil serum samples: 
 
Sera samples from six DFTD+ and six healthy (DFTD-) devils from the West Pencil Pine devil 
population were used. Serum samples had been stored at -80 °C for up to two years, so a freshly 
collected serum sample from a captive healthy devil was also assessed. Samples were couriered 
frozen (on ice) from Hobart to Victoria, Australia. 
 
Laboratory methods: 
 
A commercial veterinary laboratory (Gribbles, Veterinary Pathology, Victoria, Australia) 
carried out the following analyses on each serum sample: 
 
Albumin globulin ratio: A Siemens ADVIA 1800 analyser was used to measure the total 
protein and albumin content of each sample.  
The total protein method is based on the method of Weichselbaum using biuret reagent (cupric 
sulfate in an alkaline solution).  
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The albumin method is based on the method of Doumas, Watson, and Biggs and uses 
bromocresol green solution (BCG) as a binding dye.  
Globulin is not measured directly but calculated as the difference between TP and albumin 
 
Protein electrophoresis: Electrophoresis was performed on the Sebia Hydrasys instrument 
using separation of proteins by their electrical charge on agarose gel and stained by amidoblack 
stain. 
 
C reactive protein (CRP) method: A Randox Laboratories Ltd immunoturbidmetric assay for 
canine CRP quantification was performed on the serum samples.  
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Appendix 2 
 
Information on wild Tasmanian devils from West Pencil Pine, north west Tasmania used in 
studies described in Chapters 3 and 4 
 
Table 1. Wild devils from West Pencil Pine (WPP) used in Chapter 3. 
 
Date/ DFTD 
status 
WPP 
ID 
Menzies 
ID 
name YOB sex 
Nov-13      
DFTD+ 334 TD443 Kalahari 2011 F 
 340 TD435 Ihaha 2011 F 
 341 TD453 Limpopo 2011 F 
 343 TD446 Savuti  2011 F 
 369 TD449 Tylden 2011 M 
 408 TD414 Alamo 2012 M 
 410 TD418 Araucaria 2012 F 
 416 TD437 Gaza 2012 F 
 417 TD448 Fallujah 2012 M 
DFTD- 349 TD441 Chiricoca 2010 F 
 390 TD444 Karawinna 2012 F 
 397 TD445 Pezgato 2012 M 
 411 TD420 Acacia 2012 F 
 414 TD440 Libano 2012 M 
 422 TD442 Halhul  2012 F 
 423 TD447 Albireh 2012 M 
 424 TD451 Rafah 2011 M 
Feb-14      
DFTD+ 355 TD455 Zanzibar  2011 M 
 360 TD438 Nungwi  2011 F 
 382 TD415 Enfield  2012 M 
 387 TD463 Kallista  2012 F 
 420 TD452 Falestinya 2010 M 
DFTD- 287 TD464 Nairobi  2009 F 
 399 TD450 Chinchorro  2012 M 
 409 TD417 Lenga   2012 F 
 418 TD460 Persia  2012 F 
 425 TD457 Il Bambino  2013 M 
 428 TD456 Jujue  2013 F 
 430 TD458 Chaco  2013 M 
 433 TD459 Burruyacu  2013 F 
 434 TD461 Catamarca  2013 M 
 435 TD462 Formosa  2013 M 
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Date/ DFTD 
status 
WPP 
ID 
Menzies 
ID 
name YOB sex 
May-14      
DFTD+ 283 TD421 Kisumu 2010 F 
 381 TD433 Emerald 2012 F 
 402 TD439 Selknam 2012 M 
 403 TD473 Alacalufe 2012 M 
 406 TD422 Aromo 2012 F 
DFTD- 314 TD436 Trujillo 2009 M 
 391 TD470 Kialla 2012 F 
 404 TD474 Koru/ Chono 2013 M 
 428 TD456 Jujue 2013 F 
 437 TD472 Corrientes 2012 M 
 438 TD475 Iguazu 2013 F 
 448 TD478b Pukunui 2013 F 
 450 TD471 Waikaremoana 2012 F 
 451 TD477 Rotarua 2013 F 
Aug-14      
DFTD+ 405 TD416 Tiwanaku 2012 M 
 447 TD493 Maui 2013 F 
 449 TD478 Kahurangi 2013 F 
DFTD- 431 TD469 Mendoza 2013 M 
 441 TD468 Aroha 2013 M 
 442 TD496 Kia Ora 2102 M 
 452 TD476 Taupo 2013 F 
 455 TD491 Hobgoblin 2013 M 
 456 TD492 Wheery 2013 M 
 457 TD494 Hoppity Hare 2013 F 
 458 TD495 Wandle 2013 F 
 459 TD497 Old Speckled Hen 2013 F 
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Table 2. Wild devils from West Pencil Pine (WPP) used in Chapter 4. 
 
WPP ID Menzies ID name YOB sex 
     
69 / Esquivel 2006 F 
75 / Gengibre 2006 F 
138 / Pomaire 2006 F 
148 / Ratusratus 2006 F 
209 / Oryx 2008 F 
213 / Mandrill 2008 F 
214 / Cobra 2007 F 
219 / Honeybadger 2008 F 
220 / Hornbill 2008 F 
251 / Monse 2009 F 
253 / Concepcion 2009 F 
283 TD421 Kisumu 2010 F 
287 TD464 Nairobi 2009 F 
305 / Evita 2010 F 
314 TD436 Trujillo 2008 M 
340 TD435 Ihaha 2011 F 
341 TD453 Limpopo 2011 F 
343 TD446 Savuti 2011 F 
344 / Churrete 2011 M 
349 TD441 Chiricoca 2010 F 
353 / Matemwe 2011 F 
355 TD455 Zanzibar 2011 M 
358 / Kendwa 2011 F 
360 TD438 Nungwi 2011 F 
381 TD433 Emerald 2012 F 
382 TD415 Enfield 2012 M 
387 TD463 Kallista 2012 F 
399 TD450 Chinchorro 2012 M 
400 TD419 Diaguita 2012 F 
402 TD439 Selknam 2012 M 
403 TD473 Alacalufe 2012 M 
405 TD416 Tiwanaku 2012 M 
406 TD422 Aromo 2012 F 
408 TD414 Alamo 2012 M 
409 TD417 Lenga 2012 F 
410 TD418 Araucaria 2012 F 
411 TD420 Acacia 2012 F 
414 TD440 Libano 2012 M 
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WPP ID Menzies ID name YOB sex 
416 TD437 Gaza 2012 F 
417 TD448 Fallujah 2012 M 
418 TD460 Persia 2012 F 
420 TD452 Falestiniya 2010 M 
422 TD442 Halhul 2012 F 
423 TD447 Albireh 2012 M 
424 TD451 Rafah 2011 M 
429 / Salta 2013 F 
430 TD458 Chaco 2013 M 
431 TD469 Mendoza 2013 M 
433 TD459 Burruyacu 2013 F 
434 TD461 Catamarca 2013 M 
435 TD462 Formosa 2013 M 
438 TD475 Iguazu 2013 F 
 
 
 
 
 
 
 
